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ABSTRACT 
 
DEVELOPMENT AND SYNTHETIC APPLICATIONS 
OF ANION RELAY CHEMISTRY TACTICS  
— 
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OF THE IMMUNE CELL RECEPTOR CD4 
 
Bruno Melillo 
Professor Amos B. Smith, III 
 
This thesis comprises two independent Parts. 
Part I describes the implementation of Anion Relay Chemistry (ARC) tactics in the 
synthesis of natural products and natural product precursor scaffolds. Chapter 1 discusses 
the design and execution of a unified strategy exploiting ARC Type I and Type II four-
component fragment unions for the synthesis of natural products of the Cryptocarya 
family. The ARC tactics play here a pivotal role in generating, in a single flask, 
structurally elaborate synthetic intermediates from relatively simple, readily accessible 
starting materials, leading to increased efficiencies in the construction of the chosen 
synthetic targets compared to previous reports. Chapter 2, in turn, describes the validation 
of a Type II ARC protocol permitting the stereocontrolled introduction of a propionate 
unit in tricomponent adducts via a new aldehyde “linchpin,” followed by an application 
in the construction of a putative C16-C29 segment of natural product rhizopodin.  
Part II describes the synthesis and structure-based optimization of small-molecule 
mimics of CD4, a receptor that mediates infection of immune cells by Human 
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Immunodeficiency Virus (HIV). Chapter 1 describes the development of a synthetic route 
for the stereoselective, scalable preparation of compound JP-III-048, a small-molecule 
CD4 mimic that had exhibited promising activity in HIV entry inhibition assays. 
Structural modifications guided by crystallographic and computational data ultimately 
leading to both more potent and more broadly active analogues are discussed in Chapter 
2. Extensive studies by our collaborators have led to the discovery that these small 
molecules have the capability of sensitizing both viral particles and infected cells to 
neutralization by the immune system. These findings are discussed in Chapter 3. 
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PART I: 
DEVELOPMENT AND SYNTHETIC APPLICATIONS 
OF ANION RELAY CHEMISTRY TACTICS  
 
Introduction 
In considering the construction of architecturally complex organic chemical structures, 
significant challenges that often arise are efficient carbon-carbon bond formation and 
control of stereochemistry. Integration into synthetic plans of “key transformations” that 
ensure either or both formation of critical structural connectivity and stereochemical 
control may come at the cost of successive protecting group manipulations and, more 
generally, functional group interconversions. Such transformations, logically dictated by 
the diversity and abundance of chemical functionality present at a given synthetic stage, 
contribute to the number of steps in a linear synthetic sequence and, as such, are 
detrimental to the overall efficiency of the synthetic route. In contrast, installation of 
chemical complexity in individual chemical fragments prior to their coupling contributes 
to the convergence of the synthetic route and therefore leads at least in theory to 
increased synthetic efficiencies, in addition to permitting more facile structural variations 
in cases where efficient exploration of chemical space is of interest, [i.e., in Diversity-
Oriented Synthesis (DOS)].1 As a result, the development of chemical transformations 
that permit the efficient union of multiple molecular fragments bearing pre-built 
complexity remains important.  
 In the Smith Laboratory, efforts to achieve the convergent synthesis of architecturally 
complex natural products of the polyketide family have led to a set of tactics now 
 2 
encompassed under the terminology Anion Relay Chemistry (ARC). The fundamental 
feature of ARC lies in the migration of negative charge involving a central component, a 
so-called “linchpin,” which effectively acts as a tether between two (or more) molecular 
fragments. 
In conceptualizing Anion Relay Chemistry (ARC) as defined above by the 
exploitation of a linchpin as the negative-charge-relaying tether in tri- or multi-
component reactions, a classic case recognized as belonging to this type of reaction is the 
Michael reaction. Specifically, addition of a nucleophile to the β-position of an α,β-
unsaturated ketone leads to the formation of an enolate, which may subsequently trap an 
electrophile at the α-position of the carbonyl. In this tricomponent reaction, the enone 
effectively behaves as a “linchpin,” tethering an initiating nucleophile and a terminating 
electrophile. Because the charge relay within the linchpin occurs exclusively through the 
π-system of the enone, the Michael reaction can be considered an example of “Through-
Bond” ARC. Conversely, certain types of ARC tactics termed “Through-Space” rely on a  
!
Figure 1.1. Conceptualization of Anion Relay Chemistry (ARC). 
Anion Relay Chemistry
(ARC)
Through-Bond
(e.g. Michael) Through-Space
Type IIType I
 3 
rearrangement process as a means to transfer negative charge, thus enabling fragment 
unions. As will be detailed later, “Through-Space” Anion Relay Chemistry can be further 
subdivided into Types I and II (Figure 1.1). In this dissertation, all ARC protocols 
discussed involve a carbon-to-oxygen silyl group migration known as a Brook 
rearrangement. 
The Brook rearrangement  
The migration of a silyl group from oxygen to carbon was first reported by A. G. 
Brook in 1958.2 Indeed, it was shown that treatment of a C-silylated diphenyl carbinol 
(1.1) with sodium hydroxide or pyridine resulted in a [1,2]-silyl migration leading to silyl 
ether 1.2 (Scheme 1.1). 
 
Scheme 1.1. First Example of a [1,2]-Brook Rearrangement 
Mechanistically, the Brook rearrangement comprises an equilibrating process between 
an alkoxide (1.3) and a carbanion (1.5) with the reverse pathway, an oxygen-to-carbon 
silyl migration, termed “retro-Brook rearrangement.” A fundamental driving force for the 
Brook rearrangement is the strength of the O–Si bond (120-130 kcal/mol), greater than 
that of the C–Si bond (75-85 kcal/mol).3 This difference in bond strengths bears 
OH
SiR3PhPh
O
SiR3PhPh
O
SiR3PhPh
OSiR3
Ph
Ph
OSiR3
Ph
Ph H
1.1 1.2
1.3 1.51.4
[1,2]-Brook rearrangement
Base Protonation
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particular significance in cases where the base is employed catalytically, where the 
carbanion (1.5) is protonated in irreversible fashion by either the substrate (1.1) or the 
conjugate acid of the catalyst. In contrast, in cases where the alkoxide (1.3) is formed 
stoichiometrically at the beginning of the process, most notably in multicomponent 
fragment unions, silyl migration is strongly influenced by the relative stability of the 
alkoxide (1.3) and the carbanion (1.5). As a result, the Brook rearrangement (in the 
forward sense) is logically driven by reaction conditions or substrate choices leading to 
destabilization of the alkoxide salt and stabilization of the carbanion. Typically, the 
former is accomplished by the choice of metal cations of decreased oxophilicity (e.g. K 
vs. Li) and/or utilization of polar aprotic solvents (THF), co-solvents (HMPA, DMPU) or 
chelating additives (crown ethers) that contribute to the dissociation of the alkoxide-metal 
cation pair. The latter, in turn, requires preinstallation of Anion-Stabilizing Groups 
(ASG) such as dithianes, nitriles and vinyl groups on the pronucleophilic site.3,4  
Brook proposed that the reaction proceeds intramolecularly through a silicon-ate 
species.5 Interestingly, later results evidenced that the rearrangement entails retention of 
stereochemical configuration at the silicon center and inversion at carbon,6 although in 
certain cases, as shown by Brückner,7 the carbon configuration is retained. These results 
were more recently reconciled by ab initio calculations reported by Wang and co-
workers.8 Following the early observations by Brook on [1,2]-rearrangements, analogous 
processes involving [1,n]-Brook rearrangements (2 < n < 7) were reported,3 with the 
following limitations: (i) when n = 3, although some cases are known to lead to the 
expected silyl ethers,9 the Brook rearrangement pathway competes with an elimination 
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pathway, a feature exploited early on in the now well known Peterson olefination;10 (ii) 
the less efficient [1,6]-Brook rearrangement, contrary to its lower order congeners, 
proceeds both inter- and intra-molecularly, as evidenced by the formation of crossover 
products.11 In the following paragraphs, focus will be made on synthetic tactics exploiting 
[1,4]-Brook rearrangements. 
 
Early Fragment Unions Exploiting Through-Space Anion Relay Chemistry: Type I 
The first example of a controlled tricomponent fragment union exploiting a Brook 
rearrangement was reported by Matsuda et al. in 1979.12 Specifically, deprotonation of 
trimethylsilylacetonitrile (1.6) with LDA, followed by addition of a first epoxide (1.7), 
gave rise to alkoxide 1.8. Warming then promoted a [1,4]-Brook rearrangement leading 
to the formation of nitrile-stabilized carbanion 1.9, which, in the presence of a second 
epoxide (1.10) followed by quenching with TMSCl, led to adduct 1.11 in 73% yield. The 
critical observation by Matsuda that gave rise to this seminal result was the following: at 
lower temperatures (< –30 ºC) alkoxide 1.8 was kinetically stable, therefore ensuring 
complete consumption of the first epoxide (1.7) prior to promoting the desired Brook 
rearrangement and capture of the second epoxide (1.10) upon warming. Conversely, at 
higher temperature (> –20 ºC), alkoxide 1.8 was demonstrated to prematurely 
undergoBrook rearrangement, leading to symmetrical adduct 1.12 and pronucleophile 
1.13. 
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Scheme 1.2. Early Results from Matsuda et al. 
More recently, the Schaumann13 and Tietze14 groups reported virtually simultaneously 
the use of lithiated silyl-dithiane 1.14 as an initiating nucleophile in unions exploiting 
[1,4]-Brook rearrangements. Schaumann described the reaction of 1.14 in conjunction 
with a dielectrophile, 1.15, whereby attack of the more reactive epoxide terminus, 
followed by Brook rearrangement permitted intramolecular tosylate displacement, 
leading to spirocyclic adduct 1.16. Tietze, in turn, demonstrated that deprotonation of 
1.14 and addition of epoxide 1.17 (> 2 equivalents) in the presence of 12-C-4, followed 
by protic work-up and fluoride-mediated desilylation gave rise to C2-symmetrical adduct 
1.18. Although, contrary to the Matsuda precedent,12 no control of the Brook 
rearrangement was demonstrated here. Importantly, implementation of the dithiane group 
as anion-stabilizing functionality thereby set a valuable precedent given the potential to 
access hydroxyketones (1.19) and stereodefined polyols (1.20) by hydrolysis and 
subsequent reduction. 
TMS
CN i. LDA, DME
ii.
R
O TMS
CNO
R
CNO
R
TMS O CNO
R
TMS
iii. OH
iv. H+
1.6 1.91.8 1.11
CNO
R
TMS OH
R
1.12
R = Me: 73%
CNO
R
TMS
1.13
+
(1 equiv)
rt
–30 ºC
i.–iv.
1.6
1.7
1.10
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Scheme 1.3. Early ARC Tactics Employing TMS-Dithiane (1.14) 
Efforts towards controlling the timing of the Brook rearrangement via the choice of 
appropriate solvents were later reported by Oshima et al. Specifically, unsymmetrical  
tricomponent adducts were obtained employing halogenated (1.21)15 and allyl-bearing 
(1.24)16 linchpins. In this case, solvent choice proved crucial: a THF/Et2O (1:2) mixture 
was required to achieve the balance between reactivity of the linchpin and stability of the 
resulting alkoxide. In this setting, addition of a polar co-solvent (HMPA) was 
demonstrated to efficiently “trigger” the desired Brook rearrangement, permitting capture 
of a second electrophile (Scheme 1.4). 
Given a longstanding interest in natural product synthesis, the Smith group recognized 
the potential of allying the synthetic utility of the dithiane moiety as a carbonyl 
surrogate,17 with protocols permitting efficient control of the Brook rearrangement. Smith 
and then graduate student Armen Boldi indeed demonstrated that diverse unsymmetrical 
adducts could be constructed by deprotonation of 2-TBS-1,3-dithiane (1.27, Scheme 1.5)  
SS
TMS H
i. n-BuLi, THF
ii. 12-C-4,
R
O
1.17
iii. H2O
iv. NaF
SS
R R
OHOH
1.14 1.18
R = Ph: 65%
R = Me: 89%
B
A
SS
TMS H
i. n-BuLi, THF
ii.
1.15
iii. H+1.14
OTs
O
HO
S
S
1.1665%
R R
OHOH
R R
OHOH
O
Y
1.19
1.20
Y = H or OH
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Scheme 1.4. Tricomponent ARC Fragment Unions Controlled by HMPA 
in Et2O, addition of an epoxide (e.g. 1.28), followed by addition of a terminating 
electrophile (e.g. 1.29) in solution in Et2O and HMPA.18 This protocol found immediate 
application in total synthesis, with perhaps the most notable case being that of the 
spongistatins, where the ARC step run consistently in decagram scale permitted the 
required material throughput to complete the synthesis.19 
 
Scheme 1.5. Tricomponent Fragment Union in the Synthesis of the Spongistatins 
A common feature of the ARC tactics discussed thus far, regardless of the linchpin 
involved, lies in the fact that the negative charge is transferred back (in these cases via 
Brook rearrangement) to the initially nucleophilic locus. These linchpins thus comprise 
i. LDA, THF
ii.
R
O
1.22
iii. MeI, HMPA
XX
MeR
O
1.21 1.23
X = Br: 60%
X = Cl: 68%
TBS H
X X
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Ph3Si SiPh3
A
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ii. O
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1.24
–78 ºC to rt
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1.26 OSiPh3
Ph
OH
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BnO
OR OR SS OH ORBnO
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O
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OMe
H
Oii.
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1.27
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–78 ºC to rt
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synthons where the same carbon atom is twice nucleophilic. This feature was chosen to 
define Type I ARC, given the emergence of a conceptually distinct kind of Through-
Space ARC, to be discussed next. 
 
Through-Space Anion Relay Chemistry: Type II 
As defined a posteriori, in Through-Space Type II ARC protocols charge relay occurs 
to a distal site. The first example of such protocol was reported by Moser et al.,20 who 
demonstrated that a chromium complex of o-TMS-benzaldehyde (1.31), following 
nucleophilic attack at the aldehyde functionality, could undergo [1,4]-Brook 
rearrangement and subsequently capture an electrophile at the o-position leading to 
tricomponent adducts such as 1.32. The negative charge, initially borne by an external 
nucleophile, is thus transferred via Brook rearrangement to the linchpin (Scheme 1.6 A). 
The first incursion by the Smith group into Type II ARC was in turn illustrated by the 
design and validation of a linchpin able to react first as a vinyl nucleophile, and, 
following [1,4]-Brook rearrangement, as an allyl nucleophile (1.33, Scheme 1.6 B).21  
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Scheme 1.6. First Examples of a Type II ARC Tricomponent Fragment Union 
This example of a bis-nucleophilic Type II linchpin rapidly became an outlier: soon 
thereafter, the Smith group reported a series of linchpins also exploiting [1,4]-Brook 
rearrangements, all of which first undergo nucleophilic attack at an epoxide or aldehyde 
terminus, and upon triggering the rearrangement, are capable of relaying the negative 
charge to generate a stabilized anion to terminate the tandem reaction by trapping of an 
electrophile. The first example in this important series was 1.35,22 with several congeners 
following (see 1.36-1.41, Figure 1.2).23–27  
 
Figure 1.2. Examples of Validated Type II Bifunctional Linchpins 
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1.38OTf
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This approach to Type II Anion Relay Chemistry rapidly found application in natural 
product synthesis.23 The new generation of linchpins, carrying more functionality and 
stereochemical information than their Type I predecessors, however, were also quickly 
recognized as particularly well suited to the construction of “natural-product-like” 
compound libraries following the tenets of Diversity-Oriented Synthesis (DOS).1 A series 
of piperidines was thus efficiently prepared utilizing 1.35.28 In this particular case, 
Schlosser base was employed to generate the initial nucleophile (from 1.42): the Type II 
sequence could then be carried out in THF with the Brook rearrangement triggered by 
warming to 0 ºC, as opposed to by addition of a polar additive such as HMPA (Scheme 
1.7). 
 
Scheme 1.7. Piperidine Synthesis Exploiting Type II Linchpin 1.35 
Another important implication of these later examples of Type II ARC bifunctional 
linchpins, which carry both electrophilic and protonucleophilic termini, is the theoretical 
possibility of constructing increasingly complex scaffolds by iterative addition of 
linchpins. An example of a four-component fragment union involving two bifunctional 
linchpins is illustrated in Scheme 1.8.23 
Me H
SS
1. i. t-BuLi, t-BuOK
    ii. Linchpin 1.35
    iii. PhTsN *
THF, –78 to 0 ºC
2. TBAF, THF Me
SS OH SS
*
NHTs
Ph
*
1.42 1.44
All stereoisomers prepared
Ts
N PhMe
S S
S S
* *
55-87%
1. MsCl, Et3N
2. NaH
1.4569-74%
(2 steps)
Followed by 
dithiane hydrolysis,
reduction...
1.43
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Scheme 1.8. Example of Four-Component Type II ARC Fragment Union 
 
In the first chapter of this dissertation, the development of a unified synthetic strategy 
towards a small family of natural products exploiting ARC will be discussed. 
  
O
O
OMe
SS SSO
OTMS
O
O
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SS
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H
SSO
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i. t-BuLi, t-BuOK
H
1.46
1.35
ii.
iii.
iv. Allyl bromide
TBS
1.36
Single flask, 44% yield
1.47
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Chapter 1: A Unified Synthetic Strategy to the Cryptocarya Family of 
Natural Products Exploiting Anion Relay Chemistry 
 
As discussed above, Anion Relay Chemistry (ARC) comprises a powerful tool: (i) to 
assemble complex fragments in natural product total synthesis;29 and (ii) for application 
to Diversity-Oriented Synthesis (DOS), that is, the potential for rapid introduction of 
structural complexity from readily available fragments.27,28 In seeking to develop this 
latter facet of ARC further, we became interested in a family of biologically active, 
polyol-containing, dihydro- and tetrahydro-pyrone natural products (Figure 1.3).  
 
Figure 1.3. Synthetic Targets 
Target Selection and Prior Art 
The synthetic targets of choice belong to a structural class well known to the 
biomedical and synthetic community.30 In fact, both the bark of South African 
Cryptocarya latifolia and Chinese ant Polyrhacis lamellidens, natural sources of 1.48–
1.5131,32 and 1.5233 respectively, are used in traditional medicine as analgesics. In recent 
O
O
OAc OAc OAcO
O
OAc OAc
O
O
O OR OR
(+)-Cryptocarya diacetate 1.48 (+)-Cryptocarya triacetate 1.49
(–)-Cryptocaryolone 1.50 (R = H)
(–)-Cryptocaryolone diacetate 1.51 (R = Ac)
(+)-Polyrhacitide A 1.52
OHOHO
O
O
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years, information about possible mechanisms of action of congeners of this structural 
class has emerged from the studies of Carda et al.,34 who demonstrated that compounds 
such as 1.53 (Figure 1.4), structurally related to 1.48 bind α-tubulin via conjugate 
addition of residue Lys352 onto the α,β-unsaturated lactone. Other closely related natural 
products, the cryptocaryols (see Figure 1.4),35,36 although structurally more complex, are 
known to effect cytotoxicity in cancer cell lines, presumably via stabilization of PdCD4 
(Programmed Cell Death 4), a protein whose expression was found to be downregulated 
in cancer cells.36 
 
Figure 1.4. Related Compounds: 1.53 and Cryptocaryol A (1.51) 
Individual members and subsets of the natural product family targeted in this project 
have been the aim of numerous synthetic ventures. The first report, by Nakata,37 
described a synthesis of 1.48 and 1.49 exploiting a diastereoselective allylstannation as 
chain-elongating step, and relying notably on a Sharpless asymmetric epoxidation38-
reductive epoxide opening39 sequence to install the requisite polyol stereochemistry. The 
resulting synthetic intermediate (1.57) was then subjected to a 7-step synthetic sequence 
to complete target 1.48, and to a 13-step sequence to complete 1.49 (Scheme 1.9). 
OMeOMe
n-C12H25
O
O
1.53
OHOHOH
n-C15H31
O
1.54
O
OH OH
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Scheme 1.9. Nakata Synthesis of 1.48 and 1.49: Key Transformations 
O’Doherty and co-workers later studied the synthesis of 1.48,40 then extending the 
resulting method to the synthesis of more complex 1.49. Specifically, in this case, the 
chain-elongating step comprised a cross-metathesis reaction giving rise to an 
hydroxylated acrylate such as 1.58, then subjected to an elegant tandem intermolecular 
hemi-acetalization/ diastereoselective oxa-Michael cyclization to install the requisite 1,3-
syn-diol functionality. A four-step chain elongation then set the stage for a second 
iteration of the key step, eventually permitting completion of 1.49 (Scheme 1.10). 
 
Scheme 1.10. O’Doherty’s Synthesis of 1.49: Key Transformation 
Yadav and co-workers resorted to similar approaches, installing 1,3-syn-diols in 
diastereoselective fashion via iteration of intramolecular reactions. Two studies published 
in 2011 thus demonstrated the synthesis of polyrhacitide A (1.52): a synthetic study41 
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exploiting iterative use of iodo-carbonate cyclizations was followed by another utilizing 
O’Doherty’s chemistry42 as described above.  
In turn, the Waldmann group43 demonstrated the use of a solid support enabling 
iterative applications of a sequence comprising (i) asymmetric allylation, (ii) ozonolysis 
and (iii) silyl ether protection for the synthesis of 1.48 and a putative precursor to an 
epimer of 1.49 (Figure 1.4). The solid-supported synthesis, in this case relying on a 
polystyrene resin tethered to the substrate via a benzyl ether linkage, was completed with 
a DDQ-mediated substrate-releasing step. This strategy enabled the preparation of close 
precursors to the less complex congeners (1.48 and stereoisomers) in yields up to 60% 
over 10 steps, but targets requiring further iterations of the allylation-ozonolysis sequence 
resulted in lower yields (2% overall; see 1.63, Scheme 1.11). 
 
Scheme 1.11. Solid-Supported Synthesis of a Polyol Precursor by Waldmann et al. 
Another iterative approach to members of this family of natural products can be found 
in the work of Kirsch.44 In this approach, elongation of the carbon framework was 
accomplished by Ando olefination,45 resulting in the selective formation of a (Z)-acrylate, 
subsequently reduced and condensed to form a trichloroacetimidate (1.66). This 
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intermediate operated as the substrate for an Overman esterification46 catalyzed by 
palladium(II) complex (+)-COP-OAc (1.67). Although the stereoselectivity of the key 
esterification was dictated exclusively by the choice of catalyst [(–)-COP-OAc gave rise 
to diastereomers without loss of selectivity], the application of this chemistry came at the 
cost of a long synthetic sequence, counting in excess of 30 steps to complete (+)-
polyrhacitide A (1.52, Scheme 1.12). 
 
Scheme 1.12. Kirsch Approach to the Synthesis of 1.52. 
Finally, She47 and collaborators exploited a three-component ARC fragment union to 
access the carbon skeleton of cryptocarya triacetate 1.49. This synthetic strategy, 
however, cannot be extended to different (e.g. longer) scaffolds and requires the pre-
elaboration of comparatively complex starting materials, such as 1.69. 
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Scheme 1.13. She Synthesis of 1.49 Exploiting Type I ARC 
 
Retrosynthetic Analysis 
With this precedent, we postulated that four-component ARC fragment protocols 
would give access to the complete carbon frameworks of all our targets (1.45-1.49) from 
a limited pool of simple substrates. Beyond the scope of these synthetic studies lies our 
goal of a more general ARC whereby the controlled repetition of anion relay may, in one 
synthetic operation, lead to the construction of fully functionalized polyketide precursors. 
Our global retrosynthetic analysis is outlined in Scheme 2. All our targets may stem 
from either poly-acetylation or oxa-Michael cyclization of polyol derivatives, which 
could in turn derive from diastereoselective reductions of suitable hydroxy-ketones 
(1.73). Formation of the dihydropyrone motif may in turn result from a ring-closing 
metathesis of 1.74. Finally, the corresponding precursors (1.75) may be constructed by 
appropriate ARC tactics: Type I in the case of 1.48 and Type II in that of 1.49-1.51. The 
synthesis of 1.52 would be carried out via a simple variation of building blocks (vide 
infra). Each of our targets’ complete carbon framework would thus result from the union 
of simple fragments in a single operation (Scheme 1.14). 
O O OHSSOS S
TES
++
OTBS O
Type I
ARC
1.69 1.721.711.70
1.49 11 steps longest linear sequencefrom 1,6-heptadien-4-ol6 steps
TESTBS
(74%)
 19 
 
Scheme 1.14. Global Retrosynthetic Analysis 
Total Synthesis of Cryptocarya Diacetate 
Cryptocarya diacetate 1.48 embodied a useful first research model in the sense that it 
fueled the development of reaction conditions both for the ARC key step and for further 
transformations. In this case Type I ARC was employed, whereby after nucleophilic 
attack of (S)-methyl oxirane 1.71 by lithiated 1.27, a solvent-triggered Brook 
rearrangement regenerates a carbon nucleophile at the 2-position of the dithiane moiety, 
allowing for trapping of a second electrophile. As previously reported by our group,48 the 
lack of a stabilizing silyl-group on the newly formed dithiane anion results in a 
significant increase in basicity. This limits the use of allyl-oxiranes as second 
electrophiles, which are prone to elimination. In previous cases, simply inverting the 
order of electrophile addition solved this problem;48 nonetheless, in an effort to develop a 
general synthetic approach to our targets and to minimize protecting-group manipulation, 
we turned to (S)-epichlorohydrin 1.77 as second electrophile. Indeed, under our reaction 
conditions, lithio-dithianes are known to attack exclusively the 3-position,11 and the 
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resulting chlorohydrin anion 1.79 was found to be stable at –40 ºC. Formation of a new 
terminal epoxide can next simply be promoted by warming the reaction to room 
temperature. It was also found that introducing epichlorohydrin prior to triggering the 
Brook rearrangement resulted in increased coupling efficiency. At this point, copper-
catalyzed vinylmagnesium bromide addition to epoxide 1.80 afforded the desired adduct 
1.81 after aqueous work-up. Compound 1.81 was thus obtained in 75% yield from 
commercially available 1.71 in a single flask. On average, this represents a yield of 90% 
for each of the three carbon-carbon bonds formed in this single operation (Scheme 1.15). 
 
 
Scheme 1.15. Type I ARC in the Synthesis of Cryptocarya Diacetate 1.48  
Dithiane 1.81 was subjected to mercury(II)-mediated hydrolysis conditions,49 which in 
this case proved to be more efficient than oxidative dithiane removal protocols (see Table 
1.1).50,51 Treatment with acryloyl chloride in the presence of Hünig’s base (diethyl 
isopropyl amine, DIPEA)52 afforded acrylate 1.83 in 97% yield over two steps (Scheme 
1.17). Ring-closing metathesis (RCM) was then carried out under microwave irradiation 
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using Hoveyda-Grubbs 2nd generation catalyst (HG-II),53 forming lactone 1.84 in 87% 
yield.  
 
Table 1.1. Optimization of Dithiane Hydrolysis 
Dithiane removal prior to RCM, as well as protection of the neighboring alcohol 
proved to be beneficial to this transformation. The silyl protecting group was next 
removed in 84% yield employing trifluoroacetic acid (TFA) and thioanisole,54 thus 
setting the stage for a Narasaka55-Prasad,56 syn-diastereoselective reduction of 1.84. Even 
though the reduction itself proceeded smoothly, initially only a boronate derivative could 
be isolated instead of the expected product. We found methanolysis to be the most 
effective way to obtain the desired free diol 1.51 (70% yield), which could be bis-
acetylated to afford cryptocarya diacetate 1.48 in 66% yield, totaling 25% for the 
complete seven-step sequence from methyloxirane 1.71 (Scheme 1.17). 
 
OTBSOH OOTBSOH ConditionsSS
(–)-1.81 (–)-1.82
Entry Reagent Yield
1 NCS, AgNO3 56%
2 55%
3 HgCl2, CaCO3 99%
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CH3CN/H2O
0 ºC
0 ºC to rt
65 ºC
PhI(OC(O)CF3)2
Solvent Temperature
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Scheme 1.17. Total Synthesis of Cryptocarya Diacetate 1.48 in Seven Steps 
 
Synthesis of Cryptocarya Triacetate (1.49) and Related Congeners 
As discussed previously (see Scheme 1.14), the syntheses of the homologous 
cryptocarya triacetate 1.49 and related natural products cryptocaryolone 1.50 and 
cryptocaryolone diacetate 1.51, in turn, were projected to rely on a Type II ARC tactic 
introducing an additional alcohol motif in the target’s polyol skeleton. 
Moving forward, the ARC union of dithiane 1.42, bifunctional linchpin 1.35 and 
epichlorohydrin 1.7711 followed by addition of vinylmagnesium bromide afforded 
homoallylic alcohol 1.87 in 52% yield. The subsequent dithiane hydrolysis could not be 
optimized beyond a 52% yield, despite screening of different HgCl2:CaCO3 ratios and 
temperatures. What was found, however, was that, even at cold temperatures, the reaction 
reaches completion rapidly (< 60 min). Closely monitoring the reaction thus permitted, 
minimally, to achieve reproducibility. Next, formation of acrylate ester 1.89 and ring-
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closing metathesis under the conditions optimized for 1.48, furnished 1.90 in very good 
yield (Scheme 1.18), the structure of which was confirmed by X-ray crystal analysis. 
 
Scheme 1.18. Tricomponent Type II ARC Union and Further Elaboration 
The next step, which required optimization, was the deprotection of 1.90 to form 
alcohol 1.91 (Table 1.2). Prone to elimination, 1.90 could not be subjected to basic 
conditions for deprotection. Various acids were screened, a near quantitative yield being 
eventually achieved with trifluoroacetic acid (TFA) in the presence of water as a 
nucleophile.54 In hindsight, the steric hindrance introduced by the additional 
methylketone moiety, and the possible competition of the dihydropyrone moiety 
(Michael acceptor), are consistent with the need for a small, hard nucleophile. 
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Table 1.2. Optimization of TBS Removal 
 Next, we focused our attention on the diastereoselective reduction of diketone 1.91. 
Only one example of a double diastereoselective reduction of the sort was found in the 
literature,57 but the corresponding, protocol, employing Dibal-H, proved to be 
incompatible with 1.91. Turning back to the Narasaka-Prasad reduction,55,56  we reasoned 
that, because carbonyl reduction by sodium borohydride occurs only by internal 
activation in a preformed diethylalkoxy borane (1.92, Scheme 1.19), a stoichiometric 
amount of Brønsted acid (e.g. methanol, present as co-solvent) could induce formation of 
 
 
Scheme 1.19. Rationale for Double syn-Reduction 
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a second activation complex (1.96) following the first reduction. This would ensure the 
double syn-diastereoselectivity. 
Pleasingly, the reduction proceeded as planned, furnishing a single diastereomer of 
1.98 (Scheme 1.19). Difficulties, however, arose from the high water solubility of this 
triol. It was found that avoiding aqueous work-up conditions after reduction, and taking 
the crude material on to further steps instead, resulted in a more efficient two-step 
sequence. Specifically, peracetylation of 1.98 (Scheme 1.20) resulted in cryptocarya 
triacetate 1.49 in 65% yield (17% overall from 1.35), whereas cyclization furnished 
cryptocaryolone 1.50 in 60% yield (16% overall from 1.35). Further bis-acetylation58 of 
1.50 afforded cryptocaryolone diacetate 1.51 in near quantitative yield. Preparation of 
targets 1.49-1.51 from commercially available material (i.e., 2-TBS-1,3-dithiane) thus 
required a total of 8-9 steps (longest linear sequence). 
 
 
Scheme 1.20. Completion of Targets 1.49-1.51 
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Synthesis of (+)-Polyrhacitide A (1.52) 
To access polyrhacitide A (1.52), we exploited the previously developed ARC Type II 
protocol, now employing n-heptyldithiane 1.99 as the initiating nucleophile (prepared by 
condensation of 1,3-propanedithiol and n-octanal).59 The change in nature of the dithiane 
alkyl chain, however, had a detrimental impact on the ARC reaction efficiency (36% 
yield), probably due to the increased steric hindrance at the dithiane nucleophilic carbon 
(Scheme 1.21). Notwithstanding this shortcoming, the reaction was carried out on gram-
scale, thus readily furnishing material to complete the synthesis following a similar route 
designed for 1.49-1.51. Specifically, dithiane removal, acylation of the homoallylic 
alcohol and ring-closing metathesis led to dihydropyrone 1.101 (59% over 3 steps). 
Removal of the TBS protecting group (95%), syn-diastereoselective reduction (83%) and 
oxa-Michael cyclization (98%) then completed construction of polyrhacitide A (1.52), in 
a total of 7 steps and 16% overall yield from (–)-1.35 (Scheme 1.21). 
 27 
 
Scheme 1.21. Synthesis of Polyrhacitide A (1.52) 
In summary, exploitation of Type I and Type II ARC tactics led to the development of 
a unified synthetic strategy towards polyol-containing dihydropyrone natural products 
1.49-1.51. Cryptocarya diacetate (1.48) comprised a useful model to develop a four-
component Type I ARC fragment union that was later translated to the synthesis of 1.49-
1.52, where application of a Type II protocol with a common termination strategy 
permitted introduction of the requisite additional two-carbon alcohol unit. In these cases, 
a double directed syn-reduction was critical to complete stereoselective functionalization 
of the polyol side-chain. Overall, requiring 7-9 steps from commercially available 
materials to synthesize each target, this unified strategy exploiting ARC compares very 
favorably to previous syntheses in terms of efficiency. 
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Chapter 2: A New Aldehyde Bifunctional Linchpin for Type II Anion Relay 
Chemistry. Application to the Synthesis of a C16-C29 Fragment of 
Rhizopodin. !
With extensive research, including this and prior work, on the synthesis of 
stereodefined polyacetate scaffolds utilizing Anion Relay Chemistry (ARC), our focus 
turned to polypropionate scaffolds. In particular, we became interested in designing a 
Type II linchpin capable of introducing a stereodiad with functionality potentially finding 
wide application in the synthesis of polyketide natural products. Linchpins comprising 
chirality in the α-position of the electrophilic termini had in fact already been investigated 
in the Smith group. !
Overview of α-Chiral Linchpins for Type II ARC 
Precedent for the design and validation of Type II linchpins with additional elements 
of chirality can be found in the work of Tong25,26 and Kim.26 Examples are shown in 
Figure 1.5. In discussing the applicability and potential improvement of these linchpins to 
the synthesis of polypropionates, the following critical aspects need to be considered: (i) 
nature of the electrophilic terminus; (ii) strategy for transfer of chirality; (iii) possibility 
for post-Brook carbanion stabilization; and (iv) synthetic versatility of the anion-
stabilizing group. From this perspective, aldehyde termini, advantageous in terms of 
reactivity (i.e., reacting efficiently with wider scope of nucleophiles), do not offer the 
possibility of pre-construction of any of the four possible stereoisomers of the central 
stereodiad. In fact, among the examples shown here (Figure 1.5), all aldehyde linchpins 
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undergo nucleophilic attack under Felkin-Anh control60 leading to syn-stereodiads. Next, 
the stability of the anion derived from Brook rearrangement pertains to the applicability 
of these strategies in terms of functional group compatibility. The phenylthioalkyl and 
benzyl anions derived from 1.39 and 1.40-1.41 respectively, are 3 to 4 orders of 
magnitude (i.e., pKa units) more basic than the classic dithianyl anion,61–63 and as such 
might pose problems when applied to complex molecule synthesis. This is not the case 
for 1.104 and 1.105, where the Brook rearrangement is triggered by addition of Cu(I), 
resulting in a much softer, less basic nucleophile, which has been shown to readily 
undergo palladium-catalyzed cross-coupling reactions, an additional advantage. A 
disadvantage in this case, however, is the requirement for excess nucleophile for the 
Brook rearrangement to proceed efficiently.26 Finally, in terms of applicability to 
polyketide synthesis, the integration of a benzylic group within the main carbon chain 
(1.40-1.41) restricts the use of the linchpin. In turn, thioethers (1.37) and, especially, an 
exomethylene (1.104-1.105) provide an increased versatility, the latter via stereoselective 
  
 
Figure 1.5. Examples of α-Chiral Type II Linchpins 
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reduction or ozonolysis for example. Once again the dithiane moiety, given the 
possibility for either direct reduction to methylene or relatively mild hydrolysis to a 
ketone, appears to be a better candidate. 
 
Method Studies: An α-chiral Dithiane Linchpin for Type II ARC 
Given this analysis, ideal candidates for the development of ARC tactics applicable to 
polypropionate synthesis would be the dithianes shown in Figure 1.6. While epoxide 
1.107, subject of early studies in the Smith group, did not demonstrate sufficient 
electrophilicity to become a viable linchpin,64 postdoctoral associate Dr. Ming Z. Chen 
undertook the synthesis and evaluation of aldehyde 1.108. 
 
Figure 1.6. Possible Linchpins for Polypropionate Synthesis 
Aldehyde 1.108 was indeed first prepared in racemic series by Dr. Chen commencing 
with commercially available diol 1.109. Protection as the mono-trityl ether, followed by 
Swern oxidation and dithiane formation gave rise to 1.110 in high yield. Bis-lithiation 
followed by bis-silylation and O-desilylation set the stage for a final Parikh-Doering 
oxidation, providing 1.108 in 53% yield over 5 steps (Scheme 1.22). !
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Scheme 1.22. Synthesis of 1.108 in Heterochiral Series 
Following linchpin preparation, Dr. Chen examined the reactivity, including the 
possibility of exerting controlled Brook rearrangements, followed by appropriate capture 
of electrophiles. As expected, addition of a model nucleophile (n-BuLi) proceeded 
smoothly. Interestingly, however, the presence of THF (co-solvent) led to premature 
Brook rearrangement, with only silyl ether 1.112 being formed upon protic workup 
(Scheme 1.23). Less dissociating Et2O, in turn, permitted capture of the pre-Brook 
alcohol intermediate (1.111). Finally, addition of polar HMPA prior to protic quench 
cleanly furnished the expected product of the [1,4]-Brook rearrangement (1.112). 
Pleasingly, only one diastereomer of either 1.111 or 1.112 was observed. At this stage, 
the relative stereochemistry was assigned as syn by analogy with adducts obtained with 
α-methyl-β-trimethylsilyl aldehyde linchpins (Figure 1.5).25,26 
!!
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With these encouraging results, a brief study was initiated and led by Dr. Chen to 
determine (i) the scope of the reaction in terms of nucleophiles and electrophiles 
tolerated, and (ii) the consistency of the level of diastereoselectivity. Thus, first 
maintaining allyl bromide as the terminating electrophile, tricomponent adducts 
generated by addition of n-butyl lithium (1.114, Table 1.3), phenyl lithium (1.115), allyl 
lithium (1.116) and lithiated 2-methyl-1,3-dithiane (1.118) were observed, all in good 
yield and with only one diastereomer detected by 1H NMR in the crude reaction mixtures. 
Pleasingly, the X-ray crystal structure of 1.115 confirmed the assignment of 
diasteroselectivity. Use of lithiated benzylacetylene also gave rise to the desired 
tricomponent adduct (1.117) in good yield (66%) despite the presence of relatively acidic 
protons, both benzylic and propargylic. 
Choosing now n-butyllithium as the initiating nucleophile, different electrophiles were 
assessed in the ARC manifold. Termination with benzaldehyde led to alcohol 1.119 in 
72% yield, with, as expected, no selectivity upon the terminating reaction. Epoxides, in 
turn, exhibited satisfactory reactivity (see 1.120 and 1.121, isolated as diasteomeric 
mixtures given that the study was carried out with racemic linchpin). In particular, use of 
epichlorohydrin resulted in adduct (1.122) in 74% yield, opening the possibility for 
further functionalization by a subsequent nucleophilic attack. 
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Table 1.3. Reaction Scope 
 
Synthesis of Linchpin 1.108 in Homochiral Series 
With ongoing scope studies, validation of this new method logically required the 
synthesis of 1.108 in homochiral series, planned to proceed via known alcohol (1.110),65 
itself prepared from either enantiomer of Roche ester (1.123, Scheme 1.24). Thus, 
formation of the corresponding trityl ether followed by exhaustive reduction of the ester 
terminus furnished alcohol 1.125 in 90% yield. Next, Swern oxidation followed by 
dithiane formation with concomitant cleavage of the trityl ether furnished the desired 
intermediate (1.110), intercepting the synthesis of racemic linchpin (Scheme 1.22). The 
same lithiation-bissilylation-desilylation strategy was then employed, resulting in alcohol 
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1.127. At this point, both Swern and Parikh-Doering oxidations furnished the desired 
linchpin, although the former protocol resulted in formation of an unidentified by-product 
co-eluting with 1.108. Additionally, inconsistencies in optical rotation were observed 
employing the latter protocol, especially when run in larger scale, indicating the loss of 
stereochemical integrity in the last step of the sequence.  
 
Scheme 1.24. Synthesis of Linchpin 1.108 
Our attention first turned to the Swern oxidation, with the goal of identifying and 
suppressing the formation of by-product, attributed preliminarily to undesired oxidation 
of one or two of the dithiane sulfurs. Conditions were screened by varying the 
stoichiometry of oxalyl chloride, therefore varying the amount of formal oxidant present 
in the reaction —although the product-to-impurity ratio decreased, so did the conversion. 
Changes in the stoichiometry of DMSO and triethylamine also proved unproductive, as 
did quenching the reaction under reductive conditions, specifically employing aqueous 
sodium thiosulfate. 
Simultaneously, it was hypothesized that racemization following Parikh-Doering 
oxidations could arise from inefficient removal of residual pyridine during work-up. 
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Given pyridine’s relatively high boiling point (115 ºC), concentration of the reaction 
mixture prior to column chromatography could thus readily promote racemization via 
tautomerism. Washing the organic layers with saturated aqueous copper(II) sulfate prior 
to concentration was found to solve this problem. Indeed, (+)-1.109 was obtained in 
>99% enantiomeric excess as deemed by chromatography on chiral stationary phase. 
Enantiomer (–)-1.108, later synthesized and crystallized by postdoctoral associate Dr. 
Roberto Forestieri employing this method, also exhibited high levels of optical purity. 
 
Scheme 1.25. Optimized Synthesis of (+)- and (–)-1.108 
With enantioenriched linchpin in hand, we looked to obtain confirmation that addition 
of n-butyl lithium proceeds under Felkin-Anh control (like phenyl lithium, as deemed by 
crystallographic evidence). Aldehyde (+)-1.108 was thus subjected to nucleophilic attack 
by n-butyllithium under the now standard reaction conditions. Protic quench at low 
temperature (–78 ºC) then gave rise to alcohol (+)-1.128, subsequently subjected to 
Steglich esterification conditions employing (R)- and (S)- Mosher acids. The 
corresponding esters were analyzed by 1H NMR. The assumption of syn-coplanarity 
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between (i) the carbinol C–H bond, (ii) the ester carbonyl, and (iii) the C–CF3 bond,66 
leads in particular to expect the shielding of the dithiane and TMS protons by the phenyl 
group in the Mosher ester 1.129-R. Conversely, the butyl side-chain should be shielded in 
congener 1.129-S. This should be further confirmed by shielding of the methoxy group 
by the TMS-dithiane system. These expected trends were confirmed experimentally (see 
Table 1.4), leading to the assignment of the carbinol stereocenter as (S). Knowing the 
absolute stereoconfiguration of the linchpin stereocenter to be (R), the relative 
configuration of the adduct was confirmed as syn, and rationalized as arising from 
nucleophilic attack to the linchpin under Felkin-Anh control. We next aimed to 
demonstrate the utility of the new method by constructing a more complex scaffold. !  
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Table 1.4. Mosher Ester Analysis of Model Adduct 1.128 
 
Application to the Synthesis of a C16-C29 Fragment of Rhizopodin 
We thus turned to the C16-C29 fragment of macrodiolide natural product rhizopodin 
(1.130) (and of the monomeric congener, monorhizopodin 1.131, Figure 1.7). First 
isolated from the bacterium Myxococcus stipitatus by Sasse et al.,67 1.130 was found in 
the same study to inhibit cancer cell growth at nanomolar concentrations without causing 
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cell death, later attributed to selective, nanomolar inhibitor of actin polymerization.68 
Initially believed to be monomeric (cf. 1.131), the dimeric nature of 1.130 was elucidated 
by Horstmann and Menche by extensive NMR studies, also leading to the assignment of 
relative and absolute stereoconfigurations.69 This result was later confirmed by Sasse and 
Jansen,70 followed by the publication of the crystallographic structure of a 1.130:G-actin 
complex, whose stability was, precisely, purported to prevent further actin aggregation.71 
 
 
Figure 1.7. Structures of Rhizopodin (1.130), Monorhizopodin (1.131) 
 
Prior relevant synthetic work and retrosynthetic analysis 
To date, two syntheses of 1.13072,73 and one of 1.13174  have been completed, with 
several constructions of various segments also reported.75–80 In examining the prior work, 
two key strategies emerge as particularly common: formation of the oxazole ring by 
amide coupling-cyclodehydration, and installation of the C6-C9 (E,E)-diene by 
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synthesis of 1.131 by Nicolaou et al., in which the C15-C16 bond is constructed by the 
remarkable samarium(II)-mediated Barbier coupling of a C16-C22 fragment with the 
complete C1-C15 fragment 1.133. Although the coupling resulted in little 
diastereoselectivity, this issue corrected in facile manner via reoxidation and reduction.74 
Also of interest, the enamide terminus (at C29) could be installed at very late stages, both 
in the Nicolaou synthesis and in that by Menche et al.,72 by condensation of N-formyl-N-
methylamine on a C29 aldehyde. 
Thus, we postulated that the ARC tactic employing the new linchpin 1.108 could help 
achieve higher convergence in the overall synthetic plan by permitting efficient 
construction of the C16-C29 segment 1.135 (Scheme 1.26): the protected primary 
alcohols, C16 and C29, could be successively converted to aldehydes, for union with the 
C1-C15 fragment enamide, and for enamide formation, respectively. Continuing with the 
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Scheme 1.26. Retrosynthetic Analysis 
retrosynthetic analysis, the C18-acetate could arise from asymmetric epoxidation of an 
olefin directed by the neighboring hydroxyl, followed by reductive epoxide opening. In 
turn, considering the C22-methylene as product of a dithiane desulfurization leads to 
1.135, a viable tricomponent ARC product resulting from the union of vinyl lithium 
1.136-Li, linchpin 1.108 and epoxide 1.137. 
 
Synthesis of ARC Components 1.136 and 1.137 
With linchpin (+)-1.108 in hand, the three-component fragment union required 
preparation of vinyl iodide 1.136 and epoxide 1.137. The former was synthesized in three 
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steps by mono-protection of diol 1.138, followed by oxidation and Takai olefination81 
(first executed by Dr. Chen, Scheme 1.27).  
 
Scheme 1.27. Synthesis of Vinyl Iodide 1.136 
Although the C24 stereocenter is ultimately irrelevant since in the natural product C24 
is a carbonyl carbon (see 1.130, Figure 1.7), carrying diastereomers of all intermediates 
through the end of the synthesis would be impractical. For this reason, Dr. Chen had 
initially synthesized the requisite epoxide as an epimeric mixture (at C24) and separated 
up to 50 mg of each pure diastereomer by medium pressure liquid chromatography 
(Scheme 1.28).  
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Although this route permitted access to sufficient material to validate the key step, the 
final chromatographic separation of diastereomers suffered from poor reproducibility and 
scalability. In addition, the relative stereoconfiguration of the purified diastereomers had 
to be assigned. The assignment of stereochemistry was carried out computationally using 
the simpler epoxides 1.138a and 1.138b as models. Specifically, the NMR chemical 
shifts of individual protons in 1.138a and 1.138b were calculated following geometry 
optimization, employing: (1) minimization of conformational energy (dihedral driver, 
double angle plot); (2) energy minimization using molecular dynamics (MM2); (3) 
geometry optimization at the B3LYP level of theory [6-311+G(2d,p) basis set]; (4) 
chemical shift calculation in benzene (Gaussian 09). For each resonance, the algebraic 
difference in chemical shift between the model diastereomers (Δδ[1.138b–1.184a]) was 
extracted and compared to the corresponding experimental values for 1.137a and 1.137b 
(Δδ[1.137b–1.137a]) to complete the assignment (Table 1.5). !  
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Proton 
Predicted 
Δδ[1.138b–1.138a] 
(ppm) 
Experimental 
Δδ[1.137b–1.137a] 
(ppm) 
5, 6, 7 +0.139 +0.178 
11, 12, 13 –0.039 –0.050 
18 –0.020 –0.210 
19 –0.051 –0.100 
21 –0.168 –0.040 
22 +0.142 +0.150 
23 +0.226 +0.240 
   
Table 1.5. Assignment of Relative Stereoconfiguration of Epoxides 1.137a and 
1.137b Using Models 1.138a and 1.138b 
Pleasingly, this stereochemical assignment matched the expected catalyst selectivity in 
Hydrolytic Kinetic Resolution (HKR, Scheme 1.29),82 which was exploited as an 
alternative to access diastereoenriched epoxide. However, the need to recycle the diol to 
maximize material throughput was considered a drawback. 
 
Scheme 1.29. Synthesis of 1.137a via Hydrolytic Kinetic Resolution (HKR) 
O
H H
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O
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[(R,R)-salen]CoII
(1.144, 5 mol%)
Me
OMe
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O
(–)-1.137a (25%)
+
Me
OMe
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HO
THF, 0 ºC to rt (–)-1.145 (40%)
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Ultimately, installation of the epoxide was effected by means of iodocyclization of 
Boc-carbonate 1.146 (Table 1.6). This final strategy seemed advantageous for two 
reasons: (i) the potentially high diastereoselectivity would maximize material throughput 
without need for recycling (like in the case of HKR); (ii) in the event of mediocre 
diastereoselectivity, the rigidity of the iodocarbonate product would greatly facilitate 
chromatographic separation of diastereomers. Interestingly, N-iodosuccinimide, known to 
work efficiently in Boc-carbonates of allyl- or syn-crotyl alcohols,83 did not exhibit good 
selectivity in our case of an anti-crotyl carbonate (1.146). Additionally, use of iodine 
resulted in loss of TBDPS protection. Iodine monobromide, as developed earlier in our 
laboratory,84 did furnish the desired iodocarbonate (1.147a) in good diastereomeric ratio 
(A:B 11:1). As expected, the minor diastereomer could be separated at this stage by 
column chromatography. 
 
Table 1.6. Optimization of Iodocarbonate Cyclization 
Me
OBoc
OTBDPS Me
O
OTBDPS
O
O
IConditions
Me
O
OTBDPS
O
O
I+
Entry I source Solvent T (ºC)
(–)-1.147a (+)-1.147b
A : B a
1
3
2
NIS
NIS
I2
CH3CNc
CH3CN
CH3CN
–40 to 0
–40 to 0
–20
1 : 1.1
--
1 : 2.7
Yield Ab
35%
--
14%
Notes
Loss of TBDPS.
Conversion: 49%. Recovered 1.146: 46%
4 IBr CH2Cl2 –80
8.5 : 1
64%
Yield Bb
38%
--
25%
--
5 IBr CH2Cl2 –80
11  : 1
61% Scale: 199 mg--
(50 mg)
(+)-1.146
a determined by 1H NMR of crude reaction mixture; b after chromatographic separation; 
c dried overnight over activated 4A molecular sieve
A B
 45 
These observations may be briefly rationalized by considering the steric constraints 
involved in the interaction of the iodinating agent with the substrate (1.148, Figure 1.8) in 
the two conformations leading to diastereomers 1.149a and 1.149b. Indeed, the “cis-
pathway” is typically favored over the “trans-pathway,” given, in the latter, A1,3 strain in 
the substrate conformation. In the “cis-pathway”, however, the olefin is in pseudo-
equatorial position, forcing the iodinating agent into a trajectory comprised in the plane 
of the forming ring. Although this trajectory appears unhindered when R1 is H, it might 
become associated with a steric penalty when the iodinating agent is bulky (e.g. NIS) and 
R1 is bigger than H (e.g. Me). This seems less relevant in the “trans-pathway,” given the 
pseudo-axial position of the olefin, resulting in an approach of the iodinating agent out of 
the plane of the forming ring. As a result, the penalties arising from the mentioned steric 
clash in the “cis-pathway” and from A1,3 strain in the “trans-pathway” might become 
comparable, explaining the loss of selectivity. 
 
Figure 1.8. Iodocarbonate Cyclization: Rationalization of Stereoselectivity 
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With the optimized iodocarbonate cyclization protocol, the preparation of epoxide (–)-
1.137a was completed by basic methanolysis followed by O-methylation. This sequence 
furnished the desired product in 40% yield over 4 steps from crotylalcohol (–)-1.142 
(Scheme 1.30). 
 
Scheme 1.30. Optimized Synthesis of Epoxide 1.137a 
 
Tricomponent Type II ARC Fragment Union and Further Elaboration 
With all components in hand (1.136, 1.108 and 1.137a), the key tricomponent Type II 
ARC fragment union could be attempted. To this end, iodide 1.136 was lithiated and 
added at –78 ºC to a solution of linchpin (+)-1.108. Monitoring by TLC deemed the 
addition to the aldehyde complete within 30 min. A solution in Et2O/HMPA (10:1) of 
epoxide (–)-1.137a, the limiting reagent, was then added to the alkoxide, still at –78 ºC. 
Gradual warming to room temperature resulted in formation of the desired adduct, 
comprising the complete C16-C29 framework, as a single stereoisomer. Pleasingly, this 
procotol proved to be quite consistent, with yields ranging from 57% to 75%. We found 
that, critical to this consistency, was stirring the solution of epoxide (–)-1.137a with 
calcium(II) hydride for 10 min and decanting it prior to addition. Although it is possible 
that this epoxide is particularly hygroscopic and calcium hydride does act as a drying 
Me
O1. NaHMDS,Boc2O (quant.)
2. IBr (61%)
(–)-1.142 (–)-1.147a
Me
MeO1. K2CO3,
MeOH (67%)
2. NaH, MeI 
      (99%)
O
OTBDPS
(–)-1.137a
I
O
O
OTBDPS
24
single diastereomer
OH
Me OTBDPS
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agent, it is not possible at this point to rule out electrophile activation via chelation 
(Scheme 1.31). 
 
Scheme 1.31. Tricomponent ARC Fragment Union 
Further functionalization of the ARC adduct 1.150 first required protection of the C24 
hydroxyl as a benzyl ether, which was expected to withstand silyl ether removal 
conditions. To this end, several conditions were explored (see Table 1.7). First, 1.150 was 
treated with sodium hydride and benzyl bromide in THF. No reaction was observed even 
upon warming to ambient temperature (entry 1); starting material was recovered. A more 
polar solvent was therefore chosen, specifically DMF, and again no reaction occurred at 
0 ºC, but upon progressive warming to 50 ºC full conversion was achieved. However, 
benzylation occurred with concomitant removal of the TMS protecting group; moreover, 
1H and 13C NMR data indicated formation of the benzyl ether, not at C24 but rather at 
C20 (1.153 entry 2). Small scale experiments conducted in THF and DMF revealed that 
the reaction could be accelerated in the presence of tetra-n-butylammonium iodide, but 
again to furnish the undesired isomer 1.153 (not shown). Two pathways for the formation 
of 1.153 were considered: (i) loss of TMS caused by adventitious nucleophile (e.g. NaOH 
TMSO
Me
SS OH
Me
OMe
OTBDPSMe Me
TBSO
O
Me
TMS
SS
H
i.
ii.
Et2O, –78 ºC to rt
Me Me
LiTBSO
Et2O, –78 ºC
t-BuLi
Me Me
ITBSO
(+)-1.108
Me
OMe
OTBDPS
O
Single flask, 57–71%
1.136
1.136-Li
, HMPA (+)-1.150
16 29
24
(–)-1.137a
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contaminating NaH) followed by selective alkylation of the C20-alkoxide; (ii) 
intramolecular TMS migration followed by alkylation of the new free site. The base was 
thus replaced with KHMDS (commercially available as a solution in THF) and the 
reaction closely monitored to observe the formation of two new, isomeric, products: 
1.151 and 1.152 (entry 3). Importantly, no formation of 1.153 or any other free alcohol 
occurred, lending credit to the possibility of isomer formation via TMS migration. At this 
point, NMR studies (Figure 1.9) confirmed that the major product was indeed the desired 
isomer 1.151. Closely monitoring the reaction also demonstrated that 1.151 was formed 
first, and 1.152 only later, suggesting that TMS migration was indeed intramolecular, 
competing with the intermolecular ether formation upon decreasing concentration of 
benzyl bromide available in the reaction mixture. Thus, reaction with excess benzyl 
bromide was now fully selective (Table 1.7, entry 4). 
 
 
Table 1.7.  Optimization of Benzyl Ether Formation 
TMSO
Me
OH
Me
OMe
OTBDPSMe Me
TBSO
SS Base,
BnBr
Solvent
Temperature
TMSO
Me
OBn
Me
OMe
OTBDPSMe Me
TBSO
SS
BnO
Me
OTMSSS
Entry Temperature
4 0 ºC
BA
--91%
3 0 ºC 35%65%
BnO
Me
OHSS
Base Solvent C
--
--
Equiv BnBr
10
3
2 0 to 50 ºC ----
1 0 ºC to rt ----
66%
--
3
3NaH
NaH
THF
DMF
THF
THF
KHMDS
KHMDS
2420
2420 2420
(+)-1.150
(–)-1.151
(–)-1.152 (+)-1.153
(A)
(B) (C)
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Figure 1.9. Structural Elucidation of 1.151 and 1.152 via 2-D NMR 
The dithiane in 1.151 was next reduced to the corresponding methylene employing 
excess Raney nickel under a hydrogen atmosphere at 75 ºC. A mild acidic work-up then 
achieved selective hydrolysis of the TMS ether to furnish allylic alcohol 1.154 in 69% 
yield. Diastereoselective epoxidation of 1.154 was next carried out under Sharpless 
conditions, given that substrate stereochemistry and ligand selectivity were found to 
match.38 The first attempt was made under somewhat forcible, although not 
unprecedented,85 conditions employing near stoichiometric quantities of the bimetallic 
titanium catalyst, formed in situ; yet, no conversion was observed (entry 1). Use of 
superstoichiometric catalyst resulted in an identical outcome (entry 2). It was then 
reasoned that the ligand of choice, (–)-diisopropyl-D-tartrate (DIPT) could lead to 
excessive steric hindrance at the catalyst active site for this particular substrate.86,87 
Although an attempt at employing dimethyltartrate failed due to low solubility, 
diethyltartrate (DET) did give rise to the desired product, albeit first in low yield, 
attributed to the difficult workup given the large amount of TiOx generated (entry 3). We 
were thus pleased to find that a lower catalyst loading furnished epoxide 1.155 in very 
good yield as a single diastereomer (entry 4, analytical samples of both diastereomers 
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Me
O
Me
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OTBDPSMe Me
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SS
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HH
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H
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were obtained by m-CPBA-mediated epoxidation of 1.154). The relative configuration 
was assigned based on precedented catalyst selectivity.38,85  
 
 
Table 1.8. Optimization of Stereoselective Epoxidation 
With epoxide 1.155 in hand, several conditions were assessed in order to achieve the 
reductive opening of the epoxide regioselectively at C19 (Table 1.9), first directed by the 
neighboring free hydroxyl. Based on literature precedent,59,75,88–90 Red-Al was examined 
first. Disappointingly, even under forcing conditions, the epoxide functionality resisted 
hydride attack (entries 1-3). Because steric hindrance at C18-C19 had already proved 
problematic at the epoxidation step, we next opted a smaller hydride source, namely 
LiAlH4, which led to decomposition. Given these unfavorable results, we then applied a 
single-electron reduction protocol first reported by Nugent and RajanBabu.39 
 
OH
Me
OBn
Me
OMe
OTBDPSMe Me
TBSO
OHO
Me
OBn
Me
OMe
OTBDPSMe Me
TBSO
t-BuOOH,
Ti(Oi-Pr)4
Ligand
4A MS
CH2Cl2
Entry Equiv catalyst Ligand Temperature
1 0.6
Yield
(–)-DIPT –20 ºC to rt -- (no conversion)
2 2.4 (–)-DIPT –20 ºC to rt -- (no conversion)
3 2.4 (–)-DET –20 to 0 ºC 23%
4 0.6 (–)-DET –20 to 0 ºC 79%
(–)-1.154 (–)-1.155
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Table 1.9. Attempts at Hydride-Mediated Epoxide Opening 
Interestingly, Nakata et al. resorted to this strategy upon failure of Red-Al in their 
synthetic studies of members of the Cryptocarya family of natural products (Scheme 
1.31).37 On our substrate, however, this protocol was not successful, leading to recovery 
of starting material. 
 
Scheme 1.31. Titanium(III)-Mediated Epoxide Opening: Relevant Example 
As last resort, 1.155 was methylated at the C20-hydroxyl, then treated with TBAF 
resulting in removal of TBS and TBDPS protecting groups. Based on precedent by 
Tanner et al.88 we expected the C16-hydroxyl to now direct epoxide opening, with the 
caveat of possibly low regioselectivity. No such product was observed, with instead 
detection of the debenzylation product 1.161. 
OH
Me
OBn
Me
OMe
OTBDPSMe Me
TBSO
O
OH
Me
OBn
Me
OMe
OTBDPSMe Me
TBSO
OH
THF,
24 h
Entry (equiv)Hydride Source
1 2
Outcome
Red-Al No reaction. Recovered 1.151.
2 10Red-Al
4 20 Complex mixture.LiAlH4
No reaction. Recovered 1.151.
Hydride
source
Temperature
0 ºC to rt
0 ºC to rt
0 ºC to rt
3 20Red-Al Complex mixture; loss of TBS.0 to 50 ºC
19
18
19
18
(–)-1.155 1.156
OH
Me
O
THF, rt
TBSO
Cp2TiCl2 + Zn
t-BuSH
Cp2TiCl
OH
Me
OHTBSO
(n = 1: 78%)
(n = 3: 67%)
n n
1.1581.157
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Scheme 1.32. Reductive Epoxide Opening: Alternative Strategy 
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Summary and Conclusion 
Although the synthesis of the initially projected C16-C29 segment of rhizopodin 
(1.130) will require further investigation, we have validated the use of linchpin 1.108 in 
the convergent construction of a natural product scaffold. Indeed, Type II ARC exploiting 
this new linchpin permitted assembly of an initial C16-C29 framework. Conditions were 
then found for: (i) efficient protection of the C24 hydroxyl, (ii) dithiane removal, and (iii) 
stereoselective epoxidation (Scheme 1.33). 
 
 
Scheme 1.33. Progress Summary for Construction of the C16-C29 Fragment of 
Rhizopodin (1.130) and Monorhizopodin (1.131) 
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Experimental Procedures Relevant to Part I 
 
General Considerations 
Reactions were carried out in oven- or flame-dried glassware under a nitrogen or argon 
atmosphere, unless otherwise noted. All solvents were reagent grade. All chemicals were 
purchased from commercial vendors and used as received, unless otherwise noted. 
Anhydrous tetrahydrofuran, diethyl ether, toluene and dichloromethane were obtained 
from a Pure Solve™ PS-400 solvent purification system. Reactions were magnetically 
stirred unless otherwise stated. Reactions were monitored by thin layer chromatography 
(TLC) with 250 mm Silicycle pre-coated silica gel plates. Silica gel flash 
chromatography was performed using ACS grade solvents and silica gel from Silicycle or 
Sorbent Technologies. MPLC purification was performed using an apparatus comprised 
of a solvent pump (Waters 510 HPLC pump), injection loop (5 mL) and column (20 mm 
ID x 300 mm, ACE glass) packed with silica gel (particle size 18-32 µm, 60 Å pore size. 
Yields refer to chromatographically and spectroscopically pure compounds, unless 
otherwise stated. All melting points were obtained on a Thomas-Hoover apparatus and 
are uncorrected. Infrared spectra were recorded on a JASCO-480 Plus FT-IR 
spectrometer. Proton and carbon NMR spectra were recorded on a Bruker Avance III 
500-MHz spectrometer or a Bruker DMX500 500-MHz spectrometer. Chemical shifts (δ) 
are reported in parts per million (ppm) relative to chloroform (δ 7.26) or benzene (δ 7.16) 
for 1H NMR, and chloroform (δ 77.0) or benzene (δ 128.06) for 13C NMR. Optical 
rotations were measured on a Jasco P-2000 polarimeter. High-resolution mass spectra 
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(HRMS) were measured at the University of Pennsylvania on either a Waters LC-TOF 
mass spectrometer (model LCT-XE Premier) or a Waters GCT Premier spectrometer. 
Microwave reactions were run on a Biotage Initiator Microwave Synthesizer. 
Butyllithium and vinylmagnesium bromide were titrated using Love’s method91 prior to 
running the reactions. Supercritical fluid chromatography (SFC) analyses were performed 
with a JASCO system equipped with a Chiralpak AD-H column (10 mm × 250 mm), a 
PU-280-CO2 plus CO2 Delivery System, a CO-2060 plus Intelligent Column Thermostat, 
an HC-2068-01 Heater Controller, a BP-2080 plus Automatic Back Pressure Regulator, 
an MD-2018 plus Photodiode Array Detector (200-648 nm), and PU-2080 plus Intelligent 
HPLC Pumps. !  
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Experimental Procedures Relevant to Chapter 1 
Synthesis of (+)-Cryptocarya Diacetate 1.48 
 
Type I ARC four-component adduct 1.81. A solution of tert-butyl(1,3-dithian-2-
yl)dimethylsilane 1.27 (0.158 g, 0.672 mmol) in THF (1.1 mL) was treated with 
n-butyllithium (0.292 mL, 2.41 M in hexanes, 0.704 mmol) at rt for 5 min then cooled to 
–40 °C. A solution of (S)-2-methyloxirane (0.045 mL, 0.640 mmol) in THF (1.1 mL) was 
then added via syringe. The mixture was stirred at –40 °C and monitored by TLC (4:1 
hexanes/diethyl ether) for complete consumption of dithiane (1 hour). The reaction was 
cooled to –78 °C and diluted by slow addition of diethyl ether (2.2 mL). A solution of 
(S)-2-(chloromethyl)oxirane (1.71, 0.055 mL, 0.704 mmol)  in diethyl ether (1.0 mL) was 
then added dropwise via syringe, followed by HMPA (0.084 mL, 0.480 mmol). The 
reaction was allowed to warm to +5 ºC over 3.5 hours, then the cold bath was removed to 
complete the formation of epoxide 1.80. 
Freshly prepared vinylmagnesium bromide (2.2 mL, 0.58 M in THF, 1.280 mmol) was 
added to a precooled (–78 °C) suspension of copper(I) bromide-dimethyl sulfide complex 
(0.016 g, 0.077 mmol) in diethyl ether (1.5 mL) via syringe. The reaction mixture 
containing epoxide 1.80 was then added in via cannula over 5 min. The resulting mixture 
(1.0 equiv)(1.05 equiv)
(1.1 equiv) (1.1 equiv)S S
TBS
i. n-BuLi
O
1.27
ii.
Cl
iii.
O
HMPA
(0.75 equiv)
MgBr
CuBr•SMe2
(0.1 equiv)
then
OTBSSS
1.80
O
iv.1.77
1.71
(1.5 equiv)
1.76 OTBSSSOH
(–)-1.81
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was stirred at –78 ºC over 30 min, then the reaction vessel was placed in an ice/water 
bath (0 ºC) and allowed to warm to rt over 3.5 hours. 
An aqueous solution of Rochelle’s salt (15% w/v) was finally added and the resulting 
biphasic mixture was stirred at rt for 1 hour, then extracted with diethyl ether. Organics 
were washed with water and brine, dried over anhydrous Na2SO4 and concentrated in 
vacuo. 
Flash column chromatography (95:5 hexanes/Et2O) afforded 1.81 as a clear colorless oil 
(180 mg, 0.480 mmol, 75%). 
[α]D24 –1.91 (c 1.0, CHCl3); 
IR (thin film, KBr) νmax 2929, 1425,1215, 1132, 836, 757 cm-1; 
1H NMR (500 MHz, CDCl3) δ 5.87 (tdd, J = 7.0, 10.2, 17.2 Hz, 1 H), 5.17 - 5.07 (m, 2 
H), 4.22 (q, J = 5.4 Hz, 1 H), 4.18 - 4.08 (m, 1 H), 3.45 - 3.37 (m, 1 H), 2.97 - 2.91 (m, 1 
H), 2.90 - 2.87 (m, 1 H), 2.84 - 2.74 (m, 2 H), 2.34 (dd, J = 9.3, 15.3 Hz, 1 H), 2.29 - 2.19 
(m, 2 H), 2.14 (d, J = 5.4 Hz, 2 H), 2.05 (d, J = 1.6 Hz, 1 H), 2.00 - 1.93 (m, 2 H), 1.25 
(d, J = 5.9 Hz, 3 H), 0.88 (s, 9 H), 0.10 (s, 3 H), 0.09 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 135.0, 117.6, 68.1, 66.2, 51.5, 49.5, 45.3, 42.4, 26.7, 
26.3, 26.2, 26.1 (3 C), 24.9, 18.1, –3.8, –4.0; 
HRMS (ESI) m/z 399.1819 [(M+Na)+; calcd for C18H36O2S2Si+Na: 399.1824]. 
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Hydroxyketone 1.82. To a solution of 1.81 (0.034 g, 0.09 mmol) in acetonitrile/water 
(4:1, 5 mL) were added mercury(II) chloride (0.071 g, 0.26 mmol) and calcium carbonate 
(0.035 g, 0.35 mmol). The reaction was heated to 65 ºC over 2 hours then cooled to rt. 
Diethyl ether (25 mL) was then added and the mixture was filtered through Celite. The 
filtrate was washed with water and brine, dried over anhydrous Na2SO4 and concentrated 
in vacuo. 
Flash column chromatography (85:15 hexanes/EtOAc) afforded 1.82 as a clear colorless 
oil (0.027 g, 0.09 mmol, near quant.). 
[α]D25 –13.5 (c 1.04, CHCl3); 
IR (thin film, KBr) νmax 3019, 2930, 1704, 1378, 1216, 1130, 923, 837, 758, 668 cm-1; 
1H NMR (500 MHz, CDCl3) δ 5.81 (tdd, J = 7.1, 10.3, 17.0 Hz, 1 H), 5.16 - 5.07 (m, 2 
H), 4.34 - 4.25 (m, 1 H), 4.14 - 4.06 (m, 1 H), 3.11 - 3.02 (s, 1 H), 2.69 - 2.59 (m, 2 H), 
2.58 - 2.49 (m, 1 H), 2.44 (dd, J = 4.8, 15.1 Hz, 1 H), 2.28 - 2.19 (m, 2 H), 1.16 (d, J = 
5.9 Hz, 3 H), 0.86 (s, 9 H), 0.06 (s, 3 H), 0.03 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 211.1, 134.4, 118.0, 67.0, 65.6, 53.1, 50.1, 41.0, 25.9 (3 
C), 24.1, 18.1, –4.4, –4.8; 
HRMS (ESI) m/z 309.1858 [(M+Na)+; calcd for C15H30O3Si+Na: 309.1862]. 
OTBSSSOH HgCl2, CaCO3
4:1 CH3CN/H2O
65 °C
OTBSOH O
(–)-1.81 (–)-1.82
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Acrylate 1.83. Acryloyl chloride (0.191 mL, 2.346 mmol) was added dropwise to a stirred 
and cooled (0 ºC) solution of 1.82 (84 mg, 0.293 mmol) and DIPEA (0.512 mL, 2.93 
mmol) in dichloromethane (4.3 mL). The resulting solution was stirred overnight while 
warming to rt. Sat. aq. NaHCO3 was added to quench excess acryloyl chloride and the 
resulting biphasic mixture was extracted with diethyl ether. The organic extract was 
washed with sat. aq. NH4Cl, water, brine then dried over anhydrous Na2SO4 and 
concentrated in vacuo. 
Flash chromatography on a short pad of silica (95:5 hexanes/EtOAc) afforded 1.83 as a 
clear colorless oil (97 mg, 0.284 mmol, 97%). 
[α]D24 +5.94 (c 1.02, CHCl3); 
IR (thin film, KBr) νmax 2928, 2360, 1727, 1406, 1257, 1192, 836, 776 cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.37 (dd, J = 1.4, 17.2 Hz, 1 H), 6.06 (dd, J = 10.4, 17.3 
Hz, 1 H), 5.81 - 5.72 (m, 2 H), 5.39 (qd, J = 5.7, 7.3 Hz, 1 H), 5.14 - 5.04 (m, 2 H), 4.32 - 
4.23 (m, 1 H), 2.73 (dq, J = 7.2, 16.9 Hz, 2 H), 2.63 (dd, J = 6.9, 15.3 Hz, 1 H), 2.45 - 
2.36 (m, 3 H), 1.14 (d, J = 5.9 Hz, 3 H), 0.85 (s, 9 H), 0.05 (s, 3 H), 0.02 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 206.5, 165.4, 133.0, 130.9, 128.6, 118.6, 69.4, 65.5, 52.8, 
47.8, 38.5, 25.9 (3 C), 24.1, 18.1, –4.4, –4.8; 
OTBSO O
O
Acryloyl chloride
DIPEA, CH2Cl2
0 ºC to rt
OTBSOH O
(–)-1.82 (+)-1.83
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HRMS (ESI) m/z 363.1967 [(M+Na)+; calcd for C18H32O4Si+Na: 363.1968]. 
 
 
Dihydropyrone 1.S1. A solution of 1.83 (74 mg, 0.217 mmol) in degassed 
dichloromethane (4.4 mL) in a microwave vial was flushed with nitrogen three times. 
Hoveyda-Grubbs catalyst 2nd generation (6.81 mg, 10.87 µmol) was then added and the 
vial was sealed and heated to 60 °C over 3 hours, then allowed to cool to rt and 
concentrated in vacuo. 
Flash column chromatography (95:5 hexanes/EtOAc) afforded 1.S1 as a clear colorless 
oil (59 mg, 0.189 mmol, 87%). 
[α]D24 +79.7 (c 1.0, CHCl3); 
IR (thin film, KBr) νmax 2929, 1719, 1472, 1389, 1254, 837, 757 cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.91 - 6.82 (m, 1 H), 6.07 - 5.98 (m, 1 H), 4.86 (dddd, J = 
3.8, 5.2, 7.8, 11.6 Hz, 1 H), 4.34 - 4.24 (m, 1 H), 3.04 (dd, J = 5.2, 17.6 Hz, 1 H), 2.82 
(dd, J = 7.7, 17.6 Hz, 1 H), 2.65 (dd, J = 7.1, 14.9 Hz, 1 H), 2.56 (dddd, J = 1.1, 3.8, 6.1, 
18.3 Hz, 1 H), 2.47 (dd, J = 5.0, 14.9 Hz, 1 H), 2.34 - 2.24 (m, 1 H), 1.17 (d, J = 6.1 Hz, 
3 H), 0.86 (s, 9 H), 0.06 (s, 3 H), 0.04 (s, 3 H); 
Hoveyda-Grubbs 
2nd gen. 5 mol%
CH2Cl2
60 °C, 3 h
OTBSO O
O
OTBSO O
O
(+)-1.83 (+)-1.S1
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13C NMR (125 MHz, CDCl3) δ 206.2, 163.9, 144.9, 121.5, 73.6, 65.6, 53.0, 49.0, 29.3, 
25.9 (3 C), 24.0, 18.1, –4.4, –4.8; 
HRMS (ESI) m/z 313.1825 [(M+Na)+; calcd for C16H29O4Si+Na: 313.1835]. 
 
 
Hydroxyketone 1.84. To a precooled (0 ºC) solution of 1.S2 (316 mg, 1.011 mmol) and 
thioanisole (1.196 mL, 10.11 mmol) in dichloromethane (9.5 mL) was added TFA (1.169 
mL, 15.17 mmol). The resulting mixture was stirred at 0 ºC for 40 minutes, then 
concentrated in vacuo. 
Flash chromatography (1:1→1:9→0:10 hexanes/EtOAc) afforded 1.84 as a clear 
colorless oil (167 mg, 0.849 mmol, 84%). 
[α]D25 +153.5 (c 1.0, CHCl3); 
IR (thin film, KBr) νmax 3019, 1719, 1389, 1216, 758, 669 cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.89 (ddd, J = 2.4, 6.0, 9.8 Hz, 1 H), 6.03 (dd, J = 1.0, 2.8 
Hz, 1 H), 4.95 - 4.86 (m, 1 H), 4.33 - 4.23 (m, 1 H), 3.08 - 2.98 (m, 1 H), 2.81 - 2.68 (m, 
2 H), 2.65 - 2.60 (m, 2 H), 2.52 (dddd, J = 1.1, 3.8, 6.1, 18.3 Hz, 1 H), 2.39 - 2.29 (m, 1 
H), 1.22 (d, J = 6.3 Hz, 3 H); 
TFA, PhSMe
CH2Cl2
0 °C
OTBSO O
O
OHO O
O
(+)-1.S1 (+)-1.84
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13C NMR (125 MHz, CDCl3) δ 207.8, 163.7, 144.9, 121.5, 73.5, 64.0, 51.8, 47.9, 29.2, 
22.7; 
HRMS (ESI) m/z 221.0792 [(M+Na)+; calcd for C10H14O4+Na: 221.0790]. 
 
 
Syn-diol 1.85. To a cooled (–78 ºC) solution of 1.84 (10 mg, 0.050 mmol) in 
methanol/THF (1:1, 0.50 mL) was added diethyl(methoxy)borane (242 µL, 1 M in THF, 
0.242 mmol). The solution was stirred at –78 ºC for 30 minutes then sodium borohydride 
(11 mg, 0.288 mmol) was added in one portion. The resulting mixture was stirred at –78 
ºC for 7 hours. 
Acetic acid (50 µL) was added to stop the reaction and the mixture was subsequently 
neutralized with sat. aq. NaHCO3 and extracted with EtOAc. Organics were washed with 
water and brine, dried over anhydrous Na2SO4 and concentrated in vacuo. The crude 
residue was taken up in methanol and stored in the refrigerator (+4 ºC) overnight, then 
concentrated again. 
Flash column chromatography (1:1 hexanes/EtOAc → EtOAc) afforded 1.85 as a clear 
colorless oil (7 mg, 0.035 mmol, 70%). 
[α]D25 +74.4 (c 0.58, CHCl3); 
OHO O
O
OHO OH
O
a) Et2BOMe
b) NaBH4
1:1 THF/MeOH
−78 °C(+)-1.84 (+)-1.85
 63 
IR (thin film, KBr) νmax 3420, 3019, 2927, 1714, 1216, 756, 668 cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.90 (ddd, J = 3.8, 5.0, 9.7 Hz, 1 H), 6.03 (td, J = 1.8, 9.9 
Hz, 1 H), 4.72 - 4.64 (m, 1 H), 4.20 - 4.13 (m, 1 H), 4.12 - 4.07 (m, J = 6.1 Hz, 1 H), 2.47 
- 2.40 (m, 2 H), 2.07 - 2.00 (m, 1 H), 1.78 (ddd, J = 3.8, 5.5, 14.3 Hz, 1 H), 1.64 - 1.59 
(m, 2 H), 1.24 (d, J = 6.1 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 164.2, 145.4, 121.4, 76.5, 69.9, 69.3, 44.7, 42.5, 29.6, 
24.6; 
HRMS (ESI) m/z 223.0949 [(M+Na)+; calcd for C10H16O4+Na: 223.0946]. 
 
 
Cryptocarya diacetate 1.48. To a solution of 1.85 (16 mg, 0.080 mmol) in 
dichloromethane (2 mL) were added pyridine (323 µL, 4.00 mmol) and acetic anhydride 
(113 µL, 1.20  mmol). The reaction was stirred overnight then concentrated in vacuo. 
Flash chromatography (4:1 hexanes/EtOAc) afforded 1.48 as a clear colorless oil (15 mg, 
0.053 mmol, 66%). 
[α]D25 +45.3 (c 1.25, CHCl3); 
IR (thin film, KBr) νmax 2926, 1730, 1521, 1423, 1216, 1045 cm-1; 
OHO OH
O
OAcO OAc
O
CH2Cl2, rt
Ac2O
Pyridine
(+)-1.48(+)-1.85
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1H NMR (500 MHz, CDCl3) δ 6.86 (ddd, J = 2.5, 6.1, 9.7 Hz, 1 H), 6.01 (dd, J = 1.9, 9.8 
Hz, 1 H), 5.13 - 5.05 (m, 1 H), 5.01 - 4.93 (m, 1 H), 4.53 - 4.44 (m, 1 H), 2.44 (ddd, J = 
4.4, 5.7, 18.4 Hz, 1 H), 2.31 (tdd, J = 2.4, 11.5, 17.8 Hz, 1 H), 2.15 (ddd, J = 6.6, 8.4, 
14.7 Hz, 1 H), 2.06 (s, 3 H), 2.03 (s, 3 H), 2.05 - 1.97 (m, 2 H), 1.97 - 1.90 (m, 1 H), 1.25 
(d, J = 6.3 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 170.8, 170.7, 163.9, 144.9, 121.5, 75.0, 67.9, 67.9, 40.6, 
39.3, 29.3, 21.5, 21.3, 20.3; 
HRMS (ESI) m/z 307.1147 [(M+Na)+; calcd for C14H20O6+Na: 307.1158]. 
 
Synthesis of (+)-Cryptocarya Triacetate 1.49 
 
Type II ARC four component adduct 1.87. A solution of 2-methyl-1,3-dithiane 1.42 (505 
µL, 4.21 mmol) in THF (7.6 mL) was treated with n-butyllithium (1.69 mL, 4.21 mmol) 
at rt for 5 min. The resulting mixture was transferred via cannula into a precooled (–30 
ºC) solution of linchpin 1.35 (816 mg, 2.81 mmol, 1 equiv) in Et2O (22 mL), stirred at –
30 °C for 1 h, then cooled to –50 °C. A solution of (S)-2-(chloromethyl)oxirane (0.44 
OOHi. n-BuLi    5 min, rt
ii.
O
HMPA
iii.
(S)
Cl O
–50 °C to rt
MgBr
CuBr•SMe2
iv.
–78 °C to rt (–)-1.871.42
SSSS
H
SS
TBS
SS
–30 °C
(+)-1.35
OO SSSS
1.86
TBS TBS
(+)-1.77
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mL, 5.62 mmol, 2 equiv) in Et2O (7.6 mL) and HMPA (0.73 mL) was then added 
dropwise via syringe. The reaction mixture was allowed to warm to rt over 4 h. 
Vinylmagnesium bromide (0.57 M in THF, 9.9 mL, 5.62 mmol) was added to a 
precooled (–78 °C) suspension of copper(I) bromide-dimethyl sulfide complex (0.069 g, 
0.337 mmol) in Et2O (7.6 mL). Reaction mixture containing 1.86 was then directly added 
in slowly via cannula.  After 30 min at –78 ºC, the reaction vessel was placed in a 0 ºC 
bath and allowed to warm to rt over 4 h. Rochelle's salt (15% aq.) was added to quench 
the reaction. The resulting biphasic mixture was stirred at rt for 30 min, then extracted 
with Et2O. Organics were washed with water and brine, dried over Na2SO4, concentrated, 
and purified by flash chromatography (95:5 hexanes/EtOAc) to yield 1.87 as a clear, 
colorless oil (0.74 g, 52%). 
[α]D24 –6.43 (c 0.73, CHCl3); 
IR (thin film, KBr) νmax 3019, 2926, 2853, 2400, 1424, 1217 cm-1; 
1H NMR (500 MHz, CDCl3) δ 5.85 (tdd, J = 7.0, 10.2, 17.2 Hz, 1 H), 5.16 - 5.06 (m, 2 
H), 4.45 (app quin, J = 5.8 Hz, 1 H), 4.20 - 4.10 (m, 1 H), 3.32 (br s, 1 H), 3.05 - 3.00 (m, 
1 H), 2.99 - 2.92 (m, 3 H), 2.90 - 2.83 (m, 3 H), 2.82 - 2.76 (m, 1 H), 2.73 - 2.63 (m, 2 
H), 2.43 (dd, J = 9.3, 15.3 Hz, 1 H), 2.30 - 2.26 (m, 1 H), 2.25 - 2.19 (m, 1 H), 2.00 - 1.91 
(m, 7 H), 1.72 (s, 3 H), 0.89 (s, 9 H), 0.16 (s, 3 H), 0.15 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 134.9, 117.7, 68.5, 68.3, 51.6, 50.0, 48.9, 48.2, 47.0, 
42.3, 29.6, 27.2, 27.0, 26.9, 26.5, 26.3 (3 C), 25.3, 25.0, 18.2, -3.0, -3.4; 
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HRMS (ESI) m/z 531.1896 [(M+Na)+; calcd for C23H44O2S4Si+Na: 531.1891]. 
 
 
Hydroxyketone 1.88. To a solution of 1.87 (59 mg, 0.116 mmol) in acetonitrile/water 
(4:1, 6.6 mL) were added together mercury(II) chloride (159 mg, 0.585 mmol) and 
calcium carbonate (79 mg, 0.788 mmol). The mixture was heated to 65 ºC for 20 min 
then cooled to rt, diluted with diethyl ether (15 mL), and the mixture was filtered through 
Celite, rinsing with abundant diethyl ether. The filtrate was washed with water and brine, 
dried over anhydrous Na2SO4 and concentrated in vacuo.   
Flash column chromatography (9:1 hexanes/EtOAc) afforded 1.88 as a clear colorless oil 
(24 mg, 63% brsm).  
[α]D25 –21.88 (c 1.00, CHCl3); 
IR (thin film, KBr) νmax 3019, 2929, 1713, 1217, 1092, 837, 758, 668 cm-1; 
1H NMR (500 MHz, CDCl3) δ 5.81 (tdd, J = 7.1, 9.3, 16.6 Hz, 1 H), 5.16 - 5.06 (m, 2 H), 
4.57 (app quin, J = 5.9 Hz, 1 H), 4.16 - 4.07 (m, 1 H), 2.99 - 2.90 (m, 1 H), 2.70 - 2.63 
(m, 3 H), 2.58 (ddd, J = 1.6, 5.5, 15.7 Hz, 2 H), 2.51 (dd, J = 9.1, 17.4 Hz, 1 H), 2.28 - 
2.20 (m, 2 H), 2.16 (s, 3 H), 0.85 (s, 9 H), 0.07 (s, 6 H); 
HgCl2, CaCO3
4:1 CH3CN/H2O
65 °C
OOH
(–)-1.87
SSSS
TBS
OOH O O
TBS
(–)-1.88
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13C NMR (125 MHz, CDCl3) δ 210.1, 207.3, 134.3, 118.1, 67.0, 65.3, 50.6, 50.5, 50.1, 
41.0, 31.6, 25.9 (3 C), 18.0, –4.7, –4.7; 
HRMS (ESI) m/z 351.1977 [(M+Na)+; calcd for C17H32O4Si+Na: 351.1968]. 
 
 
Acrylate 1.89. Acryloyl chloride (0.111 mL, 1.364 mmol) was added dropwise to a stirred 
and cooled (0 ºC) solution of 1.88 (56 mg, 0.170 mmol) and DIPEA (0.298 ml, 1.705 
mmol) in dichloromethane (3.4 mL). The resulting solution was stirred overnight while 
warming to rt. Sat. aq. NaHCO3 was added to quench excess acryloyl chloride and the 
resulting biphasic mixture was extracted with diethyl ether. The organic layer was 
washed with sat. aq. NH4Cl, water, brine then dried over anhydrous Na2SO4 and 
concentrated in vacuo. 
Flash chromatography on a short pad of silica (95:5 hexanes/EtOAc) afforded 1.89 as a 
clear colorless oil (61 mg, 94%). 
[α]D24 –14.87 (c 0.83, CHCl3); 
IR (thin film, KBr) νmax 3020, 2930, 2857, 1720, 1407, 1216, 1087, 926, 838, 756, 668 
cm-1; 
Acryloyl chloride
DIPEA, CH2Cl2
0 ºC to rt
OOH O O
TBS
(–)-1.88 (–)-1.89
OO O
O
O
TBS
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1H NMR (500 MHz, CDCl3) δ 6.37 (dd, J = 1.5, 17.3 Hz, 1 H), 6.06 (dd, J = 10.5, 17.2 
Hz, 1 H), 5.81 - 5.72 (m, 2 H), 5.38 (tdd, J = 5.7, 5.9, 7.4 Hz, 1 H), 5.13 - 5.03 (m, 2 H), 
4.56 (app quin, J = 5.8 Hz, 1 H), 2.76 (dd, J = 7.3, 17.0 Hz, 1 H), 2.69 (dd, J = 5.5, 16.8 
Hz, 1 H), 2.67 - 2.53 (m, 4 H), 2.43 - 2.38 (m, 2 H), 2.14 (s, 3 H), 0.84 (s, 9 H), 0.06 (s, 3 
H), 0.05 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 207.2, 205.8, 165.4, 133.0, 130.9, 128.6, 118.7, 69.3, 
65.2, 50.5, 50.3, 47.6, 38.4, 31.6, 25.9 (3 C), 18.0, –4.7, –4.8; 
HRMS (ESI) m/z 405.2056 [(M+Na)+; calcd for C20H34O5Si+Na: 405.2073]. 
 
 
Dihydropyrone 1.90. A solution of 1.89 (110 mg, 0.288 mmol) in degassed 
dichloromethane (14.4 mL) was added Hoveyda-Grubbs catalyst 2nd generation (9.01 mg, 
0.014 mmol). The reaction mixture was heated to 80 °C in the microwave for 3 hours, 
then allowed to cool to rt and concentrated in vacuo. 
Flash column chromatography (8:2→7:3 hexanes/EtOAc) afforded 1.90 as a light brown 
solid (93 mg, 91%). 
mp 62-64 ºC; 
[α]D24 +50.5 (c 0.58, CHCl3); 
 Hoveyda-Grubbs 
2nd gen. 5 mol%
CH2Cl2
80 °C, 3 h
(–)-1.89
OO O
O
O
TBS
(+)-1.90
OO O
O
O
TBS
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IR (thin film, KBr) νmax 2929, 1719, 1472, 1389, 1254, 837, 757 cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.88 (ddd, J = 2.4, 6.1, 9.8 Hz, 1 H), 6.03 (ddd, J = 1.0, 
2.6, 9.7 Hz, 1 H), 4.94 - 4.82 (m, 1 H), 4.57 (app quin, J = 5.9 Hz, 1 H), 3.01 (dd, J = 5.4, 
17.6 Hz, 1 H), 2.81 (dd, J = 7.3, 17.6 Hz, 1 H), 2.75 - 2.50 (m, 5 H), 2.30 (tdd, J = 2.6, 
11.7, 18.2 Hz, 1 H), 2.20 - 2.12 (m, 3 H), 0.92 - 0.76 (m, 9 H), 0.07 (s, 3 H), 0.07 (s, 3 
H); 
13C NMR (125 MHz, CDCl3) δ 207.3, 205.5, 163.9, 144.9, 121.5, 73.5, 65.3, 50.4, 50.4, 
48.8, 31.7, 29.2, 25.9 (3 C), 18.0, –4.7, –4.7; 
HRMS (ESI) m/z 377.1750 [(M+Na)+; calcd for C18H30O5Si+Na: 377.1760]. 
 
 
Hydroxyketone 1.91. Dihydropyrone 1.90 (19.3 mg, 0.054 mmol) was dissolved in THF 
(1.1 mL). Water (60 µL) was added, followed by TFA (101 µL, 1.307 mmol). The 
resulting mixture was stirred at rt overnight, diluted with diethyl ether (2.2 mL), 
neutralized with sat. aq. NaHCO3, and extracted with EtOAc, dried over anhydrous 
Na2SO4 and concentrated. 
Flash chromatography (1:1 hexanes/EtOAc → EtOAc) afforded 1.91 as a clear colorless 
oil (13 mg, 99%). 
TFA, H2O
THF, rt
OHO O
O
O
(+)-1.91(+)-1.90
OO O
O
O
TBS
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[α]D25 +89.41 (c 1.0, CHCl3); 
IR (thin film, KBr) νmax 3512, 3020, 1716, 1389, 1216, 1079, 753, 668 cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.89 (ddd, J = 2.6, 6.0, 9.8 Hz, 1 H), 6.04 (ddd, J = 1.0, 
2.7, 9.8 Hz, 1 H), 4.96 - 4.86 (m, 1 H), 4.50 (dd, J = 5.7, 6.5 Hz, 1 H), 3.05 (dd, J = 6.2, 
17.1 Hz, 1 H), 2.80 (dd, J = 6.3, 17.2 Hz, 1 H), 2.69 - 2.65 (m, 4 H), 2.55 - 2.46 (m, 1 H), 
2.40 - 2.30 (m, 1 H), 2.19 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 208.7, 206.5, 163.8, 145.1, 121.4, 73.5, 64.0, 49.4, 49.2, 
47.9, 30.9, 29.2; 
HRMS (ESI) m/z 263.0889 [(M+Na)+; calcd for C12H16O5+Na: 263.0895]. 
 
 
Cryptocarya triacetate 1.49. To a cooled (–78 ºC) solution of 1.91 (5.0 mg, 0.021 mmol) 
in MeOH/THF (1:1, 0.42 mL) was added diethyl(methoxy)borane (1.0 M in THF, 25 µL, 
0.025 mmol). The reaction was stirred at –78 ºC for 30 minutes then sodium borohydride 
(2.3 mg, 0.06 mmol) was added. The resulting mixture was stirred at –78 ºC for 12 h, 
then were added AcOH (30 µL) and MeOH (1 mL), and the reaction was stirred at rt for 
4 h and concentrated in vacuo to afford crude 1.98. 
a) Et2BOMe
b) NaBH4
1:1 THF/MeOH
−78 °C
CH2Cl2, rt
Ac2O
PyridineOHO OH
O
OHOHO O
O
O OAcO OAc
O
OAc
1.98 (+)-1.49(+)-1.91
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To a cooled (0 ºC) solution of crude 1.98 in pyridine (200 µL) were added acetic 
anhydride (59.0 µl, 0.624 mmol) and DMAP (1 mg). The reaction was allowed to warm 
to rt and stirred overnight, then concentrated. Flash column chromatography (1:1 
hexanes/EtOAc) afforded 1.49 as a clear, colorless oil (5.0 mg, 0.014 mmol, 65% from 
1.91). 
[α]D25 +22.1 (c 0.33, CHCl3); 
IR (thin film, KBr) νmax 2922, 2851, 2360, 2341, 1733, 1594, 1372, 1238, 1020, 806 cm-
1; 
1H NMR (500 MHz, CDCl3) δ  6.86 (ddd, J = 2.5, 6.0, 9.8 Hz, 1 H), 6.02 (dd, J = 2.0, 
9.7 Hz, 1 H), 5.05 (dddd, J = 3.8, 6.5, 8.5, 10.3 Hz, 1 H), 4.99 (app tt, J = 5.0, 7.6 Hz, 1 
H), 4.94 (app sxt, J = 6.3 Hz, 1 H), 4.48 (tdd, J = 4.0, 6.5, 14.0 Hz, 1 H), 2.43 (ddd, J = 
4.2, 5.5, 18.2 Hz, 1 H), 2.31 (tdd, J = 2.4, 11.5, 18.0 Hz, 1 H), 2.15 (ddd, J = 6.4, 8.4, 
14.7 Hz, 1 H), 2.07 (s, 3 H), 2.06 (s, 3 H), 2.03 (s, 3 H), 1.99 - 1.92 (m, 3 H), 1.88 (ddd, J 
= 5.5, 6.5, 14.0 Hz, 1 H), 1.75 (ddd, J = 5.0, 6.1, 14.3 Hz, 1 H), 1.23 (d, J = 6.3 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 170.8, 170.7, 170.6, 163.9, 144.9, 121.5, 75.0, 68.3, 67.9, 
67.8, 40.3, 39.2, 39.1, 29.3, 21.5, 21.3, 21.3, 20.1; 
HRMS (ESI) m/z 393.1535 [(M+Na)+; calcd for C18H26O8+Na: 393.1525]. 
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Synthesis of (–)-Cryptocaryolone (1.50) and (–)-Cryptocaryolone Diacetate (1.51) 
 
Cryptocaryolone 1.50. To a cooled (–78 ºC) solution 1.91 (8.0 mg, 0.033 mmol) in 
MeOH/THF (1:1, 0.33 mL) was added diethyl(methoxy)borane (1.0 M in THF, 40.0 µl, 
0.040 mmol). The solution was stirred at –78 ºC for 30 minutes then sodium borohydride 
(3.60 mg, 0.095 mmol) was added. The mixture was then stirred at –78 ºC for 7 h, diluted 
with Et2O, and quenched with AcOH. Sat. aq. NaHCO3 was added and the reaction 
mixture was extracted with EtOAc. Organics were washed with water and brine, dried 
over Na2SO4, concentrated and taken up in MeOH. The solution was placed in the 
refrigerator (+4 ºC) overnight then reconcentrated to afford crude 1.98. 
Crude triol 1.98 was dissolved in water (1.4 mL). A 5/7 aliquot (1 mL) was transferred to 
the reaction vessel, sulfuric acid (5 mM in water, 300 µL, 1.5 µmol) was added, and the 
reaction mixture was heated to 60 ºC. After 36 h at 60 ºC, the reaction was quenched with 
sat. aq. NaHCO3 (0.01 mL) and extracted with chloroform. Organics were washed with 
brine, dried over Na2SO4 and concentrated. Flash chromatography (95:5 EtOAc/MeOH) 
afforded 1.50 as a clear, colorless oil (3.4 mg, 60% from 1.91). 
[α]D25 –55.0 (c 0.04, CHCl3); 
IR (thin film, KBr) νmax 3422, 2924, 1725, 1339, 1200, 1070, 992, 840, 752 cm-1; 
a) Et2BOMe
b) NaBH4
1:1 THF/MeOH
−78 °C
OHO OH
O
OHOHO O
O
O
1.98(+)-1.91
O
O
O OH OH
(–)-1.50
H2SO4
H2O, 60 ºC
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1H NMR (500 MHz, C6D6) δ 4.15 - 4.09 (m, 1 H), 4.10 - 4.02 (m, 1 H), 3.91 (br. s., 2 H), 
3.77 - 3.64 (m, 2 H), 3.47 - 3.39 (m, 1 H), 2.47 (br. d, J = 19.0 Hz, 1 H), 2.09 (dd, J = 5.4, 
19.0 Hz, 1 H), 1.54 (td, J = 10.0, 13.9 Hz, 1 H), 1.50 - 1.44 (m, 1 H), 1.40 (td, J = 9.3, 
14.2 Hz, 1 H), 1.24 (d, J = 6.3 Hz, 3 H), 1.18 (td, J = 2.4, 13.9 Hz, 1 H), 1.14 - 1.07 (m, 1 
H), 1.01 - 0.93 (m, 2 H), 0.88 (ddd, J = 2.2, 11.7, 13.9 Hz, 1 H); 
13C NMR (125 MHz, CDCl3) δ 168.1, 72.1, 71.9, 68.2, 66.4, 65.9, 45.6, 43.1, 37.1, 36.3, 
29.0, 24.1; 
HRMS (ESI) m/z 267.1219 [(M+Na)+; calcd for C12H20O5+Na: 267.1208]. 
 
Cryptocaryolone diacetate 1.51. To a cooled (0 ºC) solution of cryptocaryolone 1.50 
(12.5 mg, 0.051 mmol) in dichloromethane (3 mL) were added pyridine (0.021 mL, 0.256 
mmol), acetic anhydride (0.019 mL, 0.205 mmol) and DMAP (3.13 mg, 0.026 mmol). 
The reaction mixture was stirred overnight, quenched with solid NaHCO3, filtered 
through glass wool rinsing with EtOAc and concentrated in vacuo. Flash column 
chromatography (1:1 → 1:3 hexanes/EtOAc) afforded 1.51 as a clear colorless oil (18.1 
mg, near quant.). 
[α]D25 –29.6 (c 0.27, CHCl3); 
IR (thin film, KBr) νmax 2920, 2851, 2360, 1727, 1371, 1234, 1156, 1070 cm-1; 
CH2Cl2, rt
Ac2O
PyridineO
O
O OH OH
(–)-1.50
O
O
O OAc OAc
(–)-1.51
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1H NMR (500 MHz, C6D6) δ 5.21 (tt, J = 5.3, 7.5 Hz, 1 H), 5.11 (sxt, J = 6.4 Hz, 1 H), 
4.16 - 4.11 (m, 1 H), 3.85 - 3.77 (m, 1 H), 3.60 - 3.54 (m, 1 H), 2.64 (d, J = 18.8 Hz, 1 
H), 2.12 (dd, J = 5.4, 19.0 Hz, 1 H), 1.85 (td, J = 6.9, 14.5 Hz, 1 H), 1.74 - 1.66 (m, 1 H), 
1.71 (s, 3 H), 1.68 (s, 3 H), 1.51 (ddd, J = 5.2, 6.1, 14.1 Hz, 1 H), 1.60 - 1.48 (m, 1 H), 
1.39 - 1.32 (m, 1 H), 1.12 (d, J = 6.3 Hz, 3 H), 1.18 - 1.11 (m, 1 H), 0.94 (ddd, J = 2.2, 
11.7, 13.9 Hz, 1 H), 1.01 - 0.90 (m, 1 H); 
13C NMR (125 MHz, CDCl3) δ 169.8, 169.7, 168.0, 72.1, 68.2, 67.7, 66.0, 63.2, 40.4, 
40.0, 37.0, 36.2, 29.3, 20.8, 20.6, 20.1; 
HRMS (ESI) m/z 351.1405 [(M+Na)+; calcd for C16H24O7+Na: 351.1420]. 
 
Synthesis of Polyrhacitide A (1.52) 
 
Type II ARC four component adduct 1.100. A solution of 2-heptyl-1,3-dithiane 1.99 
(1.381 mL, 6.13 mmol) in THF (11 mL) was treated with n-butyllithium (2.66 mL, 2.3 M 
solution in hexanes, 6.11 mmol) at rt for 5 min. The solution was transferred via syringe 
into a precooled (–30 ºC) solution of linchpin (–)-1.35 (1.2 g, 4.13 mmol) in diethyl ether 
(33 mL). The mixture was stirred at –30 °C for 4 hours then cooled to –50 °C. A solution 
H n-C7H15
SS
i. n-BuLi
  5 min, rt
ii.
HMPAiii.
(R)
Cl
O
−50 °C to rt
MgBr
CuBr•SMe2
iv.
−78 °C to rt
OOH
n-C7H15
SSSS
(+)-1.1001.99
(–)-1.77 TBS
S S
TBS
O
(–)-1.35,  −30 °C
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of (R)-2-(chloromethyl)oxirane (0.646 mL, 8.26 mmol) in diethyl ether (11 mL) and 
HMPA (1.078 mL, 6.19 mmol) was then added dropwise. The resulting mixture was 
allowed to warm to room temperature over 2 hours then stored in the refrigerator (+4 ºC) 
overnight. 
Vinylmagnesium bromide (15.58 mL, 0.53 M solution in THF, 8.26 mmol) was added to 
a precooled (–78 °C) suspension of copper(I) bromide-dimethyl sulfide complex (0.102 
g, 0.496 mmol) in diethyl ether (11 mL). The reaction mixture containing the 
tricomponent adduct was then added via cannula. The resulting mixture was stirred at –78 
ºC for 30 min, then the reaction vessel was placed in an ice/water bath (0 ºC) and allowed 
to warm to rt over 3.5 hours. 
An aqueous solution of Rochelle’s salt (15% w/v) was finally added and the resulting 
biphasic mixture was stirred at rt for 1 hour, then extracted with diethyl ether (×3). 
Organics were washed with water and brine, dried over anhydrous Na2SO4 and 
concentrated in vacuo. 
Flash column chromatography (92:8 hexanes/diethyl ether) afforded 1.100 as a clear 
colorless oil (882 mg, 1.49 mmol, 36%). 
[α]D24 +2.99 (c 1.46, CHCl3); 
IR (thin film, KBr) νmax 3435, 3018, 2929, 2856, 1464, 1425, 1216, 1088, 757, 668 cm-1; 
1H NMR (500 MHz, CDCl3) δ 5.85 (tdd, J = 7.1, 10.1, 17.1 Hz, 1 H), 5.18 - 5.04 (m, 2 
H), 4.51 (quin, J = 5.8 Hz, 1 H), 4.24 - 4.07 (m, 1 H), 3.35 (br. s., 1 H), 3.08 - 2.74 (m, 9 
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H), 2.71 (dd, J = 5.7, 15.1 Hz, 1 H), 2.55 (dd, J = 5.8, 15.2 Hz, 1 H), 2.43 (dd, J = 9.3, 
15.3 Hz, 1 H), 2.34 - 2.15 (m, 2 H), 2.06 - 1.84 (m, 8 H), 1.58 - 1.45 (m, 2 H), 1.36 - 1.22 
(m, 8 H), 0.92 - 0.84 (m, 12 H), 0.16 (s, 3 H), 0.16 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 134.9, 117.7, 68.7, 68.3, 53.0, 51.7, 49.0, 47.2, 47.2, 
42.3, 40.6, 32.0, 30.0, 29.4, 27.0, 26.7, 26.6, 26.4, 26.3 (3 C), 25.5, 25.0, 24.7, 22.8, 18.2, 
14.2, –3.1, –3.2;  
HRMS (ESI) m/z 593.3011 [(M+H)+; calcd for C29H57O2S4Si+H: 593.3011]. 
 
 
Diketone 1.S2. To a solution of 1.100 (14 mg, 0.024 mmol) in acetonitrile/water (4:1, 
1.25 mL) were added together mercury(II) chloride (44 mg, 0.162 mmol) and calcium 
carbonate (16 mg, 0.160 mmol). The mixture was heated to 65 ºC over 15 min, cooled to 
rt, diluted with Et2O (5 mL) and filtered through Celite. The filtrate washed with water 
and brine, dried over Na2SO4, and concentrated. Flash chromatography (9:1 
hexanes/EtOAc) afforded 1.S2 as a clear, colorless oil (6.8 mg, 70%). 
[α]D24 +9.81 (c 0.58, CHCl3); 
IR (thin film, KBr) νmax 3407 (br), 2928, 2856, 1712, 1375, 1254, 1076, 837, 777 cm-1; 
HgCl2, CaCO3
4:1 CH3CN/H2O
65 °C
OOH O
n-C7H15
O
(+)-1.S2
TBS
OOH
n-C7H15
SSSS
(+)-1.100
TBS
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1H NMR (500 MHz, CDCl3) δ 5.81 (tdd, J = 7.1, 10.9, 16.4 Hz, 1 H), 5.18 - 5.02 (m, 2 
H), 4.58 (app quin, J = 5.9 Hz, 1 H), 4.12 (dtd, J = 2.8, 6.3, 9.1 Hz, 1 H), 2.73 - 2.48 (m, 
6 H), 2.47 - 2.33 (m, 2 H), 2.24 (spt, J = 7.1 Hz, 2 H), 1.54 (quin, J = 7.0 Hz, 2 H), 1.36 - 
1.17 (m, 8 H), 0.88 (t, J = 6.9 Hz, 3 H), 0.85 (s, 9 H), 0.06 (s, 3 H), 0.06 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 210.2, 209.6, 134.3, 118.1, 67.0, 65.4, 50.6, 50.0, 49.6, 
44.5, 41.0, 31.8, 29.2, 29.2, 25.9 (3 C), 23.6, 22.7, 18.0, 14.2, -4.7 (2 C). 
HRMS (ESI) m/z 435.2917 [(M+Na)+; calcd for C23H44O4Si+Na: 435.2907]. 
 
 
Acrylate 1.S3. Acryloyl chloride (7.87 µl, 0.097 mmol) was added dropwise to a stirred 
and cooled (0 ºC) solution of 1.S2 (5 mg, 0.012 mmol) and DIPEA (22 µl, 0.12 mmol) in 
dichloromethane (0.24 mL). The resulting solution was stirred overnight while warming 
to rt. 
Sat. aq. NaHCO3 was added to quench excess acryloyl chloride and the resulting biphasic 
mixture was extracted with diethyl ether. The organic layer was washed with sat. aq. 
NH4Cl, water, brine then dried over anhydrous Na2SO4 and concentrated in vacuo. 
Flash chromatography on a short pad of silica (95:5 hexanes/EtOAc) afforded 1.S3 as a 
clear colorless oil (5.4 mg, 95%). 
Acryloyl chloride
DIPEA, CH2Cl2
0 ºC to rt
OO O
O
n-C7H15
O
(+)-1.S3
TBS
OOH O
n-C7H15
O
(+)-1.S2
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 78 
[α]D24 +11.39 (c 1.0, CHCl3); 
IR (thin film, KBr) νmax 3020, 2929, 2857, 1720, 1408, 1216, 1051, 928, 754, 669 cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.37 (dd, J = 1.4, 17.4 Hz, 1 H), 6.06 (dd, J = 10.4, 17.3 
Hz, 1 H), 5.80 (dd, J = 1.4, 10.5 Hz, 1 H), 5.75 (tdd, J = 7.1, 9.7, 16.8 Hz, 1 H), 5.38 (qd, 
J = 5.7, 7.1 Hz, 1 H), 5.13 - 5.06 (m, 2 H), 4.56 (quin, J = 5.9 Hz, 1 H), 2.77 (dd, J = 7.1, 
16.8 Hz, 1 H), 2.69 (dd, J = 5.4, 16.8 Hz, 2 H), 2.65 (dd, J = 5.9, 15.7 Hz, 3 H), 2.61 - 
2.50 (m, 2 H), 2.46 - 2.32 (m, 2 H), 1.61 - 1.47 (m, 2 H), 1.35 - 1.17 (m, 8 H), 0.92 - 0.85 
(m, 3 H), 0.83 (s, 9 H), 0.05 (s, 6 H) 
13C NMR (125 MHz, CDCl3) δ 209.4, 205.8, 165.4, 133.0, 130.9, 128.6, 118.7, 69.3, 
65.3, 50.4, 49.6, 47.6, 44.5, 38.4, 31.8, 29.2, 29.2, 25.9 (3 C), 23.6, 22.7, 18.0, 14.2, –4.7, 
–4.7;  
HRMS (ESI) m/z 489.2996 [(M+Na)+; calcd for C26H46O5Si+Na: 489.3012]. 
 
 
Dihydropyrone 1.101. To a solution of acrylate 1.S3 (66 mg, 0.141 mmol) in degassed 
dichloromethane (7.1 mL) was added Hoveyda-Grubbs catalyst, 2nd generation (4.43 mg, 
7.07 µmol). The flask was sealed and heated to 80 °C in the microwave for 3 h. After 
cooling to rt, the reaction mixture was concentrated in vacuo and purified by flash 
 Hoveyda-Grubbs 
2nd gen. 5 mol%
CH2Cl2
80 °C, 3 h
OO O
O
n-C7H15
O
(+)-1.S3
TBS
OO O
O
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O
(–)-1.101
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column chromatography (4:1 hexanes/EtOAc → 1:1 hexanes/EtOAc) to give 
dihydropyrone 1.101 (55 mg, 89%). 
[α]D24 –62.30 (c 1.00, CHCl3); 
IR (thin film, KBr) νmax 2928, 2853, 2360, 1717, 1379, 1252, 1088, 836, 777 cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.88 (ddd, J = 2.4, 6.1, 9.8 Hz, 1 H), 6.03 (ddd, J = 1.0, 
2.8, 9.9 Hz, 1 H), 4.88 (dddd, J = 3.8, 5.4, 7.3, 11.3 Hz, 1 H), 4.57 (quin, J = 5.9 Hz, 1 
H), 3.01 (dd, J = 5.4, 17.6 Hz, 1 H), 2.82 (dd, J = 7.3, 17.6 Hz, 1 H), 2.70 (dd, J = 5.9, 
15.9 Hz, 1 H), 2.66 - 2.50 (m, 4 H), 2.47 - 2.35 (m, 2 H), 2.30 (tdd, J = 2.6, 11.7, 18.2 Hz, 
1 H), 1.54 (quin, J = 7.3 Hz, 2 H), 1.34 - 1.19 (m, 8 H), 0.87 (t, J = 6.7 Hz, 3 H), 0.85 (s, 
9 H), 0.07 (s, 3 H), 0.06 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 209.6, 205.5, 163.9, 145.0, 121.5, 73.5, 65.4, 50.5, 49.5, 
48.8, 44.6, 31.8, 29.2, 29.2, 25.9 (3 C), 23.6, 22.7, 18.0, 14.2, –4.7 (2 C);  
HRMS (ESI) m/z 439.2889 [(M+H)+; calcd for C24H42O5Si+H: 439.2880]. 
 
 
Alcohol 1.102. Silyl ether 1.101 (30 mg, 0.068 mmol) was dissolved in THF (1.4 mL) 
and water (0.06 mL). Trifluoroacetic acid (126 µl, 1.641 mmol) was added and the 
reaction was stirred at rt for 24 h, diluted with THF and quenched with sat. aq. NaHCO3. 
TFA, H2O
THF, rt
OHO O
O
n-C7H15
O
(–)-1.102
OO O
O
n-C7H15
O
(–)-1.101
TBS
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After extraction with EtOAc, organics were washed with water and brine, concentrated, 
and purified by flash chromatography (1:1 hexanes/EtOAc) to afford 1.102 as a clear, 
colorless oil (21 mg, 95%). 
[α]D24 –39.87 (c 1.00, CHCl3); 
IR (thin film, KBr) νmax 3410, 2928, 2856, 2253, 1718, 1388, 910, 732 cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.88 (ddd, J = 2.4, 6.0, 9.6 Hz, 1 H), 6.03 (ddd, J = 1.0, 
2.8, 9.9 Hz, 1 H), 4.91 (dtd, J = 4.5, 6.0, 11.3 Hz, 1 H), 4.49 (quin, J = 6.1 Hz, 1 H), 3.05 
(dd, J = 6.1, 17.2 Hz, 1 H), 2.80 (dd, J = 6.4, 17.1 Hz, 1 H), 2.70 - 2.59 (m, 4 H), 2.51 
(dddd, J = 0.8, 3.8, 6.1, 18.0 Hz, 1 H), 2.43 (t, J = 7.4 Hz, 2 H), 2.34 (tdd, J = 2.6, 11.7, 
18.0 Hz, 1 H), 1.70 - 1.46 (m, 2 H), 1.38 - 1.17 (m, 8 H), 0.88 (t, J = 6.9 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 211.3, 206.5, 163.8, 144.9, 121.5, 73.5, 64.2, 49.5, 48.2, 
48.0, 43.8, 31.8, 29.2, 29.1, 23.7, 22.7, 14.2;  
HRMS (ESI) m/z 347.1844 [(M+Na)+; calcd for C18H28O5+Na: 347.1834]. 
 
 
Triol 1.103. To a cooled (–78 ºC) solution of 1.102 (18 mg, 0.055 mmol) in MeOH/THF 
(1:1, 0.55 mL) was added diethyl(methoxy)borane (1.0 M in THF, 67 µL, 0.067 mmol). 
The solution was stirred at –78 ºC for 30 minutes, then sodium borohydride (6.00 mg, 
O
n-C7H15
O
OO OH OH
n-C7H15
a) Et2BOMe
b) NaBH4
1:1 THF/MeOH
−78 °C
O
OHO OH
(–)-1.102 (+)-1.103
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0.159 mmol) was added. The resulting reaction mixture was stirred at –78 ºC for 6.5 h, 
diluted with Et2O, quenched with AcOH and neutralized with sat. aq. NaHCO3. After 
extraction with EtOAc, organics were washed with water and brine, dried over Na2SO4 
and concentrated. The crude residue was taken up in MeOH and placed in the refrigerator 
(+4 ºC) overnight. After reconcentration, flash chromatography (98:2 → 90:10 
CH2Cl2/MeOH) afforded 1.103 as a clear, colorless oil (15 mg, 83%). 
[α]D24 –66.24 (c 0.75, CHCl3); 
IR (thin film, KBr) νmax 3347, 2926, 2853, 1682, 1449, 1321, 1140, 1103, 1038, 846, 818 
cm-1; 
1H NMR (500 MHz, CDCl3) δ 6.90 (ddd, J = 3.1, 5.4, 9.6 Hz, 1 H), 6.02 (br. d, J = 9.9 
Hz, 1 H), 4.78 - 4.60 (m, 1 H), 4.25 - 4.08 (m, 2 H), 3.96 - 3.84 (m, 1 H), 2.49 - 2.38 (m, 
2 H), 2.10 - 1.97 (m, 1 H), 1.82 - 1.75 (m, 1 H), 1.71 - 1.16 (m, 16 H), 0.88 (t, J = 6.5 Hz, 
3 H); 
13C NMR (125 MHz, CDCl3) δ 164.4, 145.5, 121.4, 76.3, 73.8, 73.4, 69.5, 43.6, 43.5, 
42.3, 38.5, 31.9, 29.7, 29.5, 29.4, 25.4, 22.8, 14.2;  
HRMS (ESI) m/z 351.2144 [(M+Na)+; calcd for C18H32O5+Na: 351.2147]. 
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Polyrhacitide A 1.52. Triol 1.103 (8.0 mg, 0.024 mmol) was dissolved in CH2Cl2 (1.2 
mL). DBU (49 mM in CH2Cl2, 100 µL, 4.9 µmol) was added and the reaction mixture 
was stirred at room temperature for 24 h then concentrated in vacuo. Flash column 
chromatography (98:2 CH2Cl2/MeOH) afforded 1.52 as a white solid (7.8 mg, 98%). 
mp 70–72 ºC 
[α]D26 +3.45 (c 0.59, CHCl3); 
IR (thin film, KBr) νmax 3315, 2923, 2853, 1722, 1448, 1380, 1282, 1199, 1053 cm-1; 
1H NMR (500 MHz, CDCl3) δ 4.88 (m, 1 H), 4.41 (br. s., 1 H), 4.16 - 3.97 (m, 2 H), 3.84 
(m, 1 H), 2.90 (br. d, J = 19.4 Hz, 1 H), 2.81 (dd, J = 5.2, 19.2 Hz, 1 H), 2.10 - 1.86 (m, 3 
H), 1.78 - 1.40 (m, 8 H), 1.28 (m, 9 H), 0.87 (t, J = 6.9 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 169.3, 72.8, 72.6, 72.3, 67.1, 66.2, 43.5, 43.1, 38.0, 37.4, 
36.6, 31.9, 29.8, 29.6, 29.4, 25.6, 22.8, 14.2;  
HRMS (ESI) m/z 329.2325 [(M+H)+; calcd for C18H32O5+H: 329.2328]; 351.2146 
[(M+Na)+; calcd for C18H32O5+Na: 351.2147].  
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Experimental Procedures Relevant to Chapter 2 
Examples of Tricomponent Fragment Unions 
 
Tricomponent adduct 1.116.  Allyllithium was prepared freshly according to the literature 
procedure (Seyferth, D.; Weiner, M. A. J. Org. Chem. 1961, 26, 4797) as follows: to a 
solution of allyltriphenylstannane (489 mg, 1.25 mmol) in Et2O (3.0 mL) at rt was added 
dropwise PhLi (1.30 M in dibutyl ether, 577 µL, 0.75 mmol). The resulting mixture was 
stirred for 30 min as white solids precipitated out. The supernatant (containing 
allyllithium) was then cannulated dropwise to a solution of aldehyde linchpin 1.108 (124 
mg, 0.5 mmol) in Et2O (2.0 mL) at –78 ºC.  After stirring for 30 min, a solution of allyl 
bromide (173 µL, 242 mg, 2.0 mmol) in Et2O/HMPA (1.0 mL, 10/1, v/v) was added 
dropwise.  The resulting mixture was allowed to warm slowly to rt over 1 h and stirred 
for an additional 3 h.  The reaction was then quenched with 1.0 N HCl (5 mL) and stirred 
overnight.  The reaction mixture was extracted with Et2O (3 × 10 mL).  The combined 
organic extracts were washed with brine, dried over MgSO4, filtered and concentrated in 
vacuo.  The crude product was purified by flash column chromatography on silica gel 
(95:5 hexanes/EtOAc) to afford three-component adduct 20 (syn:anti ≥ 20:1, 75 mg, 
58%) as a pale yellow oil.  The syn to anti ratio was determined by 1H NMR analysis of 
O
Me
TMS
SS HO
Me
SS
H
O
Me
TMS
SS
Et2O
–78 ºC, 30 min
HMPA/Et2O
–78 ºC to rt, 4h
BrLi
1.108 1.116
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the crude reaction mixture, and the relative stereochemistry was assigned by analogy to 
adduct 1.116. 
1H NMR (500 MHz, CDCl3) δ 6.05 - 5.75 (m, 2 H), 5.27 - 4.97 (m, 4 H), 4.53 (t, J = 6.7 
Hz, 1 H), 3.05 (tdd, J = 1.3, 6.3, 15.3 Hz, 1 H), 3.01 - 2.91 (m, 2 H), 2.82 - 2.67 (m, 3 H), 
2.40 - 2.29 (m, 2 H), 2.19 - 2.01 (m, 2 H), 1.98 - 1.83 (m, 2 H), 1.11 (d, J = 6.9 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 135.5, 134.1, 118.0, 117.4, 70.2, 57.7, 43.3, 41.0, 40.7, 
26.1, 26.0, 25.2, 7.1; 
IR (thin film, KBr) νmax 3466 (br), 2906, 1637, 1423, 1273, 915, 703 cm–1; 
HRMS (ESI) m/z  257.1052 [calcd for C13H21OS2 (M–H)+ 257.1034]. 
 
 
Tricomponent adduct 1.117. Generation of nucleophile: to a precooled (0 ºC) solution of 
3-phenyl-1-propyne (0.093 mL, 0.750 mmol) in Et2O (2 mL) was added n-butyllithium 
(0.307 mL of a 2.4 M solution in hexane, 0.750 mmol) dropwise. The cold bath was then 
removed and the reaction stirred at rt for 5 min.  
To a precooled (–78 ºC) solution of 1.108 (124 mg, 0.5 mmol) in Et2O (2 mL) was added 
the freshly prepared alkynyllithium dropwise via syringe (the original flask was rinsed 
with Et2O, 2 × 0.25 mL). The mixture was stirred for 15 min at –78 ºC, then a solution of 
Ph
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allyl bromide (173 µL, 2.00 mmol) Et2O/HMPA (1.0 mL, 10/1, v/v) was added dropwise. 
The resulting reaction mixture was stirred at –78 ºC for 1 h, then the cold bath was 
removed and the reaction was stirred for an additional 1 h.  The reaction was then 
quenched with sat. aq. NH4Cl (1 mL) and the biphasic mixture extracted with EtOAc (3 × 
2 mL). The organic extracts were combined, washed with brine, dried over Na2SO4, 
filtered and concentrated. The residue was taken up in THF (2 mL), 1 N HCl (2 mL) was 
added, and the reaction was stirred at rt overnight. Sat. aq. NaHCO3 (2 mL) was added, 
and the biphasic mixture extracted with EtOAc (3 × 2 mL). The organic extracts were 
combined, washed with brine, dried over Na2SO4, filtered and concentrated. The residue 
was then purified by flash column chromatography (95:5 hexanes/EtOAc) to furnish 
1.117 as a clear colorless oil (110 mg, 66%).  The syn to anti ratio was determined by 1H 
NMR analysis of the crude reaction mixture. 
1H NMR (500 MHz, CDCl3) δ 7.38 - 7.29 (m, 4 H), 7.27 - 7.21 (m, 1 H), 5.95 (dddd, J = 
6.2, 7.7, 10.4, 16.9 Hz, 1 H), 5.40 (dd, J = 1.8, 3.8 Hz, 1 H), 5.22 - 5.14 (m, 2 H), 3.66 (d, 
J = 1.8 Hz, 2 H), 3.11 - 3.00 (m, 1 H), 2.98 - 2.88 (m, 2 H), 2.85 - 2.76 (m, 2 H), 2.71 
(dd, J = 7.6, 15.4 Hz, 1 H), 2.57 (d, J = 4.2 Hz, 1 H), 2.25 (dq, J = 1.4, 7.1 Hz, 1 H), 2.02 
(qt, J = 3.4, 10.3 Hz, 1 H), 1.98 - 1.88 (m, 1 H), 1.33 (d, J = 7.1 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 136.7, 133.8, 128.6, 128.0, 126.7, 118.3, 83.0, 82.8, 63.8, 
56.8, 45.6, 41.0, 26.1, 26.1, 25.3, 25.0, 8.4; 
IR (thin film, KBr) νmax 3451 (br), 2920, 1495, 1452, 1422, 1074, 988 cm–1; 
HRMS (ESI) m/z 355.1170 [calcd for C19H24OS2Na (M+Na)+ 355.1166]. 
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Synthesis of Enantiomerically Enriched Aldehyde Bifunctional Linchpin (+)-1.108 
 
Alcohol 1.125. To a solution of (–)-(R)-Roche ester (1.123, 5 g, 4.69 mL, 42.3 mmol) in 
CH2Cl2 (49 mL) were added Et3N (8.85 mL, 63.5 mmol), DMAP (0.259 g, 2.116 mmol) 
and trityl chloride (12.39 g, 44.4 mmol). The mixture was stirred overnight at rt.  Sat. aq. 
NH4Cl (15 mL) was added. The layers were separated, and the aqueous layer was 
extracted with CH2Cl2 (3 × 15 mL). The combined organic layers were washed with 
brine, dried over Na2SO4, filtered and concentrated in vacuo to give 1.124 as a white 
solid, used in the next step without further purification. 
 To a rapidly stirring, precooled (0 ºC) suspension of LiAlH4 (1.605 g, 42.3 mmol) in 
THF (100 mL) was added via cannula a solution of 1.124 (15.25 g, 42.3 mmol) in THF 
(100 mL + 3 × 3 mL rinse). The reaction mixture was allowed to warm to rt and stirred 
for 2 h, then  cooled to 0 ºC, carefully quenched with H2O (15 mL) and 15% aq. 
Rochelle's salt (100 mL) and stirred overnight at rt. The biphasic mixture was extracted 
with EtOAc (3 × 100 mL). The combined organic layers were washed with brine, dried 
over Na2SO4, filtered and concentrated. The residue was purified by flash column 
chromatography (8:2 hexanes/EtOAc) to furnish 1.125 (12.60 g, 90%) as a white solid. 
[α]D22 = –23.2 (c 1.01, CHCl3); 
OMe
OOH
OMe
OTr OTrO
OH
TrCl, pyr. LiAlH4
CH2Cl2
0 ºC to rt
THF, 0 ºC
(–)-1.1251.124(–)-1.123
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1H NMR (500 MHz, CDCl3) δ 7.53 - 7.40 (m, 6 H), 7.38 - 7.30 (m, 6 H), 7.29 - 7.23 (m, 
3 H), 3.66 - 3.56 (m, 2 H), 3.26 (dd, J = 4.6, 9.1 Hz, 1 H), 3.07 (t, J = 8.1 Hz, 1 H), 2.32 
(br. s., 1 H), 2.12 - 2.01 (m, 1 H), 0.89 (d, J = 6.9 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 144.1, 128.8, 128.0, 127.2, 87.1, 67.9, 67.6, 36.2, 13.9; 
IR (thin film, KBr) νmax 3378 (br), 3061, 2921, 1490, 1448, 1034, 707 cm–1; 
HRMS (ESI) m/z 355.1677 [calcd for C23H24O2Na (M+Na)+ 355.1674]. 
 
 
Dithiane alcohol 1.110. To a precooled (–78 ºC) solution of oxalyl chloride (2.90 mL, 
33.1 mmol) in CH2Cl2 (150 mL) was added DMSO (5.87 mL, 83 mmol) dropwise. The 
mixture was stirred for 20 min at –78 ºC.  A solution of 1.125 (5.50 g, 16.54 mmol) in 
CH2Cl2 (15 mL + 2 × 2 mL rinse) was added slowly and the mixture was stirred for 30 
min at –78 ºC. Triethylamine (9.22 mL, 66.2 mmol) was then added slowly. The reaction 
mixture was allowed to warm to 0 °C. Sat. Aq. NaHCO3 (25 mL) was then added. The 
organic phase was separated, washed with H2O (100 mL), saturated aqueous CuSO4 (3 × 
100 mL), H2O (100 mL), brine (100 mL), then dried over Na2SO4, and concentrated in 
vacuo to afford 1.126 as a pale yellow solid, taken to the next step without further 
purification. 
OTr
H
OTr OH
H
SSO
OH
(COCl)2
DMSO
then NEt3
CH2Cl2
–78 ºC to rt
HS SH
BF3•OEt2
CH2Cl2
–78 ºC to rt(–)-1.125 (–)-1.1101.126
 88 
To a precooled (–78 ºC) solution of 1.126 (5.47 g, 16.54 mmol) in CH2Cl2 (48 mL) were 
added propane-1,3-dithiol (3.32 mL, 33.1 mmol) and BF3•OEt2 (4.19 mL, 33.1 mmol). 
The mixture was stirred at –78 ºC for 30 min, then the cold bath was removed and the 
mixture was allowed to warm to rt and stirred at rt for 3 h. Sat. aq. NaHCO3 (20 mL) was 
added (with caution: CO2 evolution). The mixture was extracted with CH2Cl2 (3 × 20 
mL). The organic layers were combined, dried over Na2SO4, filtered and concentrated in 
vacuo.  The residue was purified by flash chromatography (80:20 hexanes/Et2O) to 
furnish 1.110 (2.83 g, 96%) as a clear colorless oil. 
[α]D22 = –7.2 (c 1.22, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 4.31 (d, J = 5.0 Hz, 1 H), 3.77 - 3.65 (m, 2 H), 2.98 - 2.85 
(m, 4 H), 2.17 - 2.08 (m, 2 H), 1.93 - 1.82 (m, 1 H), 1.78 (br. s., 1 H), 1.12 (d, J = 6.9 Hz, 
3 H); 
13C NMR (125 MHz, CDCl3) δ 65.4, 52.0, 40.8, 31.1, 30.8, 26.4, 14.3; 
IR (thin film, KBr) νmax 3389 (br), 2897, 1490, 1421, 1275, 1036, 908, 768 cm–1; 
HRMS (CI) m/z 178.0479 [calcd for C7H14OS2 (M)+ 178.0486]. 
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Alcohol 1.127. To a precooled (0 ºC) solution of 1.110 (2.79 g, 15.65 mmol) in THF (31 
mL) was added dropwise n-BuLi (2.3 M solution in hexane, 14.97 mL, 34.4 mmol). The 
resulting red solution was stirred at 0 ºC for 30 min, then TMSCl (4.40 ml, 34.4 mmol) 
was added dropwise. The reaction mixture rapidly turned pale yellow. The ice bath was 
then removed and the reaction was allowed to warm to rt and stirred for 1.5 h, before 
quenching with 1 N aq. HCl (20 mL) and stirred for an additional 30 min. the reaction 
mixture was extracted with EtOAc (3 × 40 mL).  The combined organic extracts were 
washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude 
product was purified by flash column chromatography on silica gel (8:2 hexanes/EtOAc) 
to afford 1.127 (3.20 g, 82%) as a white solid.  
[α]D20 = –10.7 (c 1.12, CHCl3). 
1H NMR (500 MHz, CDCl3) δ 4.03 (dd, J = 10.8, 6.3 Hz, 1H), 3.62-3.55 (m, 1H), 3.13 
(t, J = 13.4 Hz, 1H), 2.98 (t, J = 13.4 Hz, 1H), 2.91 (s, 1H), 2.75 (q, J = 6.7 Hz, 1H), 
2.48-2.41 (m, 2H), 2.04 (app d, J = 13.4 Hz, 1H), 1.88 (app q, J = 12.9 Hz, 1H), 1.21 (d, 
J = 7.5 Hz, 3H), 0.23 (s, 9H); 
13C NMR (125 MHz, CDCl3) δ 67.4, 42.6, 42.1, 24.5, 24.2, 23.8, 17.1, –0.3; 
IR (thin film, KBr) νmax 3304 (br), 2949, 2904, 1456, 1420, 1247, 1021, 909, 843 cm–1; 
OH
H
SS OH
TMS
SSi. n-BuLi,ii. TMSCl
THF, 0 ºC to rt
iii. HCl
(–)-1.127(–)-1.110
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HRMS (ESI) m/z 251.0963 [calcd for C10H22OS2Si (M+H)+ 251.0960]. 
 
Linchpin 1.108. To a precooled (0 ºC) solution of 1.110 (1.668 g, 6.66 mmol) in CH2Cl2 
(33 mL) and DMSO (2.36 mL, 33.3 mmol), were added Et3N (4.64 mL, 33.3 mmol) and 
SO3•pyridine (3.18 g, 20.0 mmol). The ice/water bath was then removed and the reaction 
stirred at rt for 2.5 h, before quenching with aqueous pH 7 buffer. CH2Cl2 (50 mL) was 
added, the layers separated, and the organic layer washed with sat. aq. CuSO4 (3 × 15 
mL) and brine (15 mL), dried over Na2SO4, filtered, and concentrated in vacuo. The 
residue was purified by flash column chromatography (9:1 hexanes/EtOAc) to afford 
1.108 as a white solid (1.345 g, 81%).  
[α]D22 = +52.7 (c 0.47, CHCl3). 
1H NMR (500 MHz, CDCl3) δ 9.88 (s, 1H), 3.37-3.29 (m, 1H), 2.96 (t, J = 13.4 Hz, 2H), 
2.44 (t, J = 17.7 Hz, 2H), 2.07 (app d, J = 14.4 Hz, 1H), 1.90 (app q, J = 13.0 Hz, 1.H), 
1.28 (d, J = 7.0 Hz, 3H), 0.23 (s, 9H); 
13C NMR (125 MHz, CDCl3) δ 202.7, 52.1, 38.9, 24.4, 23.6, 23.1, 14.2, –0.8; 
IR (thin film, KBr) νmax 2952, 2901, 2831, 2730, 1714, 1455, 1423, 1386, 1250, 1101 
cm–1; 
HRMS (ESI) m/z 249.0808 [calcd for C10H20OS2Si (M+H)+ 249.0803]. 
1. n-BuLi 
    TMSCl 
2. SO3•py, DMSO
    Et3N
H
O
Me
TMS
SS
Me
SS
H
OH
(–)-1.110 (+)-1.108
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Determination of enantiomeric excess by chromatography on chiral stationary 
phase: 
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Sample tR  1 (min) Area 1 (%) tR  2 (min) Area 2 (%) 
(±)-1.108 1.487 49.79 1.973 50.21 
(–)-1.108 1.463 98.83 2.087 1.17 
(+)-1.108 1.473 0.48 2.052 99.52 
Conditions:  column: CHIRALPAK AD-H; eluent: 8:2 supercritical CO2/MeOH; flow 
rate: 4 mL/min; detection wavelength: 220 nm. 
 
Determination of diastereoselectivity of addition to linchpin 1.108: 
 
Alcohol 1.128. To a precooled (–78 ºC) solution of (+)-1.108 (50 mg, 0.201 mmol) in 
Et2O (1.0 mL) was added n-BuLi (97 µl, 2.5 M solution in hexanes, 0.241 mmol). The 
solution was stirred at –78 ºC for 30 min. Sat. aq. NH4Cl (1 mL) was then added and the 
resulting biphasic mixture was extracted with Et2O. The combined organic layers were 
dried over Na2SO4, filtered and concentrated in vacuo. 1H NMR analysis of the crude 
reaction mixture shows the presence of only one diastereomer of the desired product (dr 
> 20:1). The crude residue was then purified by column chromatography (95:5 
hexanes/EtOAc) to furnish 1.128 (43 mg, 70%) as a clear colorless oil.  
[α]D22 = +20.6 (c 0.27, CH2Cl2); 
n-Bu
OH SS
TMS
(+)-1.128
H
O
Me
TMS
SS
(+)-1.108
n-BuLi
Et2O
–78 ºC, 30 min
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1H NMR (500 MHz, CDCl3) δ 4.32 - 4.17 (m, 1 H), 3.04 - 2.86 (m, 2 H), 2.54 (qd, J = 
4.2, 13.3 Hz, 2 H), 2.37 - 2.20 (m, 2 H), 2.14 - 2.01 (m, 1 H), 1.95 - 1.82 (m, 1 H), 1.69 - 
1.50 (m, 1 H), 1.49 - 1.29 (m, 5 H), 1.22 (d, J = 7.1 Hz, 3 H), 0.93 (t, J = 7.0 Hz, 3 H), 
0.27 (s, 9 H); 
13C NMR (125 MHz, CDCl3) δ 71.9, 46.3, 42.3, 36.7, 28.7, 25.5, 25.1, 24.2, 22.9, 14.2, 
11.4, -0.5; 
IR (thin film, KBr) νmax 3414, 2932, 1681, 1441, 1138 cm–1; 
HRMS (ESI) m/z 329.1405 [calcd for C14H30ONaSiS2 (M+Na)+ 329.1402]. 
 
The Trost-Mosher esters of 1.128 were prepared and analyzed according to literature 
procedures: 
 
To a solution of 1.128 (12.3 mg, 0.040 mmol) in CH2Cl2 (0.7 mL) was added either (R)-
MTPA-OH or (S)-MTPA-OH (29 mg, 0.124 mmol), followed by DCC (26 mg, 0.124 
mmol) and DMAP (15 mg, 0.124 mmol). A white precipitate formed within one minute. 
The resulting reaction mixture was stirred overnight at rt, then filtered through cotton and 
n-Bu
OH SS
TMS
n-Bu
O SS
TMS
n-Bu
O SS
TMS
(R)-MTPA
(S)-MTPA
(R)-MTPA-OH
DCC, DMAP
CH2Cl2, rt
(S)-MTPA-OH
DCC, DMAP
CH2Cl2, rt
(+)-1.128
1.129-R
1.129-S
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concentrated in vacuo. The crude residue was chromatographed (95:5 hexanes/EtOAc) to 
furnish samples of 1.129-R and 1.129-S, analyzed by 1H NMR. 
 
Mosher ester 1.129-R. 
1H NMR (500 MHz, CDCl3) δ 7.70 - 7.63 (m, 2 H), 7.40 - 7.35 (m, 3 H), 5.60 (dd, J = 
4.8, 7.1 Hz, 1 H), 3.65 - 3.62 (m, 3 H), 2.78 - 2.63 (m, 2 H), 2.49 - 2.38 (m, 2 H), 2.34 
(ddd, J = 3.5, 5.9, 14.0 Hz, 1 H), 1.99 - 1.89 (m, 1 H), 1.82 (s, 2 H), 1.71 - 1.61 (m, 1 H), 
1.44 - 1.32 (m, 4 H), 1.28 (d, J = 7.1 Hz, 3H), 0.91 (t, J = 7.1 Hz, 3H), 0.15 (s, 9 H). 
 
Mosher ester 1.129-S. 
1H NMR (500 MHz, CDCl3) δ 7.81 - 7.52 (m, 2 H), 7.49 - 7.29 (m, 3 H), 5.71 (t, J = 6.0 
Hz, 1 H), 3.54 (s, 3 H), 2.76 (dtd, J = 3.3, 10.3, 13.8 Hz, 2 H), 2.57 (ddd, J = 3.6, 6.5, 
13.9 Hz, 1 H), 2.50 - 2.39 (m, 1 H), 2.34 (q, J = 7.3 Hz, 1 H), 2.01 (tdd, J = 3.1, 6.3, 13.2 
Hz, 1 H), 1.90 - 1.79 (m, 1 H), 1.70 - 1.59 (m, 2 H), 1.41 - 1.23 (m, 4 H), 1.21 (d, J = 7.1 
Hz, 3 H), 0.89 (t, J = 7.1 Hz, 3 H), 0.23 (s, 9 H).  
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Application to the Synthesis of a C16-C29 Fragment of Rhizopodin 
Synthesis of vinyliodide 1.136 
 
Alcohol 1.139. To a solution of 1.138 (6.08 g, 58.4 mmol) and imidazole (5.06 g, 74.3 
mmol) in CH2Cl2 (160 mL) was added TBSCl (8 g, 53.1 mmol). The mixture was stirred 
at rt for 1 hour.  Water (50 mL) was added. The layers were separated and the organic 
layer was extracted with CH2Cl2 (3 × 50 mL). The organic layers were combined, dried 
over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash 
column chromatography (90:10 hexanes/EtOAc) to furnish 1.139 as a clear colorless oil 
(6.31 g, 54%).  
1H NMR (500 MHz, CDCl3) δ 3.48 (br. t, J = 2.4 Hz, 4 H), 2.83 (t, J = 5.6 Hz, 1 H), 0.93 
- 0.88 (m, 15 H), 0.09 - 0.07 (m, 6 H); 
13C NMR (125 MHz, CDCl3) δ 72.9, 72.4, 36.5, 26.0, 21.6, 18.3, -5.5; 
IR (thin film, KBr) νmax 3389 (br), 2956, 2858, 1472, 1361, 1257, 1097, 837, 775 cm–1; 
HRMS (ESI) m/z 219.1786 [calcd for C11H27O2Si (M+H)+ 219.1780]. 
 
Me Me
OHTBSO
Me Me
OHHO
TBSCl
imidazole
CH2Cl2, rt
1.138 1.139
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Aldehyde 1.140. To a precooled (0 ºC) solution of 1.139 (1.6 g, 7.33 mmol), DMSO (5.20 
mL, 73.3 mmol) and Et3N (3.06 mL, 21.98 mmol) in CH2Cl2 (37 mL) was added 
SO3•pyridine (3.50 g, 21.98 mmol). The cold bath was removed and the reaction mixture 
stirred for 1 hour. The reaction was quenched with water and brine. The layers were 
separated and the aqueous layer was extracted with CH2Cl2 (3 × 20 mL). Organic layers 
were combined, washed with brine, dried over Na2SO4, filtered and concentrated in 
vacuo. The residue was purified by flash column chromatography (98:2 hexanes/EtOAc) 
to furnish 1.140 as a clear colorless oil (1.29 g, 82%).   
1H NMR (500 MHz, CDCl3) δ 9.58 (s, 1 H), 3.60 (s, 2 H), 1.05 (s, 6 H), 0.87 (s, 9 H), 
0.04 (s, 6 H); 
13C NMR (125 MHz, CDCl3) δ 206.3, 68.5, 48.2, 25.9, 18.7, 18.3, -5.5; 
IR (thin film, KBr) νmax 2957, 2857, 2708, 1734, 1472, 1258, 1104, 838, 777 cm–1; 
HRMS (ESI) m/z 216.1538 [calcd for C11H24O2Si (M)+ 216.1546]. 
 
 
 
Me Me
OTBSO
H
Me Me
OHTBSO
SO3•pyridine
DMSO, NEt3
CH2Cl2, 0 ºC
1.1401.139
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Vinyl iodide 1.136. To a suspension of CrCl2 (2.77 g, 22.5 mmol) in THF (35 mL) at 0 ºC 
was added a solution of aldehyde 27 (810 mg, 3.75 mmol) and CHI3 (3.0 g, 7.5 mmol) in 
THF (10 mL).  The resulting mixture was stirred in the dark at 0 ºC for 1 h, and then 
warmed to rt overnight.  The reaction mixture was quenched with saturated aqueous 
Na2S2O3 solution (30 mL) and extracted with Et2O (3 × 30 mL).  The combined organic 
extracts were washed with additional Na2S2O3 solution (3 × 30 mL) and brine, dried over 
MgSO4, filtered and concentrated in vacuo.  The crude reaction mixture was taken up in 
hexanes to precipitate out excess CHI3, filtered and concentrated in vacuo.  This process 
was repeated three times.  The crude product was purified by flash column 
chromatography on silica gel (100% hexanes) to afford vinyliodide 25 (980 mg, 77%) as 
a  clear, pale yellow oil. 
1H NMR (500 MHz, CDCl3) δ 6.56 (d, J = 15.2 Hz, 1H), 6.01 (d, J = 15.2 Hz, 1H), 3.29 
(s, 2H), 0.98 (s, 6H), 0.89 (s, 9H), 0.03 (s, 6H);  
13C NMR (125 MHz, CDCl3) δ 153.6, 73.9, 71.2, 43.2, 26.0, 23.3, 18.4, −5.3; 
IR (thin film, KBr) νmax 2956, 2929, 2856, 1731, 1600, 1471, 1390, 1361, 1256, 1102 
cm–1; 
HRMS (ESI) m/z 325.0488 [calcd for C11H22IOSi [M–CH3]+ 325.0479]. 
 
Me Me
ITBSO
Me Me
OTBSO
H
HCI3, CrCl2
THF, +4 ºC
2 days1.140 1.136
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Synthesis of Epoxide 1.137: mixture of diastereomers 1.137a and 1.137b 
 
Alcohol 1.S4. To a precooled (0 ºC) suspension of sodium hydride (0.699 g, 17.5 mmol, 
60% w/w in mineral oil) in THF (17 mL) was added a solution 1.141 (1.50 g, 16.6 mmol) 
in THF (17 mL). The mixture was stirred at 0 ºC for 1 h then a solution of TBDPSCl 
(4.80 g, 17.5 mmol) in THF (15 mL + 3 mL rinse) was added. The mixture was stirred at 
0 ºC for 2 h, then diluted with EtOAc (80 mL). Sat. aq. NaHCO3 (30 mL) was added, the 
layers were separated and the organic layer was washed with brine, dried over Na2SO4, 
filtered and concentrated in vacuo.  Flash column chromatography (95:5 → 1:1 
hexanes/EtOAc) furnished 1.S4 as a clear colorless oil (4.52 g, 83%). 
1H NMR (500 MHz, CDCl3) δ 7.73 - 7.66 (m, 4 H), 7.47 - 7.38 (m, 6 H), 3.70 (td, J = 
5.7, 21.0 Hz, 4 H), 1.74 - 1.63 (m, 4 H), 1.08 (s, 9 H); 
13C NMR (125 MHz, CDCl3) δ 135.7, 133.8, 129.8, 127.8, 64.2, 63.0, 30.0, 29.4, 27.0, 
19.3; 
IR (thin film, KBr) νmax 3348, 2928, 1472, 1427, 1112, 823 cm–1; 
HRMS (ESI) m/z 329.1933 [calcd for C20H29O2Si (M+H)+ 329.1937]. 
 
 
 i. NaH
 ii. TBDPSClHO
OH
1.141
HO
OTBDPS
1.S4THF, 0 ºC
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Aldehyde 1.S5. To a precooled (–78 ºC) solution of oxalyl chloride (1.624 mL, 18.56 
mmol) in CH2Cl2 (46 mL) was added slowly DMSO (3.29 mL, 46.4 mmol). The mixture 
was stirred at –78 ºC for 30 min, then a solution of 1.S4 (3.048 g, 9.28 mmol) in CH2Cl2 
(46 mL + 2 × 5 mL rinse) was slowly added. The mixture was then stirred at –78 ºC for 
30 min, then Et3N (5.17 mL, 37.1 mmol) was slowly added and the cold bath was 
removed. Aq. pH 7 buffer was added (30 mL). The layers were separated and the aqueous 
layer was extracted with CH2Cl2 (3 × 30 mL). Organic layers were combined, dried over 
Na2SO4, filtered and concentrated in vacuo. Flash column chromatography (95:5 
hexanes/EtOAc) afforded 1.S5 as a clear colorless oil (2.15 g, 71%).  
1H NMR (500 MHz, CDCl3) δ 9.81 (s, 1 H), 7.70 - 7.63 (m, 4 H), 7.47 - 7.37 (m, 6 H), 
3.70 (t, J = 5.9 Hz, 2 H), 2.57 (dt, J = 1.3, 7.1 Hz, 2 H), 1.91 (quin, J = 6.6 Hz, 2 H), 1.06 
(s, 9 H); 
13C NMR (125 MHz, CDCl3) δ 202.7, 135.7, 133.7, 129.8, 128.5, 127.8, 63.0, 40.9, 27.0, 
25.4, 19.3; 
IR (thin film, KBr) νmax 3071, 2930, 1726, 1589, 1472, 1428, 1390, 1362, 1112, 823, 
739, 614 cm–1; 
HRMS (ESI) m/z 349.1603 [calcd for C20H26O2NaSi (M+Na)+ 349.1600]. 
 
(COCl)2, DMSO,
Et3N
H
OTBDPS1.S5
CH2Cl2, –78 ºC
HO
OTBDPS1.S4
O
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Crotyl alcohol 1.142. 
Generation of (–)-Ipc2B((E)-crotyl): To a precooled (–78 ºC) solution of (E)-but-2-ene 
(1.80 g, 32.2 mmol) and t-BuOK (7.72 mL, 1.0 M solution in THF, 7.72 mmol) in THF 
(11 mL) was added dropwise n-BuLi (3.33 mL, 2.32 M in hexanes, 7.72 mmol). The 
reaction was allowed to warmed to –45 ºC over 15 min, stirred for 10-15 min and cooled 
to –78 ºC. A solution of (–)-Ipc2BOMe (2.441 g, 7.72 mmol) in THF (5.5 mL) was then 
added and the resulting mixture was stirred for 30 min at –78 ºC. 
Addition to aldehyde: To the previous reaction mixture was added BF3•OEt2 (0.978 mL, 
7.72 mmol), followed by a solution of 1.S5 (2.1 g, 6.43 mmol) in THF (5.5 mL + 2 × 2 
mL rinse). The resulting mixture was stirred for 1.5 h at –78 ºC.  
The reaction was quenched with 3 M aq. NaOH (13 mL) and 30% aq. H2O2 (1.6 mL), 
warmed to rt and stirred overnight. 
The mixture was extracted with EtOAc (3 × 20 mL). The organic layers were combined, 
washed with brine, dried over Na2SO4, filtered and concentrated in vacuo.  The residue 
was purified by flash column chromatography (95:5 hexanes/Et2O) to furnish 1.142 as a 
clear, colorless oil. 
[α]D22 = –2.75 (c 0.87, CHCl3); 
i. (–)-Ipc2B((E)-crotyl)
ii. NaOH, H2O2 (80%)
Me
OH
OTBDPS
(–)-1.142
H
OTBDPS1.S5
O
THF
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1H NMR (500 MHz, CDCl3) δ 7.69 (dd, J = 1.2, 6.7 Hz, 4 H), 7.47 - 7.37 (m, 6 H), 5.79 
(ddd, J = 8.1, 10.6, 16.9 Hz, 1 H), 5.15 - 5.09 (m, 2 H), 3.71 (t, J = 5.8 Hz, 2 H), 3.45 
(ddd, J = 3.0, 5.8, 8.8 Hz, 1 H), 2.23 (sxt, J = 6.9 Hz, 1 H), 1.80 - 1.60 (m, 3 H), 1.50 - 
1.40 (m, 1 H), 1.10 - 1.02 (m, 12 H); 
13C NMR (125 MHz, CDCl3) δ 140.6, 135.7, 134.0, 129.7, 127.8, 116.1, 74.6, 64.2, 44.2, 
31.0, 28.9, 27.0, 19.3, 16.3; 
IR (thin film, KBr) νmax 3434, 2930, 2858, 1427, 1111, 701 cm–1; 
HRMS (CI) m/z 383.2421 [calcd for C24H35O2Si (M+H)+ 383.2406]. 
 
Mosher esters of 1.142 were prepared according to the procedure detailed above (see 
1.128):  
 
 
 
Nucleus or Nuclei (R)-Ester (1.S6-R) δR (ppm) 
(S)-Ester (1.S6-S) 
δS (ppm) 
δR–δS 
(ppm) 
1 5.715 5.660 +0.09 
2 5.060 5.015 +0.08 
3 2.509 2.470 +0.07 
4 1.023 0.927 +0.06 
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Mosher ester 1.S6-R (single diastereomer detected) 
1H NMR (500 MHz, CDCl3) δ 7.68 - 7.61 (m, 4 H), 7.59 - 7.53 (m, 2 H), 7.46 - 7.36 (m, 
9 H), 5.77 - 5.68 (m, 1 H), 5.13 - 5.04 (m, 3 H), 3.58 (t, J = 6.1 Hz, 2 H), 3.55 (d, J = 0.8 
Hz, 3 H), 2.52 (sxt, J = 6.7 Hz, 1 H), 1.71 - 1.63 (m, 2 H), 1.51 - 1.39 (m, 2 H), 1.07 - 
1.01 (m, 12 H). 
Mosher ester 1.S6-S (single diastereomer detected) 
1H NMR (500 MHz, CDCl3) δ 7.71 - 7.63 (m, 4 H), 7.61 - 7.54 (m, 2 H), 7.48 - 7.37 (m, 
9 H), 5.72 - 5.63 (m, 1 H), 5.13 - 5.07 (m, 1 H), 5.07 - 5.00 (m, 2 H), 3.69 - 3.64 (m, 2 
H), 3.56 (s, 3 H), 2.49 (sxt, J = 6.9 Hz, 1 H), 1.78 - 1.69 (m, 2 H), 1.63 - 1.53 (m, 2 H), 
1.06 (s, 9 H), 0.94 (d, J = 6.9 Hz, 3 H). 
 
 
Methyl ether 1.143. To a precooled (0 ºC) solution of 1.142 (148 mg, 0.387 mmol) in 
THF (2.6 mL) was added NaH (46 mg, 1.2 mmol, 60% w/w in mineral oil). The mixture 
was stirred at 0 ºC for 10 min, then MeI (73 µL, 1.2 mmol) was added and the stirring 
was resumed overnight, while allowing to warm to rt. The reaction was quenched with 
sat. aq. NH4Cl (1 mL), the mixture extracted with Et2O (3 × 3 mL). The organic layers 
Me
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were combined, washed with brine, dried over Na2SO4, filtered and concentrated in 
vacuo. Ether 1.143 was used in the next step without further purification. 
[α]D23 = –7.60 (c 0.85, CHCl3); 
1H NMR (500 MHz, CDCl3) δ 7.70 - 7.67 (m, 4 H), 7.47 - 7.36 (m, 6 H), 5.85 - 5.75 (m, 
1 H), 5.07 - 5.00 (m, 2 H), 3.74 - 3.63 (m, 2 H), 3.34 (s, 3 H), 3.05 (td, J = 4.4, 7.6 Hz, 1 
H), 2.49 - 2.41 (m, 1 H), 1.74 - 1.64 (m, 1 H), 1.64 - 1.42 (m, 3 H), 1.06 (s, 9 H), 1.01 (d, 
J = 6.9 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 141.0, 135.7, 134.2, 129.6, 127.7, 114.6, 84.9, 64.1, 57.7, 
40.2, 29.0, 27.0, 26.8, 19.4, 15.0; 
IR (thin film, KBr) νmax 3071, 2930, 2857, 1427, 1111, 701 cm–1; 
HRMS (CI) m/z 397.2570 [calcd for C25H37O2Si (M+H)+ 397.2563]. 
 
Epoxide 1.137 (1:1 mixture of diastereomers). To a precooled (0 ºC) solution of 1.143 in 
CH2Cl2 (2.6 mL) was added m-CPBA (0.130 g, 0.581 mmol) portionwise. The mixture 
was stirred overnight while allowing to warm to rt, then quenched slowly with sat. aq. 
Na2S2O3 (1 mL), resulting in formation of a white suspension, which was dissolved by 
addition of sat. aq. NaHCO3 (1 mL). The mixture was extracted with CH2Cl2 (3 × 2 mL). 
The combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. 
Flash column chromatography (95:5 hexanes/Et2O) furnished 1.137 as a clear colorless 
oil (1:1 mixture of diastereomers, 142 mg, 89%). 
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[α]D22 = –8.27 (c 0.36, CH2Cl2);  
1H NMR (500 MHz, CDCl3) δ 7.71 - 7.65 (m, 8 H), 7.47 - 7.35 (m, 12 H), 3.76 - 3.64 
(m, 4 H), 3.35 (s, 6 H), 3.25 - 3.19 (m, 1 H), 3.18 - 3.10 (m, 1 H), 2.92 - 2.83 (m, 2 H), 
2.79 (t, J = 4.4 Hz, 1 H), 2.73 (t, J = 4.6 Hz, 1 H), 2.59 (dd, J = 2.8, 5.0 Hz, 1 H), 2.48 
(dd, J = 2.7, 5.1 Hz, 1 H), 1.76 - 1.53 (m, 10 H), 1.53 - 1.45 (m, 1 H), 1.06 (s, 18 H), 1.01 
(d, J = 6.9 Hz, 3 H), 0.91 (d, J = 7.1 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 135.7, 135.7, 134.2, 134.1, 129.7, 129.7, 127.7, 127.7, 
83.6, 83.3, 77.4, 77.2, 76.9, 64.1, 64.0, 58.0, 57.7, 54.7, 53.7, 47.5, 45.4, 39.6, 38.7, 28.8, 
28.3, 27.4, 27.0, 27.0, 26.9, 19.3, 12.9, 11.4; 
IR (thin film, KBr) νmax 3071, 3047, 2931, 2857, 2822, 1472, 1428, 1388, 1360, 1110 
cm–1; 
HRMS (ESI) m/z 435.2331 [calcd for C25H36O3SiNa (M+Na)+ 435.2331].  
 
Diastereomer separation was carried out by Dr. Ming Chen using Medium Pressure 
Liquid Chromatography. The data below, used in conjunction with computational studies 
to assign the relative stereoconfigurations of 1.137a and 1.137b (see Appendix, 3.), were 
collected on these initial batches. 
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Epoxide 1.137a: 
 
1H NMR (500 MHz, C6D6) δ 7.86 - 7.75 (m, 4 H), 7.29 - 7.20 (m, 6 H), 3.76 - 3.68 (m, 2 
H), 3.12 (s, 3 H), 3.11 - 3.06 (m, 1 H), 2.79 (ddd, J = 2.8, 4.0, 7.1 Hz, 1 H), 2.33 (dd, J = 
4.3, 5.1 Hz, 1 H), 2.09 (dd, J = 2.7, 5.3 Hz, 1 H), 1.81 - 1.74 (m, 1 H), 1.73 - 1.63 (m, 3 
H), 1.50 (dq, J = 3.0, 7.1 Hz, 1 H), 1.22 - 1.17 (m, 9 H), 0.80 (d, J = 7.1 Hz, 3 H). 
 
Epoxide 1.137b: 
 
1H NMR (500 MHz, C6D6) δ 7.82 - 7.76 (m, 4 H), 7.26 - 7.20 (m, 6 H), 3.68 - 3.63 (m, 2 
H), 3.07 (s, 3 H), 2.87 (dt, J = 4.5, 6.4 Hz, 1 H), 2.74 (ddd, J = 2.7, 3.9, 6.9 Hz, 1 H), 2.47 
(dd, J = 3.9, 5.3 Hz, 1 H), 2.33 (dd, J = 2.6, 5.2 Hz, 1 H), 1.70 - 1.44 (m, 5 H), 1.43 - 1.36 
(m, 1 H), 1.19 (s, 10 H), 0.98 (d, J = 6.9 Hz, 3 H). 
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Synthesis of 1.137a Employing Hydrolytic Kinetic Resolution (HKR) 
 
Kinetic resolution. To a solution of 1.144 (14 mg, 0.023 mmol) in toluene (1 mL) was 
added AcOH (13.32 µL, 0.233 mmol). The mixture was stirred at rt open to air for 30 
min then concentrated in vacuo.  A solution of 1.137a + 1.137b (1:1, 480 mg, 1.163 
mmol) in THF (1.9 mL) was then added. The mixture was cooled to 0 ºC and H2O (11 
µL, 0.593 mmol) was added. The mixture was allowed to warm to rt and stirred for 96 h. 
Aliquot analysis by 1H NMR revealed incomplete conversion, therefore 1.144 (28 mg, 
0.046 mmol) and H2O (14 µL) were added to the reaction, and stirring was resumed for 
48 h before concentration in vacuo and flash chromatography, furnishing 1.137a (122 
mg, 25%) and 1.145 (195 mg, 40%) as clear oils. 
 
Epoxide 1.137a: 
[α]D22 = –4.8 (c 0.35, CH2Cl2);  
1H NMR (500 MHz, CDCl3) δ 7.73 - 7.63 (m, 4 H), 7.47 - 7.35 (m, 6 H), 3.76 - 3.67 (m, 
2 H), 3.35 (s, 3 H), 3.25 - 3.19 (m, 1 H), 2.89 (td, J = 3.4, 7.0 Hz, 1 H), 2.73 (t, J = 4.5 
N N
O O
t-Bu
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t-Bu Co
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Hz, 1 H), 2.48 (dd, J = 2.8, 5.0 Hz, 1 H), 1.78 - 1.54 (m, 6 H), 1.06 (s, 9 H), 0.91 (d, J = 
7.1 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 135.7, 134.2, 129.7, 127.7, 83.3, 64.1, 57.7, 53.7, 45.4, 
38.7, 28.8, 27.0, 26.9, 19.4, 11.4; 
IR (thin film, KBr) νmax 3071, 2929, 2857, 1472, 1428, 1111 cm–1; 
HRMS (ESI) m/z 435.2317 [calcd for C25H36O3SiNa (M+Na)+ 435.2331 
 
 
Diol 1.145: 
[α]D22 = –13.4 (c 0.33, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.72 - 7.63 (m, 4 H), 7.47 - 7.37 (m, 6 H), 3.89 (td, J = 
3.3, 7.9 Hz, 1 H), 3.69 (t, J = 6.2 Hz, 2 H), 3.62 (dd, J = 7.9, 10.9 Hz, 1 H), 3.55 (dd, J = 
3.8, 10.9 Hz, 1 H), 3.35 (s, 3 H), 3.24 (q, J = 5.5 Hz, 1 H), 1.83 - 1.75 (m, 1 H), 1.73 - 
1.52 (m, 6 H), 1.06 (s, 9 H), 0.95 (d, J = 7.1 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 135.7, 134.0, 129.7, 127.8, 85.3, 73.2, 65.0, 63.9, 57.6, 
37.6, 27.5, 27.0, 26.6, 19.3, 12.6; 
IR (thin film, KBr) νmax 3398, 2928, 1589, 1428, 1111, 823, 701 cm–1; 
HRMS (ESI) m/z 431.2615 [calcd for C25H39O4Si (M+H)+ 431.2618]. 
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Pivalate 1.S7. To a precooled (0 ºC) solution of 1.145 (195 mg, 0.453 mmol) and DMAP 
(122 mg, 0.996 mmol) in CH2Cl2 (1.5 mL) was added pivaloyl chloride (61 µL, 0.498 
mmol) dropwise. The mixture was stirred at 0 ºC for 15 min, following which  MeOH 
(0.5 mL) was added. The reaction mixture was then concentrated in vacuo and subjected 
to flash column chromatography (85:15 hexanes/Et2O) to furnish 1.S7 (143 mg, 61%) as 
a clear colorless oil. 
[α]D22 = –8.15 (c 0.35, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.68 (dd, J = 1.4, 7.9 Hz, 4 H), 7.47 - 7.37 (m, 6 H), 4.15 
- 4.00 (m, 3 H), 3.69 (t, J = 6.1 Hz, 2 H), 3.36 (s, 3 H), 3.26 (q, J = 5.5 Hz, 1 H), 3.18 (br. 
s., 1 H), 1.82 - 1.74 (m, 1 H), 1.72 - 1.66 (m, 2 H), 1.62 - 1.54 (m, 2 H + H2O), 1.22 (s, 9 
H), 1.06 (s, 9 H), 0.98 (d, J = 7.1 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 178.7, 135.7, 134.0, 129.7, 127.8, 85.1, 69.8, 66.7, 63.9, 
57.9, 38.9, 37.6, 27.8, 27.4, 27.0, 26.8, 19.3, 11.6; 
IR (thin film, KBr) νmax 3467, 2930, 1729, 1461, 1161, 1111, 701 cm–1; 
HRMS (ESI) m/z 515.3192 [calcd for C30H47O5Si (M+H)+ 515.3193]. 
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Epoxide 1.137a from 1.S7. 
To a precooled (0 ºC) solution of 1.S7 (142 mg, 0.276 mmol) and Et3N (85 µL, 0.607 
mmol) in CH2Cl2 (2.8 mL) was added MsCl (32 µL, 0.414 mmol) dropwise. The mixture 
was stirred at 0 ºC for 30 min, following which MeOH was added (0.5 mL). The mixture 
was concentrated in vacuo and the resulting mesylate used in then next step without 
further purification. 
To a precooled (0 ºC) solution of the mesylate in MeOH/Et2O (1:2, 2.7 mL) was added 
NaH (60% w/w in mineral oil, 88 mg, 2.208 mmol) portionwise. The reaction was 
warmed to rt and stirred for 1 h, before quenching carefully with sat. aq. NH4Cl (1 mL). 
Water (1 mL) and EtOAc (3 mL) were added and the layers were separated. The aqueous 
layer was extracted with EtOAc (3 × 5 mL). The organic layers were combined, dried 
over Na2SO4, filtered and concentrated in vacuo. Flash column chromatography (95:5 
hexanes/Et2O) furnished 1.137a (72 mg, 63%) as a clear colorless oil. Spectroscopic data 
consistent with that of previous batches (vide supra). 
 
Diastereoselective Synthesis of 1.137a Employing Iodocarbonate Cyclizations 
 
Carbonate 1.142. To a precooled (0 ºC) solution of 1.142 (1.26 g, 3.19 mmol) in THF (16 
ml) was added dropwise NaHMDS (1.0 M solution in THF, 4.78 ml, 4.78 mmol). The 
NaHMDS,
Boc2O
(–)-1.142
OH
Me OTBDPS
(+)-1.S8
OBoc
Me OTBDPS
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reaction was stirred for 30 min at 0 ºC, then Boc2O (1.04 g, 4.78 mmol) was added and 
the reaction was allowed to warm to rt and stirred for 15 min.  Brine (5 mL) was added 
and the resulting mixture was extracted with Et2O (3 × 20 mL). The organic layers were 
combined and dried over Na2SO4, filtered and concentrated in vacuo. The residue 
purified by flash column chromatography  (8:2 hexanes/Et2O) to afford 1.S8 as a clear 
colorless oil (1.70 g, quant.). 
[α]D22 = +2.9 (c 0.92, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.67 (d, J = 7.3 Hz, 4 H), 7.46 - 7.36 (m, 6 H), 5.77 (ddd, 
J = 8.1, 10.3, 18.4 Hz, 1 H), 5.11 - 5.02 (m, 2 H), 4.66 - 4.60 (m, 1 H), 3.73 - 3.62 (m, 2 
H), 2.43 (sxt, J = 6.8 Hz, 1 H), 1.74 - 1.51 (m, 4 H), 1.48 (s, 9 H), 1.09 - 1.01 (m, 12 H); 
13C NMR (125 MHz, CDCl3) δ 153.9, 139.6, 135.7, 134.1, 129.7, 127.7, 115.7, 81.7, 
80.1, 63.6, 41.9, 28.7, 28.0, 27.9, 27.6, 27.0, 19.4, 16.0; 
IR (thin film, KBr) νmax 3454, 2931, 1737, 1368, 1278, 1166, 1111 cm–1; 
HRMS (ESI) m/z 505.2755 [calcd for C29H42O4NaSi [M+Na]+ 505.2750]. 
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Iodocarbonate 1.147a. To a precooled (–85 ºC, Et2O/dry ice bath) solution of 1.S8 (199 
mg, 0.400 mmol) in CH2Cl2 (4.0 mL) was added IBr (124 mg, 0.600 mmol). The 
resulting reaction mixture was stirred at –85 ºC for 30 min, then  warmed to 0 ºC. Were 
then added sat. aq. Na2S2O3 (1 mL), sat. aq. NaHCO3 (1 mL). Layers were partitioned 
and the aqueous layer was extracted with Et2O (3 × 5 mL), dried over Na2SO4, filtered 
and concentrated in vacuo. 1H NMR analysis of the crude reaction mixture revealed a 
diastereomeric ratio of 8.5:1. Flash column chromatography (85:15 → 1:1 
hexanes/EtOAc) afforded 1.147a (single diastereomer) as a clear pale yellow oil (135 mg, 
61%). 
[α]D22 = –0.1 (c 2.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.72 - 7.62 (m, 4 H), 7.48 - 7.37 (m, 6 H), 4.23 - 4.16 (m, 
1 H), 3.81 - 3.69 (m, 3 H), 3.57 (dd, J = 2.9, 11.6 Hz, 1 H), 3.37 (dd, J = 4.0, 11.7 Hz, 1 
H), 2.04 - 1.91 (m, 2 H), 1.90 - 1.79 (m, 1 H), 1.75 - 1.61 (m, 2 H), 1.07 (s, 9 H), 0.97 (d, 
J = 6.7 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 148.8, 135.7, 133.8, 133.8, 129.9, 127.9, 82.5, 80.5, 63.1, 
37.0, 29.0, 27.0, 19.4, 12.1, 6.7; 
IR (thin film, KBr) νmax 2929, 2854, 1755, 1427, 1387, 1223, 1187, 1111 cm–1; 
Me
O
(–)-1.147a
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HRMS (EI, H) m/z calcd for C25H33O4NaSiI [M+Na]+ 575.1091, found 575.1096. 
Iodocarbonate 1.147b (analytical sample) 
 
[α]D22 = +31.7 (c 1.0, CH2Cl2);  
1H NMR (500 MHz, CDCl3) δ 7.66 (d, J = 6.7 Hz, 4 H), 7.48 - 7.38 (m, 6 H), 4.63 (ddd, 
J = 3.4, 6.3, 9.5 Hz, 1 H), 4.31 - 4.25 (m, 1 H), 3.79 - 3.69 (m, 2 H), 3.35 (dd, J = 6.3, 
10.3 Hz, 1 H), 3.17 (dd, J = 8.6, 10.2 Hz, 1 H), 2.35 - 2.27 (m, 1 H), 1.90 - 1.72 (m, 3 H), 
1.72 - 1.61 (m, 1 H), 1.09 - 1.04 (m, 12 H); 
13C NMR (125 MHz, CDCl3) δ 148.0, 135.7, 133.8, 129.9, 127.9, 84.1, 77.9, 63.0, 32.0, 
31.0, 28.0, 27.0, 19.4, 11.0, 0.7; 
IR (thin film, KBr) νmax 2929, 2854, 1751, 1427, 1387, 1174, 1111 cm–1; 
HRMS (ESI) m/z 575.1091 [calcd for C25H33O4NaSiI (M+Na)+ 575.1091]. 
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Epoxide 1.S9. To a solution of 1.147a (1.26 g, 2.030 mmol) in MeOH (20 mL) was added 
K2CO3 (0.842 g, 6.09 mmol) and the resulting mixture was stirred at rt overnight.  Sat. 
aq. NaHCO3 (3 mL) was then added, followed by water (3 mL) and sat. aq. Na2S2O3 (3 
mL). The mixture was extracted with EtOAc (3 × 20 mL). The organic layers were 
combined, dried over Na2SO4, filtered and concentrated. The residue was purified by  
flash column chromatography (85:15 hexanes/EtOAc) to afford 1.S9 as a clear colorless 
oil (563 mg, 67%). 
[α]D22 = +5.66 (c 1.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.72 - 7.66 (m, 4 H), 7.48 - 7.37 (m, 6 H), 3.76 - 3.68 (m, 
3 H), 2.96 (s, 1 H), 2.77 (t, J = 4.5 Hz, 1 H), 2.73 (br. s., 1 H), 2.50 (dd, J = 2.8, 5.0 Hz, 1 
H), 1.80 - 1.66 (m, 3 H), 1.60 - 1.51 (m, 1 H), 1.37 (sxt, J = 7.1 Hz, 1 H), 1.07 (s, 9 H), 
0.98 (d, J = 6.9 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 135.7, 133.8, 129.8, 127.8, 77.4, 64.3, 54.7, 45.3, 42.2, 
31.3, 28.7, 27.0, 19.3, 12.8; 
IR (thin film, KBr) νmax 3427, 2930, 2856, 1471, 1427, 1111 cm–1; 
HRMS (ESI) m/z 421.2161 [calcd for C24H34O3NaSi (M+Na)+ 421.2175]. 
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Epoxide 1.137a. To a precooled (0 ºC) solution of 1.S9 (0.535 g, 1.342 mmol) in THF 
(13.5 mL) was added NaH (60% w/w in mineral oil, 0.161 g, 4.03 mmol). The resulting 
mixture was stirred at 0 ºC for 10 min, then MeI (0.839 ml, 13.42 mmol) was added. The 
reaction was then allowed to warm to rt and stirred for 36 h, and finally quenched with 
sat. aq. NH4Cl (3 mL) and 1 M aq. Na2S2O3 (3 mL). Et2O (25 mL) was added and the 
layers were separated. The organic layer was dried over Na2SO4, filtered and 
concentrated in vacuo. Flash column chromatography (9:1 hexanes/EtOAc) afforded  
1.137a as a clear colorless oil (551 mg, 99%). Spectroscopic data consistent with that of 
previous batches (vide supra). 
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Tricomponent ARC Fragment Union and Further Elaboration 
 
ARC adduct 1.150: To a precooled (–78 ºC) solution of 1.136 (253 mg, 0.743 mmol) in 
Et2O (3 mL) was added t-BuLi (1.55 M solution in pentane, 0.959 mL, 1.487 mmol) 
dropwise. The reaction was stirred at –78 ºC for 10 min.  A solution of linchpin 1.108 
(180 mg, 0.725 mmol) in Et2O was then added dropwise via syringe (1 mL + 2 × 0.5 mL 
rinse). The reaction was stirred at –78 ºC for 30 min. A solution of 1.137a (150 mg, 0.363 
mmol) in Et2O/HMPA (1.0 mL, 10/1, v/v), pre-dried for 10 min over CaH2, was added 
dropwise via syringe, having allowed the solid to decant. The flask originally containing 
1.137a was then carefully rinsed with Et2O (2 × 0.5 mL) to ensure complete transfer of 
the epoxide. The reaction was stirred at –78 ºC for 30 min, then the cold bath was 
removed and the reaction was stirred for an additional 3 h, gradually warming to rt. Sat. 
aq. NH4Cl (4 mL) and EtOAc (4 mL) were added. The layers were separated and the 
organic layer was extracted with EtOAc (2 × 10 mL). The combined organic layers were 
then washed with brine (4 mL) dried over Na2SO4, filtered, and concentrated in vacuo. 
The residue was purified by flash column chromatography (9:1 hexanes/EtOAc) to 
furnish 1.150 as a clear colorless oil (219 mg, 69% yield).  
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[α]D22 = +2.93 (c 1.0, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.72 - 7.66 (m, 4 H), 7.45 - 7.36 (m, 6 H), 5.66 - 5.55 (m, 
1 H), 5.54 - 5.43 (m, 1 H), 5.00 (d, J = 6.9 Hz, 1 H), 4.09 (t, J = 8.2 Hz, 1 H), 3.75 - 3.64 
(m, 2 H), 3.54 (s, 1 H), 3.41 - 3.35 (m, 1 H), 3.32 - 3.29 (m, 5 H), 2.91 - 2.80 (m, 2 H), 
2.79 - 2.66 (m, 2 H), 2.18 (q, J = 6.8 Hz, 1 H), 2.12 - 1.84 (m, 5 H), 1.80 - 1.59 (m, 3 H), 
1.47 - 1.35 (m, 1 H), 1.10 (d, J = 6.9 Hz, 3 H), 1.06 (s, 9 H), 1.01 - 0.97 (m, 6 H), 0.91 (s, 
9 H), 0.83 (d, J = 6.9 Hz, 3 H), 0.12 (s, 9 H), 0.04 (s, 6 H); 
13C NMR (125 MHz, CDCl3) δ 137.9, 135.7, 134.3, 131.0, 129.6, 127.7, 81.6, 73.8, 72.0, 
70.0, 64.3, 58.1, 56.8, 44.8, 40.9, 39.7, 38.1, 28.6, 27.0, 26.1, 26.0, 25.6, 24.8, 24.2, 24.0, 
19.4, 18.4, 10.8, 8.4, 1.2, -5.3, -5.4; 
IR (thin film, KBr) νmax 3429, 2955, 2856, 1589, 1471, 1428, 1389, 1249, 1105, 839 cm–
1; 
HRMS (ESI) m/z 897.4864 [calcd for C47H82O5NaSi3S2 (M+Na)+ 897.4809]. 
 
 
Benzyl ether 1.151. To a precooled (0 ºC) solution of 1.150 (10 mg, 0.011 mmol) in THF 
(0.1 mL) were added KHMDS (0.5 M solution in toluene, 69 µL, 0.034 mmol) and 
benzyl bromide (14 µL, 0.114 mmol). The reaction was stirred at 0 ºC for 10 min and  
KHMDS, BnBr
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Me
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quenched at that temperature with sat. aq. NH4Cl (1 mL). The mixture was extracted with 
EtOAc (3 × 2 mL). The combined organic layers were washed with brine, dried over 
Na2SO4, filtered and concentrated in vacuo.  The residue was purified by flash column 
chromatography (99:1 → 90:10 hexanes/EtOAc) to furnish 1.151 as a clear colorless oil 
(10 mg, 91%). 
[α]D22 = –14.7 (c 0.5, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.71 - 7.67 (m, 4 H), 7.45 - 7.36 (m, 8 H), 7.30 (t, J = 7.4 
Hz, 2 H), 7.26 - 7.19 (m, 1 H), 5.58 (d, J = 15.9 Hz, 1 H), 5.47 (dd, J = 6.7, 14.9 Hz, 1 
H), 5.11 (d, J = 6.7 Hz, 1 H), 4.78 (d, J = 11.5 Hz, 1 H), 4.50 (d, J = 11.7 Hz, 1 H), 4.19 
(dd, J = 2.3, 8.2 Hz, 1 H), 3.70 (t, J = 6.0 Hz, 2 H), 3.37 - 3.28 (m, 5 H), 3.12 - 3.04 (m, 1 
H), 2.96 - 2.87 (m, 1 H), 2.82 - 2.73 (m, 1 H), 2.67 - 2.52 (m, 2 H), 2.31 - 2.21 (m, 2 H), 
2.13 - 2.04 (m, 1 H), 1.95 (br. s., 1 H), 1.91 - 1.80 (m, 2 H), 1.76 (d, J = 16.1 Hz, 1 H), 
1.70 - 1.47 (m, 3 H + H2O), 1.18 - 1.11 (m, 3 H), 1.07 (s, 9 H), 0.97 (br. s, 6 H), 0.91 (s, 9 
H), 0.84 (d, J = 6.7 Hz, 3 H), 0.10 (s, 9 H), 0.04 (s, 6 H); 
13C NMR (125 MHz, CDCl3) δ 140.3, 137.4, 135.7, 134.2, 131.5, 129.6, 128.0, 127.7, 
127.4, 126.8, 81.5, 76.8, 73.7, 72.1, 69.9, 64.4, 59.1, 56.6, 43.5, 38.2, 38.0, 36.1, 29.8, 
27.0, 26.8, 26.6, 26.1, 25.8, 25.6, 25.0, 24.3, 24.1, 19.4, 18.5, 10.5, 8.4, 1.1, -5.3; 
IR (thin film, KBr) νmax 3434, 2928, 2845, 1653, 1472, 1249, 1105, 839, 701 cm–1; 
HRMS (ESI) m/z 987.5242 [calcd for C54H88O5NaSi3S2 (M+Na)+ 987.5279]. 
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Benzyl ether 1.152: 
 
[α]D22 = –6.3 (c 0.75, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.71 - 7.66 (m, 4 H), 7.46 - 7.35 (m, 8 H), 7.30 (t, J = 7.5 
Hz, 2 H), 7.25 - 7.20 (m, 1 H), 5.70 (d, J = 15.9 Hz, 1 H), 5.47 (dd, J = 7.1, 15.9 Hz, 1 
H), 4.63 (d, J = 6.9 Hz, 1 H), 4.55 - 4.42 (m, 2 H), 4.38 (d, J = 11.5 Hz, 1 H), 3.68 (t, J = 
6.2 Hz, 2 H), 3.37 - 3.31 (m, 2 H), 3.29 (s, 3 H), 3.03 (td, J = 4.4, 8.3 Hz, 1 H), 2.92 - 
2.60 (m, 4 H), 2.39 (q, J = 7.1 Hz, 1 H), 2.11 (dd, J = 8.1, 16.4 Hz, 1 H), 2.04 - 1.69 (m, 5 
H), 1.61 (td, J = 7.0, 14.4 Hz, 2 H), 1.51 - 1.41 (m, 1 H), 1.20 (d, J = 7.1 Hz, 3 H), 1.07 
(s, 9 H), 1.03 - 0.98 (m, 6 H), 0.91 (s, 9 H), 0.78 - 0.72 (m, 3 H), 0.17 (s, 9 H), 0.04 (s, 6 
H); 
13C NMR (125 MHz, CDCl3) δ 139.9, 139.4, 135.7, 134.2, 129.6, 128.1, 127.9, 127.7, 
127.6, 127.1, 81.9, 80.1, 72.1, 70.4, 70.3, 64.4, 58.8, 56.4, 43.7, 43.2, 38.3, 37.5, 27.1, 
27.0, 26.5, 26.2, 26.0, 26.0, 25.1, 24.3, 19.3, 18.4, 10.3, 9.1, 1.3, -5.3; 
IR (thin film, KBr) νmax 2954, 2857, 1471, 1428, 1388, 1248, 1105, 838, 775, 701 cm–1; 
HRMS (ESI) m/z 965.5470 [calcd for C54H89O5Si3S2 (M+H)+ 965.5459]. 
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Benzyl ether 1.153: 
 
[α]D22 = +4.52 (c 0.65, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.72 - 7.65 (m, 4 H), 7.45 - 7.22 (m, 11 H + HCCl3), 5.73 
(d, J = 15.9 Hz, 1 H), 5.46 (dd, J = 7.3, 15.7 Hz, 1 H), 4.62 (d, J = 7.3 Hz, 1 H), 4.50 (d, J 
= 11.7 Hz, 1 H), 4.38 (d, J = 11.7 Hz, 1 H), 4.06 (app. t, J = 8.1 Hz, 1 H), 3.75 - 3.65 (m, 
2 H), 3.62 (br. s, 1 H), 3.36 - 3.30 (m, 3 H), 3.26 (s, 3 H), 2.87 - 2.79 (m, 3 H), 2.78 - 
2.72 (m, 1 H), 2.32 - 2.25 (m, 1 H), 2.16 (d, J = 15.5 Hz, 1 H), 2.04 (dd, J = 9.5, 15.9 Hz, 
1 H), 1.99 - 1.91 (m, 2 H), 1.85 (q, J = 6.9 Hz, 1 H), 1.75 - 1.57 (m, 2 H + H2O), 1.40 - 
1.22 (m, 2 H), 1.18 (d, J = 7.1 Hz, 3 H), 1.06 (s, 9 H), 1.01 (s, 3 H), 1.01 (s, 3 H), 0.90 (s, 
9 H), 0.75 (d, J = 6.9 Hz, 3 H), 0.04 (s, 6 H); 
13C NMR (125 MHz, CDCl3) δ 140.4, 139.2, 135.7, 134.3, 129.6, 128.2, 127.7, 127.3, 
81.5, 79.9, 72.0, 70.1, 70.1, 64.3, 57.9, 56.6, 44.6, 40.8, 39.8, 38.4, 29.8, 28.5, 27.0, 26.2, 
26.0, 25.5, 24.9, 24.3, 24.2, 19.4, 18.4, 10.7, 8.8, -5.3; 
IR (thin film, KBr) νmax 3416, 2927, 2855, 1589, 1472, 1105, 701 cm–1; 
HRMS (ESI) m/z 915.4883 [calcd for C51H80O5NaSi2S2 (M+Na)+ 915.4883]. 
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Alcohol 1.154: THF was degassed by sparging with N2 during 15 min prior to the 
reaction. Raney nickel (W. R. Grace 2800, 0.5 mL of a 89% slurry in H2O, excess) was 
added via syringe to a 50-mL round-bottom flask fitted with a septum and stir bar under 
N2 atmosphere. Water was removed via syringe, and the nickel was rinsed with water (4 
× 4 mL), then with degassed THF (4 × 4 mL), stirring vigorously between each rinse. 
Degassed THF (2 mL) and a solution of 1.151 (39 mg, 0.040 mmol) in THF (2 mL) were 
then added. The flask was then evacuated and backfilled with H2 (x 5), fitted with a 
reflux condenser, and warmed to 75 ºC. The suspension was stirred vigorously at 75 ºC 
under H2 atmosphere for 2 h. The reaction was allowed to cool to rt and the headspace of 
the flask was flushed with N2. The supernatant was filtered through Celite, eluting with 
EtOAc, and rinsing the metal residue with EtOAc (4 × 4 mL) taking special care never to 
leave any metal residue dry and exposed to air —risk of fire. The filtrate was 
concentrated in vacuo and the residue taken up in THF (4 mL). Aq. HCl (0.2 N, 4 mL) 
was then added, and the biphasic mixture was stirred vigorously for 5 min. Sat. aq. 
NaHCO3 (2 mL) was then added, the layers partitioned, and the aqueous layer extracted 
with EtOAc (3 × 3 mL). The organic layers were combined, washed with brine (2 mL), 
dried over Na2SO4, filtered and concentrated in vacuo. The residue was purified by flash 
column chromatography (95:5 hexanes/EtOAc) to furnish 1.154 as a clear colorless oil 
(22 mg, 69%). 
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[α]D22 = –12.1 (c 0.33, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.68 (d, J = 7.1 Hz, 4 H), 7.46 - 7.30 (m, 11 H), 5.65 (d, J 
= 15.9 Hz, 1 H), 5.44 (dd, J = 6.8, 15.8 Hz, 1 H), 4.46 (s, 2 H), 3.98 - 3.91 (m, 1 H), 3.72 
- 3.63 (m, 2 H), 3.48 (d, J = 5.2 Hz, 1 H), 3.32 - 3.20 (m, 6 H), 2.16 - 2.08 (m, 1 H), 1.80 
- 1.67 (m, 1 H), 1.65 - 1.47 (m, 8 H), 1.46 - 1.35 (m, 2 H), 1.32 - 1.22 (m, 2 H), 1.06 (s, 9 
H), 0.98 (d, J = 5.5 Hz, 6 H), 0.90 (s, 9 H), 0.81 (d, J = 7.1 Hz, 3 H), 0.02 (s, 6 H); 
13C NMR (125 MHz, CDCl3) δ 139.9, 139.2, 135.7, 134.2, 129.7, 128.4, 127.9, 127.7, 
127.5, 81.8, 80.0, 77.2, 72.0, 71.4, 64.3, 56.8, 39.0, 38.3, 37.5, 29.8, 28.3, 28.0, 27.5, 
27.0, 26.1, 26.0, 24.2, 24.1, 19.4, 18.4, 14.7, 10.3, -5.3; 
IR (thin film, KBr) νmax 3441, 2926, 2855, 1462, 1384, 1094, 836, 701 cm–1; 
HRMS (ESI) m/z 811.5109 [calcd for C48H76O5NaSi2 [M+Na]+ 811.5129]. 
 
 
 
Epoxide 1.155. To a precooled (–20 ºC), stirred suspension of flame-dried molecular 
sieve (4 Å, powder, 60 mg) in CH2Cl2 (0.2 mL) were added a solution of (–)-diethyl-D-
tartrate in CH2Cl2 (90 µL, 0.2 M, 0.018 mmol) and a solution of titanium(IV) 
isopropoxide in CH2Cl2 (75 µL, 0.2 M, 0.015 mmol). The suspension was stirred for 30 
OH
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OTBDPSMe Me
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min at –20 ºC. Was then added  tert-butyl hydroperoxide (5.5 M solution in nonane over 
molecular sieve, 10 µL, 0.055 mmol), and the mixture was stirred for an additional 30 
min at –20 ºC.  A solution of 1.154 (6 mg, 7.60 µmol) in CH2Cl2 (0.1 mL + 2 × 0.1 mL 
rinse) was finally added dropwise via syringe. The reaction was warmed to 0 ºC and 
stirred overnight.  NaOH (1 mL, 0.5 M in brine) was then added. The cold bath was 
removed and the reaction stirred for 10 min at rt. The mixture was extracted with CH2Cl2 
(3 × 3 mL), dried over Na2SO4, filtered and concentrated. The residue was purified by 
flash column chromatography (90:10 hexanes/EtOAc) to afford 1.155 as a clear colorless 
oil (4.8 mg, 79%).  
[α]D22 = –7.63 (c 0.34, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.70 - 7.65 (m, 4 H), 7.45 - 7.35 (m, 6 H), 7.35 - 7.29 (m, 
4 H), 7.26 - 7.23 (m, 1 H), 4.46 (s, 2 H), 3.75 - 3.62 (m, 3 H), 3.52 - 3.44 (m, 1 H), 3.43 - 
3.32 (m, 2 H), 3.29 - 3.26 (m, 3 H), 3.25 - 3.20 (m, 1 H), 2.99 - 2.94 (m, 2 H), 2.13 (q, J 
= 6.8 Hz, 1 H), 1.77 - 1.17 (m, 10 H), 1.06 (s, 9 H), 0.98 (d, J = 6.6 Hz, 3 H), 0.91 (s, 9 
H), 0.88 (s, 3 H), 0.86 (s, 3 H), 0.81 (d, J = 7.1 Hz, 3 H), 0.06 - 0.04 (m, 6 H); 
13C NMR (125 MHz, CDCl3) δ 139.1, 135.6, 134.1, 129.5, 128.3, 127.8, 127.6, 127.4, 
81.7, 79.8, 72.0, 71.2, 69.5, 64.2, 60.0, 56.7, 56.6, 37.4, 36.2, 35.8, 29.7, 29.7, 28.7, 28.2, 
27.3, 26.9, 26.0, 25.9, 20.8, 20.3, 19.2, 18.3, 14.2, 14.1, 10.2, -5.5, -5.5; 
IR (thin film, KBr) νmax 3416, 2925, 2853, 1462, 1383, 1095, 837, 701 cm–1; 
HRMS (ESI) m/z 827.5098 [calcd for C48H76O6NaSi2 [M+Na]+ 827.5078]. 
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PART II: 
DESIGN, SYNTHESIS AND VALIDATION OF SMALL-MOLECULE 
MIMICS OF THE IMMUNE CELL RECEPTOR CD4 
 
Introduction 
An estimated 35 million people currently live with Human Immunodeficiency Virus 
(HIV) worldwide, and, despite a decline in recent years, the yearly number of new 
infections remains high at 2.1 million.1 The observed deceleration of new infections 
reflects the efficacy of combined antiretroviral therapies (Highly Active AntiRetroviral 
Therapies, HAART), which increase the patients’ life expectancy and decrease virus 
levels to undetectable concentrations.2 This general therapeutic approach, however, is not 
curative in the sense that suspension of treatment typically leads to disease relapse and 
progression.3 In addition, given the requirement for patients to remain on treatment in 
order to maintain low levels of viremia, there exists a risk of emergence of HAART-
resistant HIV-1 strains. As a result, it is of paramount importance to develop new 
therapies that both (i) hamper HIV transmission and (ii) lead to the eradication of both 
the virus and infected cells from the host organism (i.e., suppressing the so-called “viral 
reservoir”). 
To define a background for this research project in the ever-changing context of 
antiretroviral therapies, a brief account of the HIV-1 viral replication cycle will be 
presented next, followed by a more detailed discussion of the mechanism of viral entry, 
the latter of particular interest given the focus of this work. 
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Mechanism of Viral Replication and Classes of Anti-HIV Drugs  
Entry of HIV into host human cells is mediated by a protein-protein interaction 
between the envelope spike glycoprotein (Env), located on the surface of the virion, and 
the receptor CD4 on the host cell. This interaction leads to a conformational change of 
Env and the subsequent recognition of co-receptors on the surface of the host cell, 
ultimately resulting in the fusion of viral and cell membranes and the release of the viral 
load (comprising both genetic material and functional proteins) into the now infected 
cell.3 In turn, viral RNA is converted by reverse transcriptase into DNA, which, upon 
penetration of the cell nucleus, is integrated into the host cell DNA (mediated by the viral 
integrase). The host cell itself is now involved in the viral replication process: expression 
of the viral genes (in certain cases involving post-translational modifications via viral 
protease) and in turn transport of the resulting proteins and viral RNA near the surface of 
the infected cell then gives way to the so-called “budding” of a new virion (Figure 2.1). 
For reference, each HIV infected cell has been estimated to give rise to 103-104 new 
virions over its life span.4 
Given this replication mechanism, drugs have been developed and approved that 
inhibit the viral enzymes involved [i.e., reverse transcriptase (e.g. azidothymidine, 
emtricitabine, tenofovir), integrase (e.g. raltegravir) and protease (e.g. atanazavir, 
darunavir)]. Notably, emergence of some of these classes of drugs followed very closely 
the discovery of HIV and the associated Acquired Immune Deficiency Syndrome 
(AIDS): azidothymidine (AZT, Burroughs-Wellcome), the first antiretroviral, reached the 
clinic (Phase I trials) in 1985 and was approved in 1987, a mere four years after the 
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seminal reports by Gallo5–8 and Montaigner and Barré-Sinoussi.9 In contrast, the idea of 
viral entry as a druggable process only came to fruition relatively recently, with the 
approval of peptide enfuvirtide (Roche), and small molecule maraviroc (Pfizer) in 2003 
and 2007, respectively. Efforts by Bristol-Myers Squibb have led to a class of small-
molecules typified by BMS-378806, analogues of which are still in clinical development. 
These three compounds, distinct in their mechanisms of action, also differ from the class 
of viral entry inhibitors investigated in this work. The understanding of the mechanism of 
viral entry played a pivotal role in enabling the rational design of inhibitors. 
 
Figure 2.1. HIV Replication Cycle 
Structure of Env and Mechanism of Viral Entry 
In a mature virion, the envelope spike (Env) is comprised of a trimer of 
transmembrane protein gp41 in non-covalent interaction with a trimer of an extensively 
glycosylated protein, gp120, located further away from the viral membrane.10 
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Figure 2.2. Images of Mature Unliganded Env Obtained by Cryo-Electron 
Microscopy11 
As briefly discussed above, HIV entry into the host human cell is mediated by the 
interaction of Env and the host cell receptor CD4. The molecular basis of this interaction 
was first reported in a seminal publication by Wayne Hendrickson and co-workers,10 who 
obtained a crystallographic structure of Env subunit gp120 bound simultaneously to 
soluble CD4 and to the Fab fragment of antibody 17b. Specifically, the interaction of 
gp120 and CD4 is localized at the interface of the outer domain, inner domain and 
bridging sheet of gp120 and covers a surface area of approximately 740-800 Å2 of each 
gp120 and CD4, although actual molecular contacts occur in only a fraction of this area.10 
The gp120:CD4 interaction is indeed dominated by two hotspots (see Figure 2.3, inset): 
(i) a hydrophobic cavity located at the interface of the inner domain, the outer domain 
and the bridging sheet of gp120 that hosts the aromatic side-chain of CD4Phe43; and (ii) 
the well conserved residue gp120Asp368, which engages in a strong electrostatic 
interaction with CD4Arg59.10  
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Figure 2.3. Co-crystal structure of gp120:CD4 (PDB: 1GC1) – critical interactions. 
The binding event thus described is known to give rise to a series of what are now 
known as massive structural rearrangements within Env, in particular leading to the 
exposure of secondary binding sites, which can subsequently reach chemokine co-
receptors CCR5 or CXCR4 on the surface of the host cell. The resulting secondary 
interactions translate into the formation of a six-helix bundle within the trimeric gp41 
subunit of Env and leads to the fusion of the virus and host cell membranes, ultimately 
permitting viral replication.12 Thus, while maraviroc acts as a negative allosteric 
modulator of co-receptor CCR5, enfuvirtide in turn inhibits formation of the virus-cell 
fusion complex. The work presented in this thesis focuses instead on a distinct class of 
viral entry inhibitors that lead to viral inactivation by targeting specifically the CD4 
binding site of gp120. 
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Figure 2.4. Viral entry process*,3 
 
Discovery, Evolution and Validation of Small-Molecule CD4 Mimics as Inhibitors of 
HIV-1 Entry 
The work to be discussed in the remainder of this thesis arises from a 
multidisciplinary, multiinstitutional program project (NIH P01). In addition to the 
synthetic chemistry developed in the Smith Laboratory, the interacting disciplines and 
corresponding group leaders are: 
– Virology, Joseph Sodroski (Dana-Farber Cancer Institute), 
– Crystallography, Wayne Hendrickson (Columbia University), 
– Equilibrium thermodynamics, Ernesto Freire (Johns Hopkins University), 
– Trimer dynamics, Walther Mothes (Yale University), 
–  Computational chemistry, Judith Lalonde (Bryn Mawr University), recently 
replaced by Cameron Abrams (Drexel University), !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
* Reproduced from “Entry Inhibitors in the Treatment of HIV-1 Infection,” Tilton, J. C.; Doms, R. W. 
Antivir. Res. 2010, 85, 91, with permission from Elsevier.  
P
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– Synthesis of peptide inhibitors, Irwin Chaiken (Drexel University). 
 
The involvement of this collaborative program with the design, synthesis and 
evaluation of small-molecule inhibitors of HIV-1 commenced with the discovery of 
NBD-556 (2.1) and NBD-557 (2.2), by Debnath and co-workers at the New York Blood 
Bank.13 Initially reported to inhibit entry of certain HIV-1 strains into cells expressing 
both receptor CD4 and co-receptor CCR5 (i.e., CD4+CCR5+ cells), these compounds 
were later shown by the NIH P0-1 team to enhance viral infectivity into cells expressing 
only the co-receptor (i.e., CD4–CCR5+ cells), an enhancement that was also proved to be 
specific to HIV. In addition, isothermal titration calorimetry studies (ITC) evidenced 
similar enthalpic and entropic contributions to those elicited by the binding of gp120 by 
soluble CD4 (sCD4) and by these small molecules, even though the overall free energies 
of binding, and therefore the binding affinities differed significantly (sCD4: Kd = 3 nM; 
2.1: Kd = 3.7 µM). Of note, BMS-378806 (2.3), a strong ligand of gp120 (Kd = 3–62 
nM), does not elicit such an allosteric (i.e., entropic) signal upon binding, suggesting that 
2.1 and 2.2 define a mechanistically different class of entry inhibitors. These observations 
motivated further investigations involving both computational docking and mutagenesis 
studies that demonstrated that 2.1 and 2.2 bind gp120 at the CD4Phe43 cavity, later 
confirmed by X-ray crystallography. Taken together, these results led to the conclusion 
that 2.1 and 2.2 in fact behave as structural and functional mimics of the immune cell 
receptor CD4. 
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Figure 2.5. Structures of NBD-556 (2.1) and -557 (2.2) and BMS-3788806 (2.3) 
The hypothesis, confirmed shortly thereafter,14 that small-molecule CD4 mimics 
prematurely and transiently activate the virus —leading rapidly to viral decay in the 
absence of a target cell— demanded (vide infra) the development of a new generation of 
congeners of the NBD compounds (2.1 and 2.2, Figure 2.5). 
 
 
Structure Activity Relationship Studies: Methods 
Within the collaborative NIH-supported program project, the Smith group thus 
engaged in the rational design, synthesis and biological evaluation of small molecule 
inhibitors of HIV-1 infection targeting the gp120:CD4 protein-protein interface. 
Specifically, Structure-Activity Relationship (SAR) studies were initiated on the NBD 
scaffold, typified by an aromatic ring in Region I, an oxalamide linker in Region II and a 
piperidine ring in Region III (Figure 2.6). 
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Figure 2.6. NBD-556 (2.1) and NBD-556:gp120 Co-Crystal Structure.15,16  
The SAR campaign was guided both computationally and experimentally, the latter by 
infectivity assays employing cells pseudotyped with Env from various HIV-1 strains 
(initially mainly YU-2), as well as from an unrelated virus serving as control, namely 
amphotropic murine leukemia virus (A-MLV). These infectivity assays were 
systematically carried out at Harvard both on CD4+CCR5+ cells and CD4–CCR5+ cells. 
Additionally, binding affinities of new compounds were measured at Hopkins by ITC 
employing monomeric YU2gp120. This technique also permitted the assessment of the 
enthalpic and entropic contributions from each new compound to the overall free energy 
of binding. Viral infectivity assays and thermodynamic measurements were completed in 
cases with interesting biological profiles by solution of crystallographic structures at 
Columbia of the target:ligand complex, also employing monomeric gp120. 
 
Structure Activity Relationships Studies: Results 
Early efforts to increase inhibitor efficiency by varying systematically Regions I-III of 
NBD-556 (2.1) rapidly demonstrated that: (i) introduction of a fluorine atom in Region I 
Cl
H
N
O
N
H
O NH
NBD-556 (2.1)
Region I Region II Region III
(PDB: 3TGS)
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led to increased binding affinity and more efficient viral entry inhibition; (ii) variations in 
Region II led to the loss of specificity of antiviral activity. However, these early 
analogues (see JRC-II-191 and TS-II-224, Figure 2.6) maintained high levels of 
enhancement of CD4-independent viral entry, and in some cases even increased this 
enhancement, in good correlation with strong entropic contributions (–TΔS > 0) to their 
respective free energies of binding to gp120. 
Considering (i) the hydrophobicity of the Phe43 cavity naturally surrounding Region I 
and (ii) the virtually impossible replacement of Region II, a thorough fragment-based 
screening for potential replacements of Region III was conducted. The goal here was to 
establish contacts with so-called “affinity hotspots” (i.e., residues of gp120 that 
contribute exclusively or nearly exclusively to the enthalpy of binding with CD4) as 
defined by an elegant study combining ITC and alanine-scanning mutagenesis.17 One 
such hotspot is the highly conserved β15 residue gp120Asp368, also critical to the native 
CD4:gp120 interaction (vide supra). This residue was therefore privileged in the 
computational query. 
With computational guidance, the piperidine Region III was initially replaced with an 
amino indane scaffold (see 2.6, Figure 2.7), to which, eventually, was incorporated 
guanidinium functionality. The design and synthesis in the Smith group of aminoindane 
compound (+)-DMJ-I-228 (2.7) was considered a major breakthrough in the program, 
showing for the first time potent inhibition of the gp120:CD4 interaction without 
enhancement of YU2HIV viral entry in CD4-negative T cells.18 A further increase in 
potency was later observed upon introduction of a methylene spacer between the indane 
scaffold and the terminal guanidine in compound (+)-DMJ-II-121 (2.8), the most 
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effective compound in this series (Kd = 0.11 µM; YU-2 IC50 = 2.3 µM).19 An X-ray co-
crystal structure of gp120 and (+)-DMJ-II-121 (2.8) provided evidence for hydrogen 
bonding with gp120 residues Asn425, Gly473 and Met426. 
Remarkably, although the increase both in affinity and potency was unambiguous, 
none of the compounds computationally designed to interact directly with Asp368 did so 
in their respective crystallographic gp120-bound structures. The presence of affinity 
hotspots in the vicinity of the new indane Region III, however, paved the way for the 
design of inhibitors capable of establishing additional interactions with the target protein 
via additional substitution of the indane scaffold. 
 
 
Figure 2.7. Evolution of CD4 Mimetic Compounds. 
Interactions of 2.8 with Protein Target.19 
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The first chapter of Part II of this Thesis will discuss efforts in the development of a 
stereoselective synthesis of indane-containing small-molecule CD4 mimics. In the second 
chapter of Part II, focus will be made on the optimization of inhibitory activity. Recently 
discovered potential therapeutic applications of CD4 mimics will be briefly described in a 
last chapter. !  
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Chapter 1: Development of a Stereoselective Synthesis of Aminoindane CD4 
Mimics 
 
The first example of a small-molecule CD4 mimic comprising a trisubstituted indane 
in Region III arose from computational studies carried out by our collaborator Dr. Judith 
Lalonde, indicating that installation of an amine moiety in Region III could lead to a 
hydrogen-bonding interaction with the backbone carbonyl of gp120Gly472, an affinity 
hotspot as defined previously by Freire.17 Interestingly, the computational model also 
predicted, like in previous instances, a binding interaction with gp120Asp368. The 
compound resulting from this design (2.9, Figure 2.8), first synthesized by postdoctoral 
associate Dr. Jongwoo Park in the Smith group, indeed exhibited a marked increase in 
protein affinity. Although only a modest increase in inhibitory activity against viral entry 
was observed, several HIV-1 strains showed increased sensitivity to 2.9, in particular the 
neutralization-resistant strain JR-FL.  
 
 
Figure 2.8. Comparison of bioactivities of 2.8 and 2.9 
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First synthesis of JP-III-048 (2.9) 
The first synthesis of (+)-2.9 was valuable in providing sufficient material for our 
collaborators to draw a preliminary bioactivity profile, thus establishing that 2.9 was in 
fact a compound of interest. However, relying on chromatographic separations for 
resolution of stereoisomers and requiring a total of 19 steps to reach the target, this 
diversity-oriented route was not sufficiently efficient (1.3% overall yield) to prepare 
amounts of the compound for extensive evaluation (Scheme 2.1). 
The initial synthesis began with the installation of the requisite amine side-chain. To 
this end, protection of bromoindanone 2.10 as the corresponding dioxolane, followed by 
lithiation and formylation furnished aldehyde 2.11 in 88% yield (2 steps). Next, reductive 
amination and protection (as the Boc carbamate), with subsequent dioxolane solvolysis 
provided the functionalized indanone 2.12 in 77% yield (3 steps). The sodium enolate of 
2.12 was carboxylated, leading to β-keto ester 2.13. Exhaustive reduction of 2.13 
mediated by NaBH4 then resulted in diol 2.14, obtained as a mixture of diastereomers. 
Selective protection of the primary alcohol, however, permitted the chromatographic 
separation of diastereomers (2.15). In turn, resolution by esterification with (R)-mandelic 
acid (2.16), chromatographic separation and basic ethanolysis furnished enantioenriched 
2.15. This alcohol was next subjected to diphenylphosphoryl azide (DPPA) resulting in 
azide installation with complete inversion of stereochemistry. Palladium catalyzed 
hydrogenation furnished the corresponding amine (2.17). Next, coupling with oxalic acid 
2.18 followed by fluoride-mediated deprotection gave rise to alcohol 2.19, which was 
converted to the corresponding mesylate, preparing for SN2 displacement with sodium 
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azide and reduction, furnishing primary amine 2.20. Amidyl transfer employing 2.21 and 
global deprotection led to the target compound, 2.9. 
 
 
Scheme 2.1. Initial Synthesis of (+)-JP-III-048 (2.9) 
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Development of an Enantioselective Synthesis of JP-III-048 (2.9) 
Given the need for higher material throughput, we set out to redesign the Park 
synthesis to prepare both (+)- and (–)-2.9 in a stereoselective fashion. While the initial 
installation of the requisite (methylamino)methylene (2.12, Scheme 2.1) requires five 
steps, the sequence is operationally straightforward and allowed the preparation of 4.2 g 
of 2.12 in one run and 68% overall yield with limited optimization. This strategy was 
therefore maintained in the interest of advancing material to more critical steps. Indeed, 
ketoester (±)-2.13 could be subjected to asymmetric reduction conditions reported by 
Lassaletta, Fernández et al.20 to furnish β-hydroxyester (+)-2.23 in 93% yield as a single 
stereoisomer (relative and absolute stereoconfiguration were ultimately confirmed by X-
ray crystallography). 
Reduction to the diol employing sodium borohydride and methanol as the solvent 
resulted in partial epimerization. It was therefore reasoned that a more reactive hydride 
source in a non-alcoholic solvent at lower temperatures would prevent enolization; 
pleasingly, lithium aluminum hydride (THF, 0ºC) indeed furnished the diol in 87% yield 
as a single diastereomer. Closely following Park chemistry, the primary alcohol was then 
selectively protected (2.15, 95% yield); azidation of the benzylic position, and reduction 
to the amine furnished 2.17 in quantitative yield. The requisite oxalamide moiety was 
then installed via a TBTU-mediated coupling, and removal of the silyl protecting group 
furnished primary alcohol 2.19 (80% yield over 2 steps). Installation of the guanidine 
moiety, in turn, was expedited with a microwave-assisted Mitsunobu reaction,21 which 
furnished the desired product in 71% yield directly from 2.19, an improvement over the 
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4-step sequence exploited previously. Removal of Boc protection completed the synthesis 
of 2.9 in 15 steps and 20% overall yield (Figure 3). 
Notably, this route permitted preparation of > 250 mg of the target in a single synthetic 
run, a 10-fold improvement compared to the largest batch previously prepared. Similarly, 
114 mg of the corresponding enantiomer, (–)-2.9, were prepared in order to confirm that 
only one enantiomer, (+)-2.9, was in fact active against HIV entry. 
 
 
Scheme 2.2. Revised Synthesis of (+)-2.9 
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Determination of Salt Form 
A question that arose from early preparations of 2.9 was that of the salt form. Indeed, 
while the final deprotection employed trifluoroacetic acid (TFA), HPLC purification 
originally employed formic acid-buffered solvents, aimed at isolating the product as a 
formate salt. These purification conditions likely failed to effect the desired salt 
exchange, as evidenced by preliminary 1H NMR data obtained by Dr. Park. Although the 
salt form did not have an impact on the biological and thermodynamic assays themselves, 
the formula masses of the bis-formate salt and bis-TFA salt of 2.9 differ by 25% (538 and 
675 g/mol, respectively), leading to a similar error in calculating the protein binding 
affinity and potency of the compound and, a relatively minor problem, miscalculation of 
the chemical yield. 
Given now sufficient material, elemental analysis (C, H, N, F, Cl) confirmed that the 
formic acid HPLC buffer does not result in formation of 2.9•2(HCOOH), with the TFA 
salt 2.9•2(CF3COOH) being isolated instead. Given the cost of elemental analysis, both in 
terms of time and material, a more efficient and non-destructive analytical technique to 
quantify TFA content was preferable. 
Thus, with the help of Dr. Jun Gu (NMR facility, Penn Department of Chemistry), a 
carbon-decoupled quantitative 19F NMR spectroscopy was demonstrated to match the 
result obtained by elemental analysis. Indeed, with the product itself acting as internal 
standard, the 19F NMR spectrum obtained in this fashion displayed two singlets 
integrating in 6:1 ratio, evidencing six 19F nuclei (2 CF3COOH) for every one in the 
compound (Figure 2.9). Seeking the further validation of this method, HPLC was 
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performed on the same batch of 2.9•2(CF3COOH), now employing ammonium formate 
as buffer. The 19F NMR method revealed a 0.4:1 ratio between the same signals, 
corresponding to >93% salt exchange (Figure 2.9). 
 
     
Figure 2.9. Quantitation of TFA via 19F NMR. 
 
Synthetic Revision of (+)-DMJ-II-121 
The previous lead compound still being of interest to our collaborators, the chemistry 
optimized for JP-III-048 (2.9) was applied to the synthesis of both (+)- and (–)-DMJ-II-
121 (2.8).  
Indeed, the original synthetic route to 2.8 (Scheme 2.3) relied on a [2+2] cycloaddition 
of indene (2.25) and isocyanate 2.26 to furnish β-lactam 2.27 in racemic form. 
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Enantioenrichment was thus achieved by enzymatic resolution, furnishing cis-β-
aminoacid 2.28 in very high optical purity (> 99% ee). While highly stereoselective, these 
first two transformations proceed in very low yield (12% over 2 steps). In addition, the 
target compound (2.8) contains trans-relative stereochemistry on the indane scaffold —
completion of the synthesis therefore requires epimerization at C2 (see 2.28), 
accomplished via adjustments of oxidation state. Thus, the 10-step sequence proceeds in 
a low overall yield of 1.3%.19 
 
Scheme 2.3. Original synthesis of 2.8: key transformations 
In contrast, the route developed for the synthesis of JP-III-048 proceeded generally 
smoothly. Thus, the gram-scale preparation of enantiopure amine (+)-2.32 was achieved 
in 6 steps and 57% overall yield from 1-indanone (2.29, Scheme 2.4). An unforeseen 
difficulty arose from the low solubility in typical organic solvents of the later synthetic 
intermediates, possibly accountable for the relatively lower efficiency of the 
corresponding transformation. This issue notwithstanding, the overall yield (14%, Figure 
4) was 10-fold higher than that of the published synthetic route.19 
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Of note, analysis by SFC on chiral stationary phase confirmed the stereochemical 
identity and purity of DMJ-II-121 (2.8) prepared via this new route. Additionally, like for 
JP-III-048 (2.9), this route provides the trifluoroacetate (TFA) salt of 2.8. 
Thermodynamic and viral entry inhibition assays carried out by our collaborators (Dr. 
Arne Schön and Dr. Navid Madani, respectively), then confirmed that the formate and 
TFA salts displayed identical protein binding and inhibitory properties. 
 
 
Scheme 2.4. Revised synthesis of DMJ-II-121 (2.8) 
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Chapter 2: Optimization of Viral Entry Inhibition 
 
Having developed an efficient and scalable synthesis of the more potent CD4 mimics, 
we explored different means of increasing the antiviral (i.e., inhibitory) activity of these 
small molecules. Given, as discussed previously, that replacements of Region II 
invariably led to undesired results in terms of either activity or specificity, we focused on 
modifications of Regions I and III, which primarily relied on structural data obtained by 
our collaborators at Columbia via X-ray diffraction of protein:ligand complexes. 
  
Region I Analogues 
Two generations of indane scaffolds were employed for the design of Region I 
Analogues. The first example discussed here employed DMJ-II-121 (2.8) as parent 
compound. In turn, a later set of analogues was based on JP-III-048 (2.9). 
 
Region I analogues of DMJ-II-121 
The analogues of DMJ-II-121 (2.8, Figure 2.10) presented next were designed in 
collaboration with Dr. Joel Courter (Smith group) based on work by Martin and 
Kessler,22 who reported the neutralization of HIV by a series CD4-mimetic miniproteins. 
The most potent example, M48U12, comprises a cyclohexyl motif that was demonstrated 
to occupy the Phe43 cavity of gp120, the hotspot occupied by the so-called Region I of 
our CD4-mimetic small molecules (Figure 2.10). Of note, M48U12 displayed picomolar 
affinity for gp120 (Kd = 12 pM). In order to investigate the impact of a saturated Region I 
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on the small-molecule scaffold, we set out to prepare both enantiomers of compound 
2.34.  
 
Figure 2.10. Region I Analogues of 2.8: design rationale. 
The new efficient route to amine 2.32 (Scheme 2.4) provided us with a valuable 
synthetic handle to readily explore this type of replacement. Both enantiomers of 2.32 
were thus taken through an identical sequence involving coupling with oxalic acid 2.35, 
desilylation, installation of protected guanidine and TFA-mediated deprotection, to 
furnish (+)- and (–)-2.34 (Scheme 2.5). 
 
Scheme 2.5. Synthesis of Region I Analogue 2.34 
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Disappointingly, neither enantiomer of 2.34 displayed detectable inhibition of viral 
entry or even binding to monomeric gp120, demonstrating that the saturated functionality 
does not comprise a viable replacement for the aromatic Region I, at least in these small 
molecule scaffolds. Notably, in turn, peptide scaffolds have been demonstrated to tolerate 
such replacements, in some cases even leading to improved bioactivity,22 thereby  
suggesting that interactions in the vicinity of the hydrophobic “Phe43 cavity” of gp120 
may modulate interactions inside the cavity. Also supporting this idea, earlier work by 
our collaborators had shown that gp120 is capable of binding analogues of the protein 
CD4 while accommodating in the Phe43 cavity large fragments of various chemical 
natures (cyclohexyl, adamantyl, naphthyl) —this strategy had failed to translate to the 
small molecule arena.12,23 
  
Region I Analogues of JP-III-048 
The crystal structure of gp120-bound JP-III-048 (2.9), obtained by our collaborators 
Dr. Shuaiyi Liang and Prof. Wayne Hendrickson at Columbia, evidenced, relative to (+)-
DMJ-II-121 (2.8), two additional hydrogen-bonding interactions: one between the 
backbone carbonyl of gp120Gly472 with the Region III amine side-chain, and another 
between the backbone carbonyl of gp120Gly431 and the Region III guanidinium (Figure 
2.11). Of note, while this experimental result corresponded to the computational model as 
discussed previously, once again there was no crystallographic evidence of contact with 
gp120Asp368. 
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We reasoned, however, that the new stabilizing interactions near this hydrophobic 
Phe43 cavity might, remotely, enable new modifications to Region I. A computational 
fragment screen was thus carried out by our colleague Dr. Francesca Moraca (Abrams 
group, Drexel) revealing, after docking, the potential for increased gp120 binding affinity 
with naphthyl- and quinolyl-analogues 2.36 and 2.37 (Figure 2.11). 
 
Figure 2.11. Design of Region I Analogues 2.36 and 2.37 
Thus, 2.17, a late intermediate in the synthesis of the parent compound 2.8, was 
subjected to coupling conditions with oxalic acids 2.38 and 2.39. Deprotection then 
furnished alcohols 2.40 and 2.41. Surprisingly, the Mitsunobu protocol employed in the 
synthesis of 2.8, which called for microwave-assisted heating, led to complex mixtures 
with these substrates. Pleasingly, at room temperature the otherwise same protocol 
furnished the desired products (2.44 and 2.45) in good yields. Removal of Boc protection 
with trifluoroacetic acid completed the synthesis of Region I analogues 2.36 and 2.37. 
The corresponding enantiomers were prepared following the same sequence. 
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Scheme 2.6. Synthesis of 2.36 and 2.37 
Disappointingly, once again all synthesized Region I analogues failed to inhibit viral 
entry. The computational metric was therefore revised to account for this lack of activity, 
and our efforts were now focused on improving potency via alterations of Region III. 
 
Region III Analogues 
Given the diverse nature of the hotspots located in proximity to the CD4Phe43 cavity, 
(i.e., their varying contributions to the global allosteric signal elicited upon binding of 
CD4), subtle structural modifications resulting in changes in ligand orientation might 
have a significant impact on bioactivity. To this end, the first approach consisted of 
varying the substitution pattern on Region III. 
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Position Isomerism 
The route optimized for the synthesis of (+)-JP-III-048 (2.8) was exploited to access 
the position isomer bearing substitution on indane position, namely (+)-BNM-III-170 
(2.46, Figure 3). The (–)-congener was prepared, following the same procedures, by 
undergraduate student Daniel Wendler. 
Although the binding affinity of 2.46 decreased by approximately 50% with respect to 
the parent compound 2.8, the potency increased across HIV-1 strains of Clades B and C 
(geometric mean titer IC50 = 3.5 µM and 5.4 µM, respectively), and in particular against 
neutralization-resistant strain JR-FL (Table 2.1). Evaluation of the (–)-congener, in turn, 
evidenced only marginal activity.  
 
Table 2.1. Comparison of Bioactivity of Di- and Trisubstituted Indane Scaffolds 
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Based on the more potent inhibition of HIV infectivity, (+)-BNM-III-170 (2.46) was 
retained as the new parent or lead scaffold for Structure-Activity Relationship (SAR) 
studies. In order to meet also the increasing demand for 2.46 associated with more 
complex biological studies, a gram-scale synthesis was undertaken. Pleasingly, the first 
route did not require significant optimization to meet this goal: the only difficulty was 
encountered during azide reduction, where undesired loss of the TBS group was 
observed. Decreasing catalyst loading and replacing methanol with ethanol as the 
reaction solvent addressed this issue. Overall, 4.6 g of the last intermediate (2.53) were 
prepared, a fraction of which was converted to 2.46 (furnishing 0.6 g). On scale, the 15-
step sequence could furnish up to 13% yield of 2.46 (Scheme 2.7). 
 
Scheme 2.7. Gram-Scale Synthesis of 2.46 
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Late-Stage Derivatization 
The derivatization campaign was next focused on the nature of the substitution of the 
indane aromatic portion. Indeed, the amine side-chain in 2.46 was seen as a potential 
handle for late-stage derivatization, with two goals in mind: (i) forcing a change in 
binding mode permitting contact of currently installed functionality with different 
hotspots in the cavity vestibule, ideally with the still seemingly elusive gp120Asp368; (ii) 
establishing a direct interaction with residues located further from the cavity (i.e., near 
gp120Gly472, specifically: Ile371, Trp427, Leu455 and Asp474, Figure 2.12). 
 
Figure 2.12. Targeted Residues Near the gp120 Phe43 Cavity 
Pleasingly, reductive aminations performed directly on the bioactive compound 2.46 
granted rapid access in good yields to a first series of analogues possessing additional 
apolar saturated and aromatic hydrocarbon chains (2.54–2.59, Table 2.2). Reductive 
amination employing glyoxylic acid permitted in turn appendage of a carboxylate (2.60) 
and, amidyl transfer, that of an additional guanidinium (2.61). Position isomer 2.62 was 
prepared in a similar fashion (from 2.9). 
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Scheme 2.8. Late-Stage Derivatization of 2.46 
While most modifications were tolerated without resulting in significant changes in 
inhibitory activity, aromatic (2.58 and 2.59) and basic (2.60) substitutions led to lower 
potencies than that of the parent compound (2.46, JR-FL IC50 14.5 µM). We were 
delighted to see, however, a two-fold improvement in potency in the case of 
diguanidinium (+)-BNM-IV-147 (2.61, JR-FL IC50 6.2 µM). Of note, the position isomer 
2.62, although more potent than the compound from which it was derived (i.e., 2.9) 
remained less active than 2.61. 
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Table 2.2. Inhibitory Activity of Region III Analogues 
!  
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Chapter 3: Summary and Future Directions 
 
The development of a scalable synthesis of indane-containing CD4 mimetic 
compounds proved crucial in enabling the exploration, if brief, of chemical space in the 
so-called Regions I and III of (+)-DMJ-II-121 (2.8) and (+)-JP-III-048 (2.9). Position 
isomer (+)-BNM-III-170 (2.46) and diguanidinium analogue (+)-BNM-IV-147 (2.61) 
each led to gradual improvements in inhibitory activity HIV-1 strains, leading to a 5-to-
10-fold improvement overall with respect to the parent indane 2.8 (Table 2.3). 
 
 Viral entry inhibition (IC50, µM)  Binding energy (kcal/mol) 
 JR-FL YU-2 AD8 Control KD (nM) ΔG ΔH –TΔS 
2.8 66.8 ± 9.5 3.8 ± 1.3 8.5 ± 2.1 94.3 ± 5.7 110 –9.5 –17.9 +8.4 
2.9 37.3 ± 13.8 2.1 ± 0.9 6.7 ± 0.6 > 100 24 –10.4 –28.2 +17.8 
2.46 14.5 ± 1.5 1.3 ± 0.2 3.1 ± 1.7 > 100 47 –10.0 –20.7 +10.7 
2.61 6.1 ± 0.5 0.8 ± 0.1 1.6 ± 0.9 > 100 95 –9.6 –15.4 +5.8 
         
Table 2.3. Biological activity of representative compounds. 
Inhibition of viral entry against HIV-1 pseudovirus strains JR-FL, YU-2 and AD8, and A-MLV 
pseudovirus (control). Binding energy measured by ITC employing monomeric YU-2 gp120. 
 
 
A disconcerting observation can however be made from the comparison of the trends 
in inhibitory activity and protein binding affinity (Table 2.3), which appear to be 
inversely correlated in the series of trisubstituted indanes (2.9, 2.46 and 2.61). 
Compatible with the trend in affinity, emerging crystal structures of 2.46:gp120 and 
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2.61:gp120 in fact show fewer protein-ligand hydrogen bonding interactions than 
2.9:gp120, the most stable complex as deemed by calorimetry. 
A possible explanation for this apparent contradiction arises from the fact that 
calorimetric and crystallographic data are obtained using monomeric gp120, a much 
simpler system than the heterohexamer [(gp41)3(gp120)3] that comprises the real 
envelope spike glycoprotein (Env). This becomes particularly relevant given the 
mechanism of action of our small molecules: mimicking CD4 implies triggering 
conformational changes in Env. It is thus not unlikely that the increased activity in this 
series of multivalent ligands is due to interactions that are not obvious from the monomer 
crystal structure, and that calorimetric measurements on the monomer will therefore not 
detect. 
One way to shed more light onto this issue consists in evaluating small molecules 
comprising now tetrasubstituted indanes at Region III. This approach should lead to 
establishing additional protein:ligand interactions, aiming particularly for gp120Asp368. 
Given structural data (see Figure 2.12), compounds such as 2.63 (Figure 2.13) could 
potentially fulfill this requirement. This hypothesis was later corroborated computatio-
nally by Drs. Moraca and Abrams. The corresponding tetrasubsituted indane cores (2.64) 
were envisioned to arise from cyclotrimerization reactions involving appropriately 
chosen alkynes (2.66) and cyclopentenone (2.67, Scheme 2.9 A), as described by Ikeda et 
al. (Scheme 2.9 B).24 With encouraging preliminary results, this project has now been 
taken over by graduate student Melissa Grenier in the Smith group. 
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Scheme 2.9. A. Retrosynthetic analysis of tetrasubstituted indane analogues (2.63) 
B. Cyclotrimerization precedent by Ikeda et al.24 
This research angle notwithstanding, the ability to measure, systematically and 
accurately, interactions of our small molecules and the actual Env, and the 
conformational changes involved, in experimental setups that more closely reflect in vivo 
scenarios is therefore crucial to the further optimization of biological activity in the 
context of rational drug design, as opposed to a by-and-large exploratory approach. To 
this end, our collaborators are currently investigating the use of Surface Plasmon 
Resonance (SPR) and Förster Resonance Energy Transfer (FRET) techniques. The ability 
to measure, and eventually predict, the nature and extent of conformational 
rearrangements in Env elicited by the small-molecule CD4 mimics would have immense 
value, in particular, in enhancing by rational design a recently discovered property: the 
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unique ability of CD4 mimics to sensitize virus and virus-infected cells to neutralization 
by the immune system. Pivotal to the design of future CD4 mimics with enhanced 
antiviral activity will be detailed structural information about the mature, unliganded Env 
trimer. A significant difficulty in this regard is the intrinsic instability of Env. 
Importantly, contrary to trimer structures obtained employing antibodies, our collaborator 
Joseph Sodroski has reported cryo-electron microscopy images of surfactant-stabilized 
unliganded trimer at 6-Å resolution.11 
 
Sensitization of Virus and Virus-Infected Cells to Immune Neutralization 
The therapeutic potential of small-molecule CD4 mimics, initially optimized for 
inhibition of HIV-1 entry, has recently grown due to the discovery by our co-workers at 
Harvard and more recently at Université de Montréal that binding of 2.8 and related 
congeners to the virus envelope glycoprotein (Env) leads to immune responses against 
HIV via two distinct pathways with a common origin: the conformational changes in Env 
caused by binding of our small molecules results in the exposure of conserved epitopes 
that are otherwise concealed by the Env glycan shield. These important observations 
directly impact HIV vaccine research, given that one of the major difficulties that this 
field has met precisely relates to the need to raise antibodies directed at elements of Env 
that remain unaltered among HIV strains. 
The first report, by Madani, Sodroski et al.25 demonstrated that the Env conformation 
induced by 2.8 (Table 2.3) on live HIV-1 virus, including strain JR-FL, results in 
recognition and subsequent neutralization of the viral particles by monoclonal antibodies 
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directed at CD4-induced epitopes, which are typically present, or readily elicited in HIV-
infected individuals. Specifically, HIV-1 virus was pretreated with CD4-mimetic 
compounds (30 min, 37 ºC), then antibody was titrated in, measuring the extent of virus 
neutralization. It was thus found that the concentration of antibody needed for 
neutralization was inversely correlated with the concentration of CD4 mimetic 
compound, with no neutralization occurring in the absence of CD4 mimic. 
More recently, a study led by our collaborator Andrés Finzi26 revealed that CD4 
mimics are capable of formally reversing a complex mechanism exploited by HIV-
infected cells to evade immune recognition. Specifically, as discussed previously, viral 
replication requires the expression of Env on the surface of the infected immune cells. 
The presence of CD4 on the surface (a practical necessity for HIV entry into the cell) 
could potentially lead to the formation of CD4:Env complexes and subsequent exposure 
of Env epitopes, eventually leading to cell death in a process known as Antibody-
Dependent Cell-mediated Cytotoxicity (ADCC). The virus has in fact evolved to escape 
this pathway by downregulating the expression of CD4 on the surface of infected cells. 
Importantly, our collaborators have shown that 2.9 (Table 2.3) can enhance ADCC on 
infected cells in the presence of antibodies present in sera of HIV-infected individuals.26 
Encouraging ongoing studies (unpublished) have shown that more recent congeners 
(2.46, 2.61, Table 2.3) are better enhancers of ADCC directed against HIV-infected cells. 
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Experimental Procedures Relevant to Part II 
 
General Considerations 
All reactions were conducted in oven-dried glassware under an inert atmosphere of 
nitrogen or argon, unless otherwise stated. All solvents were reagent or high performance 
liquid chromatography (HPLC) grade. Anhydrous CH2Cl2 and THF were obtained from 
the Pure SolveTM PS-400 system under an argon atmosphere. All reagents were 
purchased from commercially available sources and used as received. Microwave heating 
was conducted with a Biotage Initiator system equipped with an autosampling arm, using 
either 0.5-2.0 mL, 2.0-5.0 mL, or 20-mL sealed reaction vials. Reactions were 
magnetically stirred under a nitrogen atmosphere, unless otherwise noted and reactions 
were monitored by either thin layer chromatography (TLC) with 0.25 mm E. Merck pre-
coated silica gel plates or analytical high performance liquid chromatography (HPLC). 
Yields refer to chromatographically and spectroscopically pure compounds. Optical 
rotations were measured on a JASCO P-2000 polarimeter. Proton (1H) and carbon (13C) 
NMR spectra were recorded on a Bruker Avance III 500-MHz spectrometer or on a 
Bruker DRX500 500-MHz spectrometer. Chemical shifts (δ) are reported in parts per 
million (ppm) relative to chloroform (δ 7.26) or dimethyl sulfoxide (δ 2.50) for 1H NMR, 
and chloroform (δ 77.0) or dimethyl sulfoxide (δ 39.4) for 13C NMR. Fluorine (19F) NMR 
spectra were recorded on a Bruker DMX300 300-MHz spectrometer. Infrared spectra 
were recorded using a JASCO 480-Plus FT-IR spectrometer, or a Perkin-Elmer Spectrum 
Two FT-IR spectrometer. High-resolution mass spectra (HRMS) were recorded at the 
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University of Pennsylvania Mass Spectroscopy Service Center on either a VG Micromass 
70/70H or VG ZAB-E spectrometer. Analytical HPLC was preformed with a Waters 
HPLC-MS system, consisting of a 515 pump and Sunfire C18 reverse phase column (20 
µL injection volume, 5 µm packing material, 4.5 × 50 mm column dimensions) with 
detection accomplished by a Micromass ZQ mass spectrometer and 2996 PDA detector. 
Preparative scale HPLC was preformed with a Gilson 333/334 preparative pump system 
equipped with a 5 mL injection loop, Sunfire C18 OBD column (5 µm packing material, 
19 x 100 mm column dimensions) equipped with a UV-Vis dual wavelength (210 and 
254 nm) detector and 215 liquid handling module. Solvent systems were comprised of 
H2O containing 0.1% formic acid, and acetonitrile. SFC analyses were performed with a 
JASCO system equipped with a PU-280-CO2 plus CO2 Delivery System, a CO-2060 plus 
Intelligent Column Thermostat/Selector, an HC-2068-01 Heater Controller, a BP-2080 
plus Automatic Back Pressure Regulator, an MD-2018 plus Photodiode Array Detector 
(200-648 nm), and PU-2080 plus Intelligent HPLC Pumps. Lyophilization was performed 
in a Labconco FreeZone 12 Plus lyophilizer (0.035 mbar). The purity of new compounds 
was judged by NMR and LCMS (>95%). Elemental analyses were outsourced to the 
Robertson Microlit Laboratories (Ledgewood, NJ 07852). 
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Enantioselective Synthesis of (+)-JP-III-048 (2.9) 
 
Dioxolane 2.S1. To a solution of bromoindanone 2.10 (5 g, 23.69 mmol) in benzene (158 
mL) were added ethane-1,2-diol (26.4 mL, 474 mmol) and tosic acid monohydrate (0.045 
g, 0.237 mmol). The flask was fitted with a Dean-Stark apparatus pre-filled with benzene 
and a reflux condenser and heated to 115 ºC over 48 h. The reaction mixture was diluted 
with EtOAc and neutralized with sat. aq. NaHCO3. Layers were separated and the 
resulting aqueous layer was extracted with EtOAc. The combined organic layers were 
dried over anhydrous Na2SO4 and concentrated in vacuo. Flash column chromatography 
(95:5 hexanes/EtOAc) afforded 2.S1 as a clear, pale yellow oil (5.73 g, 95%). 
 
1H NMR (500 MHz, CDCl3) δ 7.47 (d, J = 1.8 Hz, 1 H), 7.84 (dd, J = 1.8, 8.0 Hz, 1 H), 
7.11 (d, J = 8.0 Hz, 1 H), 4.15–4.20 (m, 2 H), 4.06–4.11 (m, 2 H), 2.89 (t, J = 7.0 Hz, 2 
H), 2.30 (t, J = 7.0 Hz, 2 H); 
13C NMR (125 MHz, CDCl3) δ 144.5, 142.7, 132.7, 126.9, 126.6, 120.6, 116.9, 65.5, 
37.5, 28.3; 
IR (thin film, KBr) νmax 2959, 2882, 1473, 1303, 1253, 1044, 922 cm–1; 
HRMS (ESI) m/z 253.9947 [calcd for C11H11BrO2 (M)+ 253.9942]. 
 
 
Br
O
Br O
OEthylene glycol
TsOH (1 mol%)
Benzene, reflux, 2d
2.10 2.S1
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Aldehyde 2.11. To a precooled (–78 ºC) solution of 2.S1 (5.73 g, 22.46 mmol) in THF 
(32.1 mL) was slowly added butyllithium (9.88 mL of a 2.5 M solution in hexane, 24.71 
mmol). The reaction mixture was stirred at –78 ºC for 10 min, then N,N-
dimethylformamide (2.078 mL, 27.0 mmol) was added. The resulting mixture was stirred 
at –78 ºC for an additional 15 min, then allowed to warm to rt and stirred for a final 30 
min. The reaction was quenched with sat. aq. NaHCO3 and diluted with EtOAc. The 
combined organic layers were washed with water and brine, dried over anhydrous 
Na2SO4 and concentrated in vacuo. Flash column chromatography (5:1 hexanes/EtOAc) 
afforded 2.11 as a clear orange oil (4.61 g, 92%). 
 
1H NMR (500 MHz, CDCl3) δ 10.0 (s, 1 H), 7.87 (s, 1 H), 7.84 (dd, J = 7.8, 1.3 Hz, 1 H), 
7.39 (d, J = 7.8 Hz, 1 H), 4.21–4.25 (m, 2 H), 4.10–4.15 (m, 2 H), 3.02 (t, J = 7.0 Hz, 2 
H), 2.36 (t, J = 7.0 Hz, 2 H); 
13C NMR (125 MHz, CDCl3) δ 192.0, 151.2, 143.6, 136.1, 131.5, 126.0, 125.0, 116.5, 
65.6, 37.3, 29.1; 
IR (thin film, KBr) νmax 2959, 2885, 1697, 1614, 1311, 1143, 1042 cm–1; 
HRMS (ESI) m/z 204.0785 [calcd for C12H12O3 (M)+ 204.0786]. 
 
 
  
Br O
O OO
H
O
a) n-BuLi
b) DMF
THF, –78 ºC, 45 min
2.S1 2.11
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Carbamate 2.S3. At 0 ºC, methylamine (41.5 ml of a 2 M solution in THF, 83 mmol) was 
added to 2.11 (neat, 4.61 g, 20.77 mmol). The reaction was warmed to rt and stirred for 
30 min, then cooled to 0 ºC. MeOH (41.5 ml) was then added, followed by sodium 
borohydride (0.393 g, 10.38 mmol). The resulting mixture was stirred at 0 ºC for 40 min. 
A second portion of sodium borohydride (0.393 g, 10.38 mmol) was then added. The 
reaction mixture was stirred for an additional 40 min, then quenched with water and 
extracted with EtOAc. The combined organic layers were washed with brine, dried over 
Na2SO4 and concentrated in vacuo. The resulting crude amine (2.S2) was dissolved in 
acetonitrile (83 mL) and added to a solution of Boc2O (5.30 mL, 22.85 mmol) in 
acetonitrile (83 mL). The mixture was stirred at rt for 15 min, then concentrated in vacuo. 
Flash column chromatography (95:5 to 70:30 hexanes/EtOAc) afforded 2.S3 as a clear 
colorless oil (5.48 g, 83%). 
 
1H NMR (500 MHz, CDCl3) δ 7.10–7.17 (m, 3 H), 4.34 (s, 2 H), 4.05–4.11 (m, 2 H), 
3.96–4.00 (m, 2 H), 2.84 (t, J = 6.8 Hz, 2 H), 2.69–2.76 (2br s, 3 H, rotamer 1 and 2), 
2.21 (t, J = 7.0 Hz, 2 H), 1.42 (s, 9 H); 
OO
N
H
Me
a) MeNH2
b) NaBH4
THF/MeOH 1:1
rt to 0 ºC
OO
H
O O
O
N
Boc
Me
CH3CN, rt, 15 min
Boc2O
2.11 2.S2 2.S3
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13C NMR (125 MHz, CDCl3, mixture of rotamers) δ 155.9, 155.5, 142.5, 142.3, 136.7, 
129.1, 128.4, 125.0, 122.4, 121.8, 116.8, 79.4, 65.1, 64.9, 52.3, 51.6, 37.1, 33.6, 28.3, 
28.0; 
IR (thin film, KBr) νmax 3391, 2974, 1694, 1391, 1143, 1054 cm–1; 
HRMS (ESI) m/z 319.1798 [calcd for C18H25NO4 (M)+ 319.1784]. 
 
 
Indanone 2.12. To a solution of 2.S3 (5.47 g, 17.13 mmol) in acetone (171 mL) was 
added bis(acetonitrile)-palladium(II) dichloride (0.089 g, 0.343 mmol). The reaction 
mixture was stirred at rt for 30 min then concentrated in vacuo. The resulting residue was 
taken up in EtOAc (150 mL) and washed with sat. aq. NaHSO3 (20 mL × 3). The 
combined organic layers were dried over anhydrous Na2SO4 and concentrated in vacuo. 
Flash column chromatography (85:15 to 70:30 hexanes/EtOAc) afforded 2.12 as a clear 
colorless oil that, upon standing, precipitated to form a white solid (4.67 g, 94%). 
 
1H NMR (500 MHz, CDCl3) δ 7.54 (s, 1 H), 7.39–7.41 (m, 2 H), 4.42 (s, 2 H), 3.07 (t, J 
= 5.5 Hz, 2 H), 2.76–2.78 (2br s, 3 H, rotamer 1 and 2), 2.64 (t, J = 6.0 Hz, 2 H), 1.43 (s, 
9 H); 
13C NMR (125 MHz, CDCl3, mixture of rotamers) δ 206.8, 156.2, 155.6, 154.4, 137.8, 
137.4, 134.4, 133.9, 127.0, 122.4, 80.0, 52.4, 51.6, 36.6, 34.1, 28.5, 25.6; 
IR (thin film, KBr) νmax 2975, 2916, 1694, 1392, 1151 cm–1; 
N
Boc
Me
OAcetone
PdCl2(CH3CN)2
rt, 30 min
OO
N
Boc
Me
2.S3 2.12
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HRMS (ESI) m/z 298.1434 [calcd for C16H21NO3Na (M+Na)+ 298.1419). 
 
 
 
β-Ketoester 2.13. To a precooled (–78 ºC) solution of 6 (1.23 g, 4.47 mmol) in THF (45 
mL) was slowly added NaHMDS (9.0 mL of a 1 M solution in THF, 9.0 mmol). The 
mixture was stirred at –78 ºC for 10 min, then ethyl carbonocyanidate (0.57 mL, 5.8 
mmol) was added and stirring was continued at –78 ºC for 1 h. The reaction was 
quenched with sat. aq. NH4Cl and diluted with EtOAc. Layers were separated and the 
resulting aqueous layer was extracted with EtOAc. The combined organic layers were 
washed with brine, dried over Na2SO4 and concentrated in vacuo. Flash column 
chromatography (85:15 hexanes/EtOAc) afforded 2.13 as a clear purple oil (1.31 g, 82%). 
 
1H NMR (500 MHz, CDCl3) δ 10.34 (s, enol OH), 7.52 (s, ketoester 1 H), 7.45–7.55 (m, 
ketoester 2 H), 7.15–7.30 (m, enol 3 H), 4.38 (br s, ketoester 2 H and enol 2 H), 4.22 (q, J 
= 7.2 Hz, enol 2 H), 4.11–4.17 (m, ketoester 2 H), 3.64 (dd, J = 3.8, 8.3 Hz, ketoester 1 
H), 3.43 (dd, J = 3.3, 17.3 Hz, ketoester 1 H), 3.39 (s, enol 2 H), 3.27 (dd, J = 8.3, 17.3 
Hz, ketoester 1 H), 2.71–2.75 (2 br. s, ketoester 3 H and enol 3 H, rotamer 1 and 2), 1.39 
(s, ketoester 9 H and enol 9 H), 1.26 (t, J = 7.0 Hz, enol 3 H), 1.21 (t, J = 7.0 Hz, 
ketoester 3 H); 
N
Boc
Me
O O
NMe
Boc OEt
Oa) NaHMDSb) NCCO2Et
THF, –78 ºC, 90 min
(±)-2.132.12
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13C NMR (125 MHz, CDCl3, mixture of rotamers + enol) δ 199.3, 169.3, 169.0, 156.1, 
155.5, 152.8, 142.2, 138.3, 137.3, 137.0, 135.5, 135.1, 134.5, 128.9, 128.4, 126.8, 124.8, 
123.0, 119.7, 119.5, 102.9, 79.8, 61.6, 60.0, 53.6, 52.1, 51.4, 34.0, 33.9, 32.2, 30.0, 28.4, 
14.4, 14.1; 
IR (thin film, KBr) νmax 2977, 2921 1694, 1392, 1366, 1147, 875 cm–1; 
HRMS (ESI) m/z 370.1641 [calcd for C19H25NO5Na (M+Na)+ 370.1630]. 
 
 
 
β-Hydroxyester 2.23. RuCl(p-cymene)[(S,S)-Ts-DPEN] (2.22, 0.163 g, 0.256 mmol) was 
added in one portion to a solution of 2.13 (5.13 g, 14.77 mmol) in HCOOH/Et3N (5:2, 
7.38 mL). The reaction mixture was stirred at room temperature for 3 days, diluted with 
CH2Cl2 and washed with H2O (×2). The combined organic layers were dried over Na2SO4 
and concentrated in vacuo. Flash column chromatography (hexanes/EtOAc 7:3) afforded 
2.23 as a clear pale pink oil (4.80 g, 93%).  [!]!!" +23.7 (c 1.13, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.30 (br s, 1 H), 7.25–7.20 (m, 1 H), 7.17 (br s, 1 H), 
5.35–5.30 (m, 1 H), 4.42 (br s, 2 H), 4.25 (q, J = 7.1 Hz, 2 H), 3.45–3.36 (m, 2 H), 3.14–
2.95 (m, 1 H), 2.95–2.75 (m, 3 H), 1.53–1.44 (m, 9 H), 1.32 (t, J = 7.1 Hz, 3 H); 
O
NMe
Boc OEt
O (S)
(S)
OH
NMe
Boc OEt
O
5:2 HCO2H/Et3N
rt, 3 days
2 mol%
N
H2
Ru
N
Ts
Ph
Ph Cl
Me
i-Pr
(+)-2.23(±)-2.13 RuCl(p-cymene)
[(S,S)-Ts-DPEN]
(2.22)
(S,S)-2.22
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13C NMR (125 MHz, CDCl3, mixture of rotamers) δ 173.1, 143.1, 140.8, 137.3, 124.9, 
75.7, 60.9, 49.6, 33.9, 32.6, 28.5, 14.2; 
IR (thin film, KBr) νmax 3432, 2976, 1735, 1691, 1476, 1393, 1246, 1147 cm–1; 
HRMS (ESI) m/z 372.1789 [calcd for C19H27NO5Na (M+Na)+ 372.1787). 
 
(–)-2.23: data consistent with (+)-isomer — [!]!!! –25.8 (c 1.67, CH2Cl2). 
 
Enantiomeric excess determined by SFC (see figure below): 
 
(+)-(S,S)-2.23 
+ (–)-(R,R)-2.23 
(+)-(S,S)-2.23 (–)-(R,R)-2.23 
   
 er = 99:1 er = 98:2 
 
Method: column: Chiralpak AS-H; eluent: 30% MeOH in supercritical CO2; flow rate: 4 
mL/min; pressure: 12 MPa. Retention times: (+)-(S,S)-2.23: 0.9 min, (–)-(R,R)-2.23: 1.2 
min. 
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Chromatogram Information  
User Name Administrator  
Date Modified 8/27/2013 5:58:30 PM  
Description  
HPLC System Name  Jasco SFC 
Injection Date 8/27/2013 6:08:31 PM  
Volume  15.00 [µL] 
Sample Number  2 
Project Name Chiral 
Acquisition Time  6.0 [min]  
Acquisition Sequence JP-III-91 
Control Method  Solv 1 Col 5 Iso30%B 4mL-min 12MPa 6min  
Peak ID Table  
Calibration Method  
Additional Information   
 
 
Channel & Peak Information Table  
Chromatogram Name BM-2-288 rac 5-CH9 
Sample Name   
Channel Name 220.0nm 
Sampling Interval 100 [msec]  
Peak Method  (Manual)  
Formula  
Decision  
 
# Peak Name CH tR [min]  Area [µV·sec] Height [µV] Area% Height% Quantity NTP Resolution Symmetry Factor  Warning 
1 Unknown  9 0.997 2993261 678555 64.629 53.237 N/A 1061 1.989 0.838  
2 Unknown  9 1.187 1638197 596038 35.371 46.763 N/A 4709 N/A 0.918  
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Chromatogram Information  
User Name Administrator  
Date Modified 8/27/2013 6:21:34 PM  
Description  
HPLC System Name  Jasco SFC 
Injection Date 8/27/2013 6:15:31 PM  
Volume  15.00 [µL] 
Sample Number  3 
Project Name Chiral 
Acquisition Time  6.0 [min]  
Acquisition Sequence JP-III-91 
ntrol Method  Solv 1 Col 5 Iso30%B 4mL-min 12MPa 6min  
e k ID Table  
Calibration Method  
Additional Information   
 
 
Channel & Peak Information Table  
Chromatogram Name BM-2-288 S_S-CH9 
Sample Name   
Channel Name 220.0nm 
Sampling Interval 100 [msec]  
Peak Method  (Manual)  
Formula  
Decision  
 
# Peak Name CH tR [min]  Area [µV·sec] Height [µV] Area% Height% Quantity NTP Resolution Symmetry Factor  Warning 
1 Unknown  9 0.993 2336180 627536 99.080 98.805 N/A 1542 2.220 0.898  
2 Unknown  9 1.187 21696 7589 0.920 1.195 N/A 4177 N/A 0.834  
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Chromatogram Information  
User Name Administrator  
Date Modified 8/27/2013 6:27:48 PM  
Description  
HPLC System Name  Jasco SFC 
Injection Date 8/27/2013 6:21:45 PM  
Volume  15.00 [µL] 
Sample Number  4 
Project Name Chiral 
Acquisition Time  6.0 [min]  
Acquisition Sequence JP-III-91 
Control Method  Solv 1 Col 5 Iso30%B 4mL-min 12MPa 6min  
Peak ID Table  
Calibration Method  
Additional Information   
 
 
Channel & Peak Information Table  
Chromatogram Name BM-2-289 R_R-CH9 
Sample Name   
Channel Name 220.0nm 
Sampling Interval 100 [msec]  
Peak Method  (Manual)  
Formula  
Decision  
 
# Peak Name CH tR [min]  Area [µV·sec] Height [µV] Area% Height% Quantity NTP Resolution Symmetry Factor  Warning 
1 Unknown  9 0.998 98118 27667 2.474 2.269 N/A 1618 2.114 1.073  
2 Unknown  9 1.192 3868485 1191421 97.526 97.731 N/A 3212 N/A 0.961  
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Diol 2.S4. To a precooled (0 ºC) suspension of lithium aluminum hydride (0.336 g, 8.84 
mmol) in THF (10 mL) was added dropwise over 5 min via cannula a solution of 2.23 
(1.03 g, 2.95 mmol) in THF (20 mL). The reaction was stirred for 30 min at 0 ºC then 
quenched with 15% aq. sodium potassium tartrate and stirred at rt for an additional 10 
min. Water was added, followed by EtOAc. The resulting biphasic mixture was filtered 
through Celite, rinsing with abundant water and EtOAc. The layers were separated and 
the resulting aqueous layer was extracted with EtOAc. The combined organic layers were 
dried over Na2SO4 and concentrated in vacuo. Flash chromatography (1:1 to 0:1 
hexanes/EtOAc) afforded 2.S4 as a clear colorless oil (840 mg, 87%). [!]!!" +15.0 (c 0.75, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.28 (br s, 1 H), 7.21 (d, J = 7.7 Hz, 1 H), 7.14 (d, J = 7.5 
Hz, 1 H), 5.31 (d, J = 6.3 Hz, 1 H), 4.42 (br s, 2 H), 3.95 (dd, J = 4.4, 11.1 Hz, 1 H), 3.90 
(dd, J = 7.7, 11.3, 1 H), 2.90 (d, J = 7.7 Hz, 2 H), 2.82 (br s, 3 H), 2.78–2.62 (m, 1 H), 
2.52 (br s, 2 H), 1.49 (s, 9 H); 
13C NMR (125 MHz, CDCl3) δ 144.7, 142.1, 136.9, 127.9, 125.2, 124.0, 80.0, 77.3, 63.1, 
52.0, 45.4, 34.1, 32.5, 28.6, 28.2; 
IR (thin film, KBr) νmax 3388, 2927, 1671, 1393, 1248, 1146 cm–1; 
HRMS (ESI) m/z 330.1689 [calcd for C17H25NO4Na (M+Na)+ 330.1681]. 
 
(–)-2.S4: data consistent with (+)-isomer — [!]!!" –20.9 (c 2.25, CH2Cl2). 
(S)
(S)
OH
NMe
Boc OEt
O
THF, 0 ºC, 45 min
(R)
(S)
OH
NMe
Boc OH
LiAlH4
(+)-2.23 (+)-2.S4
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Silyl ether 2.15. To a precooled (0 ºC) solution of 2.S4 (830 mg, 2.54 mmol) and 1 H-
imidazole (346 mg, 5.08 mmol) in CH2Cl2 (25.4 mL) was added tert-butyl-
chlorodimethylsilane (650 mg, 4.31 mmol). The resulting mixture was stirred for 30 min 
at 0 ºC, then diluted with EtOAc and washed with water. The combined organic layers 
were dried over Na2SO4 and concentrated in vacuo. Flash chromatography (9:1 to 1:1 
hexanes/EtOAc) afforded 2.15 as a clear colorless oil (1.01 g, 95%). 
 [!]!!" +8.41 (c 0.14, CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 7.30 (br s, 1 H), 7.23–7.14 (m, 1 H), 7.12 (br s, 1 H), 5.26 
(t, J = 5.9 Hz, 1 H), 4.57–4.33 (m, 2 H), 3.98 (dd, J = 4.8, 10.3 1 H), 3.90 (dd, J = 7.3, 
10.1 Hz, 1 H), 3.39–3.18 (m, 1 H), 2.91 (dd, J = 15.3, 8.5 Hz, 1 H), 2.86–2.76 (m, 4 H), 
2.76–2.55 (m, 1 H), 1.49 (s, 9 H), 0.87 (s, 9 H), 0.09 (s, 3 H), 0.06 (s, 3 H); 
13C NMR (125 MHz, CDCl3, mixture of rotamers) δ 141.4, 136.7, 124.7, 77.1, 63.7, 
45.0, 33.8, 32.9, 28.5, 25.7, 18.0, –5.5, –5.6; 
IR (thin film, KBr) νmax 3388, 2926, 2854, 1674, 1146 cm–1; 
HRMS (ESI) m/z 444.2544 [calcd for C23H39NO4SiNa (M+Na)+  444.2546]; 
 
(–)-2.15: data consistent with (+)-isomer — [!]!!" –24.0 (c 0.53, CH2Cl2). 
 
CH2Cl2, 0 ºC, 45 min
(R)
(S)
OH
OTBS
TBSCl, imidazole NMe
Boc
(R)
(S)
OH
NMe
Boc OH
(+)-2.15(+)-2.S4
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Azide 2.S5. To a solution of 2.15 (600 mg, 1.423 mmol) in toluene (14.2 mL) was added 
diphenyl phosphoryl azide (0.920 mL, 4.27 mmol). The mixture was stirred at rt for 5 
min, then DBU (0.643 ml, 4.27 mmol) was added. After stirring at rt for 10 min, the 
reaction mixture was heated to 70 ºC and stirred overnight. EtOAc was added, and the 
resulting mixture was washed with water and brine. The combined organic layers were 
dried over Na2SO4 and concentrated in vacuo. Flash column chromatography (98:2 
hexanes/EtOAc) afforded 2.S5 as a clear colorless oil (650 mg, quant.). 
 
 
Amine 2.17. Palladium (10 wt% on carbon, 150 mg, 0.141 mmol) was added to a solution 
of 2.S5 (630 mg, 1.410 mmol) in MeOH (26.9 mL). The reaction vessel was evacuated 
and backfilled with hydrogen gas (x4). The reaction mixture was stirred at rt overnight 
under a hydrogen atmosphere, then filtered though Celite, rinsing with abundant EtOAc. 
The resulting solution was concentrated in vacuo to give 2.17 as a clear colorless oil (593 
mg), used in the next step without further purification. 
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Oxalamide 2.S6. To a solution of 2.17 (583 mg, 1.386 mmol), 2-((4-chloro-3-
fluorophenyl)amino)-2-oxoacetic acid 2.18 (362 mg, 1.663 mmol) and TBTU (578 mg, 
1.802 mmol) in CH2Cl2 (27.7 mL) was added DIPEA (0.363 mL, 2.079 mmol). The 
resulting mixture was stirred at rt overnight. Once the stirring period was complete, the 
mixture was diluted with EtOAc, washed with water, 1N aq. HCl, sat. aq. NaHCO3 and 
brine. The resulting organic layer was dried over Na2SO4 and concentrated in vacuo. 
Flash column chromatography (7:3 hexanes/EtOAc) afforded 2.S6 as a white solid (739 
mg, 87% from 2.15). 
 [!]!!" +49.77 (c 0.23, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 9.37 (s, 1 H), 7.73 (dd, J = 2.5, 10.6 Hz, 1 H), 7.65 (d, J 
= 9.7 Hz, 1 H), 7.37–7.42 (m, 1 H), 7.24–7.26 (m, 1 H), 7.17–7.23 (m, 1 H), 7.13 (br s, 1 
H), 7.08 (s, 1 H), 5.37 (t, J = 8.6 Hz, 1 H), 4.38 (br s, 2 H), 3.81 (d, J = 5.5 Hz, 2 H), 
3.09 (dd, J = 8.0, 16.0 Hz, 1 H), 2.71–2.87 (m, 4 H), 2.51–2.58 (m, 1 H), 1.42–1.51 (m, 9 
H), 0.86–1.01 (m, 9 H), 0.08 (s, 3 H), 0.07 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 159.2, 157.5, 143.5, 141.3, 137.2, 130.9, 125.0, 115.9 (d, 
JCF = 3.5 Hz), 108.4 (d, JCF = 26 Hz), 70.9, 69.4, 63.8, 57.0, 51.0, 33.9, 33.2, 28.4, 25.8, 
18.2, –5.5; 
IR (thin film, KBr) νmax 3280, 2926, 1667, 1515, 1147, 838 cm–1; 
(S)
(R)
NMe
Boc OTBS
Cl
H
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O
O HN
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HRMS (ESI) m/z 642.2548 [calcd for C31H43N3O5SiClFNa (M+Na)+ 642.2542). 
 
(–)-2.S6: data consistent with (+)-isomer — [!]!!" –47.4 (c 1.9, CH2Cl2). 
 
 
Alcohol 2.19. To a solution of 2.S6 (0.73 g, 1.177 mmol) in THF (23.5 mL) at rt was 
added TBAF (1 M solution in THF, 2.35 ml, 2.35 mmol). The reaction was stirred at rt 
overnight, then diluted with EtOAc and washed with water and brine. The resulting 
organic layer was dried over Na2SO4 and concentrated in vacuo. Flash column 
chromatography (1:1 hexanes/EtOAc) afforded 2.19 as a white solid (550 mg, 92%). [!]!!" +31.4 (c 0.275, EtOAc); 
1H NMR (500 MHz, DMSO-d6, mixture of rotamers) δ 11.12 (br. s., 1 H), 9.43 - 9.34 (m, 
1 H), 7.97 (dd, J = 2.1, 11.8 Hz, 1 H), 7.76 (dd, J = 1.7, 8.8 Hz, 1 H), 7.59 (t, J = 8.7 Hz, 
1 H), 7.20 (d, J = 7.5 Hz, 1 H), 7.12 - 6.91 (m, 2 H), 5.29 - 5.20 (m, 1 H), 4.72 (t, J = 4.9 
Hz, 1 H), 4.39 - 4.22 (m, 2 H), 3.62 - 3.50 (m, 2 H), 3.06 - 2.97 (m, 1 H), 2.79 - 2.66 (m, 
5 H), 1.35 (2 br. s, rotamer 1 and rotamer 2, 9 H); 
13C NMR (125 MHz, DMSO-d6, mixture of rotamers) δ 160.3, 159.5, 157.4 (d, JCF = 244 
Hz), 155.2, 144.2, 141.9, 139.0 (d, JCF = 10 Hz), 137.0, 131.2, 127.7, 125.1, 123.3, 117.9 
(d, JCF = 4 Hz), 114.9 (d, JCF = 18 Hz), 109.0 (d, JCF = 26 Hz),, 79.3, 62.2, 56.5, 52.2, 
51.4, 48.9, 42.0, 34.2, 34.0, 33.7, 28.7, 28.6; 
(S)
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IR (thin film, KBr) νmax 3267, 2923, 1662, 1591, 1514, 1428, 1144, 736 cm–1; 
HRMS (ESI, neg.) m/z 504.1709 [calcd for C25H28ClFN3O5 (M‒H)‒ 504.1702]. 
 
(–)-2.19: data consistent with (+)-isomer — [!]!!" –38.3 (c 0.40, EtOAc). 
 
 
tetra-Boc-JP-III-048 2.S7. To a solution of 2.19 (250 mg, 0.494 mmol) in THF (16.5 mL) 
were added N,N',N''-tri-Boc-guanidine (533 mg, 1.482 mmol) and triphenylphosphine 
(194 mg, 0.741 mmol). The suspension was cooled to 0 ºC and DEAD (0.338 mL, 0.741 
mmol) was added dropwise. The reaction vessel was sealed and heated to 80 °C for 90 
min under microwave conditions. After cooling to rt, the reaction was quenched by 
addition of sat. aq. NaHCO3 and extracted with EtOAc. The combined organic layers 
were washed with brine, dried over Na2SO4 and concentrated in vacuo. Flash column 
chromatography (10:1 to 2:1 hexanes/EtOAc) afforded 2.S7 as a white foam (298 mg, 
71%). 
 [!]!!" +22.6 (c 1.15, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 9.38 (s, 1 H), 7.79 (d, J = 9.1 Hz, 1 H), 7.74 (dd, J = 2.4, 
10.7 Hz, 1 H), 7.37 (t, J = 8.2 Hz, 1 H), 7.22–7.26 (m, J = 8.7, 1.2, 1.2 Hz, 1 H), 7.18 (d, 
J = 7.7 Hz, 1 H), 7.11 (br s, 1 H), 7.03 (s, 1 H), 5.24 (t, J = 8.7 Hz, 1 H), 4.36 (br s, 2 H), 
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4.08–4.23 (m, 2 H), 3.15 (dd, J = 8.1, 15.5 Hz, 1 H), 2.83–2.91 (m, 1 H), 2.71–2.83 (m, 4 
H), 1.46–1.51 (m, 27 H), 1.44 (s, 9 H); 
13C NMR (125 MHz, CDCl3, mixture of rotamers) δ 187.8, 159.5, 158.3, 158.1 (JCF = 
246 Hz) 157.7, 157.3, 153.1, 140.9, 137.2, 136.4, 130.7, 125.0, 117.0, 115.8 (d, JCF = 4 
Hz), 108.3 (d, JCF = 27 Hz), 83.5, 58.4, 49.8, 48.3, 34.7, 33.8, 28.4, 28.1, 28.0, 27.9, 27.9; 
IR (thin film, KBr) νmax 3280, 2978, 1665, 1607, 1515, 1368, 1243, 1146 cm–1; 
HRMS (ESI) m/z 847.3782 [calcd for C41H57N6O10ClF (M+H)+847.3809]. 
 
(–)-2.S7: data consistent with (+)-isomer — [!]!!" –25.1 (c 2.0, CH2Cl2). 
 
 
 
JP-III-048 2.9. To a solution of 2.S7 (0.442 g, 0.522 mmol) in CH2Cl2 (10.4 mL) was 
added TFA (1.849 mL, 23.99 mmol). The reaction mixture was stirred at rt for 4 h then 
concentrated in vacuo. The crude residue was taken up in water/acetonitrile (90:10, 5 
mL). Formic acid (0.1 mL) was added. The resulting clear solution was purified by 
HPLC (5 injections of 1300 µL each). Eluant: 90:10 to 60:40 water/acetonitrile (12-
minute gradient). Flow rate: 15 mL/min. Product retention time: 5-6 min. Product 
fractions were combined and acetonitrile was removed in vacuo. The resulting aqueous 
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solution was deep-frozen (–78 ºC bath) and lyophilized (0.035 mbar) to afford the bis-
trifluoroacetate salt 2.9 as a white powder (256 mg, 73%). [!]!!" +27.3 (c 0.29, CH3OH); 
1H NMR (500 MHz, DMSO-d6) δ 11.10 (s, 1 H), 9.45 (d, J = 8.9 Hz, 1 H), 8.68 (br s, 2 
H), 7.99 (dd, J = 2.2, 11.7 Hz, 1 H), 7.81 (t, J = 5.5 Hz, 1 H), 7.78 (dd, J = 1.7, 8.8 Hz, 1 
H), 7.61 (t, J = 8.7 Hz, 1 H), 7.32 (s, 2 H), 7.25 (s, 1 H), 5.19 (t, J = 8.9 Hz, 1 H), 4.05 (s, 
2 H), 3.26–3.45 (m, 4 H), 3.13 (dd, J = 8.1, 15.7 Hz, 1 H), 2.83–2.91 (m, 1 H), 2.68 (dd, J 
= 9.5, 15.5 Hz, 2 H); 
13C NMR (125 MHz, DMSO-d6) δ 160.5, 159.4, 158.9 (q, JCF = 31 Hz, TFA), 157.7, 
157.4 (d, JCF = 244 Hz), 143.7, 142.6, 138.9 (d, JCF = 10 Hz), 131.9, 131.3, 129.9, 125.5, 
125.4, 119.1, 117.9 (d, JCF = 3 Hz), 115.1 (d, JCF = 18 Hz), 109.1 (d, JCF = 25 Hz), 57.5, 
52.1, 46.0, 43.5, 34.3, 32.9; 
19F NMR (282 MHz, DMSO-d6) δ -73.5 (6 F), -114.5 (1 F); 
IR (ATR) νmax 3277, 1665, 1512, 1427, 1200, 1131, 975, 836, 800 cm–1; 
HRMS (ESI) m/z 447.1711 ([M–H]+; calcd for C21H25N6O2ClF: 447.1712); 
Anal. Calcd for C25H26ClF7N6O6: C, 44.49; H, 3.88; Cl, 5.25; F, 19.70; N, 12.45; O, 
14.22. Found: C, 44.48; H, 3.93; Cl, 5.29; F, 18.26; N, 12.16; O, n/d. 
 
(–)-2.9: data consistent with (+)-isomer — [!]!!" –27.3 (c 0.53, CH3OH). 
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Salt exchange. Solvents for HPLC were prepared as follows: 
– solvent A: H2O (1.85 L), HCOOH (1.9 mL), NH4OH (33%, 3.9 mL) 
– solvent B: H2O (0.15 L), CH3CN (0.85 L), HCOOH (1.1 mL), NH4OH (33%, 2.1 mL) 
The TFA salt of 2.9 (10 mg, 0.015 mmol) was dissolved in 90:10 A/B (0.5 mL) and 
injected in HPLC column. Eluant: 88:12 to 53:47 A/B (10-minute gradient). Flow rate: 
15 mL/min. Product retention time: 9-10 min. Product fractions were combined and 
acetonitrile was removed in vacuo. The resulting aqueous solution was deep-frozen (–78 
ºC bath) and lyophilized (0.035 mbar) to afford the bis-formate salt 2.9 as a white powder 
(5.7 mg, 71%). 
19F NMR (282 MHz, DMSO-d6) δ -73.4 (trace); -114.6 (1 F). 
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Enantioselective Synthesis of (+)-DMJ-II-121 (2.8)  
 
β-Ketoester 2.30. To a precooled (–78 ºC) solution of indanone 2.29 (2 g, 15.13 mmol) in 
THF (150 mL) was added slowly NaHMDS (1.0 M solution in THF, 37.8 mL, 37.8 
mmol). The mixture was stirred at –78 ºC for 10 min, then ethyl carbonocyanidate (1.928 
mL, 19.67 mmol) was added and the mixture was stirred at –78 ºC for 1 hour.  The 
reaction was quenched by addition of sat. aq. NH4Cl (50 mL), then diluted with EtOAc 
(150 mL) and extracted with EtOAc (3 × 100 mL). The organic layers were combined, 
washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The residue 
was purified by flash column chromatography (95:5 hexanes/EtOAc) to furnish 2.30 
(2.52 g, 80%) as a clear, purple oil. Spectroscopic data evidences a 85:15 ketone/enol 
equilibrium. 
 
1H NMR (500 MHz, CDCl3) δ 10.46 (br. s, 1 H enol), 7.79 (d, J = 7.7 Hz, 1 H ketone), 
7.70 - 7.59 (m, 1 H ketone + enol), 7.56 - 7.35 (m, 2 H ketone + 3 H enol), 4.34 (q, J = 
7.1 Hz, 2 H enol), 4.29 - 4.23 (m, 2 H ketone), 3.73 (dd, J = 4.0, 8.3 Hz, 1 H ketone), 
3.57 (dd, J = 4.2, 17.2 Hz, 1 H ketone + 2 H enol), 3.39 (dd, J = 8.1, 17.2 Hz, 1 H enol), 
1.38 (t, J = 7.1 Hz, 3 H enol), 1.32 (t, J = 7.1 Hz, 3 H ketone); 
O O
OEt
Oa) NaHMDSb) NCCO2Et
THF, –78 ºC, 90 min
2.29 (±)-2.30
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13C NMR (125 MHz, CDCl3) δ 199.7, 169.3, 153.8, 143.4, 137.1, 135.6, 135.5, 135.4, 
129.5, 127.9, 126.9, 126.7, 124.9, 124.8, 120.8, 102.6, 61.9, 60.2, 53.5, 32.7, 30.4, 29.4, 
14.6, 14.3; 
IR (thin film, KBr) νmax 3406, 2982, 1712, 1648, 1207, 1019, 764 cm-1; 
HRMS (CI) m/z 204.0779 [calcd for C12H12O3 (M)+ 204.0786]. 
 
 
β-Hydroxyester 2.31. To a solution of 2.30 in HCOOH/Et3N (5:2, 3.5 mL) at rt was added 
(S,S)-2.22 (90 mg, 0.142 mmol) and the resulting mixture was stirred at rt for 48 h. The 
reaction mixture was next diluted with CH2Cl2 (50 mL) and washed with H2O (2 × 15 
mL). The organic layer was then dried over Na2SO4, filtered and concentrated in vacuo. 
The residue was subjected to flash column chromatography (85:15 hexanes/EtOAc) to 
furnish 2.31 (1.44 g, 98%) as a clear colorless oil. 
 
[α]D22 –45.3 (c 0.98, EtOH); 
1H NMR (500 MHz, CDCl3) δ 7.45 (d, J = 7.1 Hz, 1 H), 7.34 - 7.24 (m, 3 H), 5.36 (t, J = 
6.0 Hz, 1 H), 4.26 (q, J = 7.1 Hz, 2 H), 3.49 - 3.36 (m, 2 H), 3.12 (dd, J = 7.6, 15.4 Hz, 1 
H), 2.91 (d, J = 6.1 Hz, 1 H), 1.33 (t, J = 7.1 Hz, 3 H); 
(S)
(S)
OH
OEt
O(S,S)-2.22
2 mol%
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13C NMR (125 MHz, CDCl3) δ 173.2, 142.8, 142.0, 129.2, 127.3, 125.2, 125.0, 76.0, 
61.1, 49.6, 33.0, 14.4; 
IR (thin film, KBr) νmax 3452, 2918, 1736, 1374, 1183, 1038, 756 cm-1; 
HRMS (ESI) m/z 229.0846 [calcd for C12H14O3Na (M+Na)+ 229.0841]. 
 (+)-2.31: data consistent with (–)-isomer — [α]D22 +44.5 (c 0.69, EtOH). 
 
 
 
Diol 2.S8. To a precooled (0 ºC) suspension of LiAlH4 (0.760 g, 20.03 mmol) in THF (22 
mL) was added a solution of 2.31 (1.377 g, 6.68 mmol) in THF (44 mL) dropwise over 5 
min, and the resulting mixture was stirred for 30 min at 0 ºC.  The reaction was quenched 
by slow addition of 15% aq. Rochelle's salt (25 mL). The resulting biphasic mixture was 
stirred vigorously at rt for 10 min. Water (10 mL) and EtOAc (25 mL) were added, and 
the mixture was filtered through Celite to remove metal salts. The layers of the filtrate 
were separated. The aqueous layer was extracted with EtOAc (2 × 50 mL). The combined 
organic layers were dried over Na2SO4, filtered, mixed with silica gel (2.5 g) and 
concentrated in vacuo.  Purification by flash column chromatography (dry loading, 1:1 
hexanes/EtOAc  EtOAc) furnished 2.S8 (928 mg, 85%) as a white solid. 
 [α]D24 +0.22 (c 1.28, CH2Cl2); 
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1H NMR (500 MHz, CDCl3) δ 7.42 (d, J = 7.1 Hz, 1 H), 7.32 - 7.23 (m, 3 H), 5.32 (t, J = 
5.4 Hz, 1 H), 3.98 - 3.86 (m, 2 H), 2.92 (d, J = 7.7 Hz, 2 H), 2.75 - 2.66 (m, 2 H), 2.59 (d, 
J = 5.2 Hz, 1 H); 
13C NMR (125 MHz, CDCl3) δ 144.1, 143.1, 128.9, 127.1, 125.2, 124.8, 77.6, 63.1, 45.2, 
32.8; 
IR (thin film, KBr) νmax 3340, 3218, 2923, 1459, 1293, 1069, 1031, 744 cm-1; 
HRMS (ESI) m/z 187.0739 [calcd for C10H12O2Na (M+Na)+ 187.0735]. 
 (–)-2.S8: data consistent with (+)-isomer — [α]D22 –3.0 (c 1.44, CH2Cl2). 
 
 
Silyl ether 2.S9. To a precooled (0 ºC) solution of 2.S8 (903 mg, 5.50 mmol) and 
imidazole (749 mg, 11.00 mmol) in CH2Cl2 (55 mL) was added TBSCl (1.4 g, 9.4 
mmol). The mixture was stirred for 30 min at 0 ºC, diluted with EtOAc (100 mL), washed 
with water (2 × 20 mL), dried over Na2SO4, filtered and concentrated in vacuo. Flash 
column chromatography (9:1  1:1 hexanes\EtOAc) provided 2.S9 (1.55 g, quant.) as a 
clear colorless oil. 
[α]D24 +1.94 (c 0.93, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.48 - 7.42 (m, 1 H), 7.27 - 7.21 (m, 3 H), 5.29 (t, J = 5.9 
Hz, 1 H), 3.98 (dd, J = 5.0, 10.5 Hz, 1 H), 3.92 (dd, J = 7.3, 10.3 Hz, 1 H), 3.24 (d, J = 
CH2Cl2, 0 ºC, 45 min
(R)
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5.5 Hz, 1 H), 2.94 (dd, J = 8.1, 15.7 Hz, 1 H), 2.85 (dd, J = 6.3, 16.1 Hz, 1 H), 2.74 - 2.66 
(m, 1 H), 0.88 (s, 9 H), 0.11 (s, 3 H), 0.08 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 144.8, 142.5, 128.4, 126.9, 124.9, 124.8, 77.3, 63.8, 45.0, 
33.4, 25.9, 25.8, 18.2, -5.3, -5.4; 
IR (thin film, KBr) νmax 3433, 2928, 2856, 1615, 1461, 1389, 1254, 1076, 837, 776 cm-1; 
HRMS (ESI) m/z 277.1631 [calcd for C16H25O2Si (M–H)+ 277.1624]. 
 (–)-2.S9: data consistent with (+)-isomer — [α]D22 –5.56 (c 1.02, CH2Cl2). 
 
 
Azide 2.S10. To a solution of 2.S9 (1.532 g, 5.5 mmol) in toluene (55 mL) was added 
DPPA (3.56 mL, 16.50 mmol). The mixture was stirred at rt for 5 min then DBU (2.49 
mL, 16.50 mmol) was added slowly. After stirring at rt for 10 min, the mixture was 
heated to 70 ºC and stirred overnight. Next, the reaction was allowed to cool to rt,  diluted 
with EtOAc (60 mL), washed with H2O (15 mL) and brine (15 mL), dried over Na2SO4, 
filtered, and concentrated in vacuo.  Flash column chromatography (98:2 
hexanes/EtOAc) furnished 2.S10 (1.52 g, 91%) as a clear, colorless oil.  
[α]D24 +32.3 (c 1.45, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.41 - 7.38 (m, 1 H), 7.31 - 7.24 (m, 3 H), 4.77 (d, J = 5.7 
Hz, 1 H), 3.81 (dd, J = 5.5, 10.3 Hz, 1 H), 3.68 (dd, J = 6.2, 10.2 Hz, 1 H), 3.10 (dd, J = 
(R)
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8.2, 16.0 Hz, 1 H), 2.75 (dd, J = 6.7, 16.1 Hz, 1 H), 2.63 (quind, J = 6.1, 8.0 Hz, 1 H), 
0.92 (s, 9 H), 0.10 (s, 3 H), 0.09 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 142.5, 140.5, 128.8, 127.0, 125.2, 124.8, 67.7, 63.7, 49.4, 
33.4, 26.1, 26.0, 25.8, 18.5, -5.2, -5.3; 
IR (thin film, KBr) νmax 2928, 2856, 2093, 1602, 1461, 1252, 1111, 836 cm-1; 
HRMS (ESI) m/z 276.1781 [calcd for C16H26NOSi (M+H–N2)+ 276.1784]. 
 (–)-2.S10: data consistent with (+)-isomer — [α]D22 37.4 (c 1.07, CH2Cl2). 
 
 
Amine 2.32. A solution of 2.S10 (1.482 g, 4.88 mmol) in MeOH (100 mL) was evacuated 
and backfilled with nitrogen gas (×4). Palladium on carbon (10% w/w, 0.520 g, 0.488 
mmol) was then added and the flask evacuated and backfilled with hydrogen gas (×4). 
The mixture was stirred at rt under hydrogen atmosphere overnight, filtered though Celite 
and concentrated in vacuo to furnish 2.32 (1.238 g, 91%) as a clear, colorless oil. 
[α]D24 +5.13 (c 1.14, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.34 (d, J = 6.9 Hz, 1 H), 7.26 - 7.19 (m, 3 H), 4.19 (br. d, 
J = 4.8 Hz, 1 H), 3.90 (dd, J = 5.5, 10.1 Hz, 1 H), 3.84 (dd, J = 6.5, 9.9 Hz, 1 H), 2.98 
(dd, J = 8.0, 15.8 Hz, 1 H), 2.66 (dd, J = 9.3, 15.7 Hz, 1 H), 2.30 - 2.21 (m, 1 H), 1.63 
(br. s., 2 H), 0.93 (s, 9 H), 0.11 (s, 6 H); 
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13C NMR (125 MHz, CDCl3) δ 147.0, 141.9, 127.3, 126.7, 124.7, 123.6, 65.3, 60.2, 54.4, 
33.5, 26.1, 25.8, 18.5, -5.2, -5.2; 
IR (thin film, KBr) νmax 3391, 3048, 2928, 2855, 1594, 1471, 1388, 1253, 1110, 837, 776 
cm-1; 
HRMS (ESI) m/z 278.1931 [calcd for C16H28NOSi (M+H)+ 278.1940]. 
 (–)-2.32: data consistent with (+)-isomer — [α]D22 –25.6 (c 1.00, CH2Cl2). 
 
 
Oxalamide 2.S11. To a solution of 2.32 (0.842 g, 3.03 mmol), 2.18 (0.792 g, 3.64 mmol) 
and TBTU (1.267 g, 3.94 mmol) in CH2Cl2 (61 mL) was added DIPEA (0.795 mL, 4.55 
mmol). The mixture was stirred at rt overnight,  diluted with EtOAc (120 mL), washed 
with water (25 mL), 1 N HCl (25 mL), sat. aq. NaHCO3 (25 mL), brine, dried over 
Na2SO4, filtered and concentrated in vacuo.  Flash column chromatography (70:30 
hexanes/EtOAc) furnished 2.S11 (1.291 g, 89%) as a white solid. 
 
[α]D24 +67.8 (c 0.5, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 9.55 (s, 1 H), 7.80 (d, J = 9.3 Hz, 1 H), 7.75 (dd, J = 2.2, 
10.5 Hz, 1 H), 7.39 - 7.33 (m, 1 H), 7.32 - 7.20 (m, 5 H), 5.37 (t, J = 8.5 Hz, 1 H), 3.87 - 
(S)
(R)
NH2
OTBS
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Cl
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F
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3.78 (m, 2 H), 3.10 (dd, J = 8.3, 16.1 Hz, 1 H), 2.86 (dd, J = 8.3, 16.1 Hz, 1 H), 2.60 - 
2.51 (m, 1 H), 0.89 (s, 9 H), 0.09 (s, 3 H), 0.07 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 159.4, 158.2 (d, JCF = 249 Hz), 157.8, 158.2, 142.4, 
141.6, 136.5 (d, JCF = 10 Hz), 130.9, 128.5, 127.1, 125.1, 124.2, 117.2 (d, JCF = 18 Hz), 
116.2 (d, JCF = 3 Hz), 108.6 (d, JCF = 25 Hz), 64.0, 57.3, 51.0, 33.7, 26.0, 18.4, -5.3, -5.3; 
IR (thin film, KBr) νmax 3288, 2934, 2855, 1666, 1594, 1111 cm-1; 
HRMS (ESI, neg.) m/z 475.1621 [calcd for C24H29O3ClFSi (M–H)– 475.1620]. 
 (–)-2.S11: data consistent with (+)-isomer — [α]D22 –75.3 (c 0.82, CH2Cl2). 
 
 
Alcohol 2.S12.  To a solution of 2.S11 (1.228 g, 2.57 mmol) in THF (52 mL) at rt was 
added TBAF (1.0 M solution in THF, 5.15 mL, 5.15 mmol). The mixture was stirred 
overnight at rt, then  diluted with EtOAc (200 mL), and washed with water (30 mL) and 
brine (30 mL). The resulting organic layer was dried over Na2SO4, filtered and 
concentrated in vacuo. Trituration with 1:1 CH2Cl2/hexanes provided 2.S12 as a white 
solid (620 mg, 67%). 
[α]D22 +112.3 (c 0.5, DMSO); 
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1H NMR (500 MHz, DMSO-d6) δ 11.07 (s, 1 H), 9.31 (d, J = 8.7 Hz, 1 H), 7.97 (dd, J = 
2.1, 11.8 Hz, 1 H), 7.75 (d, J = 8.7 Hz, 1 H), 7.58 (t, J = 8.7 Hz, 1 H), 7.28 - 7.13 (m, 4 
H), 5.24 (t, J = 8.2 Hz, 1 H), 4.71 (t, J = 4.9 Hz, 1 H), 3.62 - 3.50 (m, 2 H), 3.06 (dd, J = 
6.7, 14.7 Hz, 1 H), 2.78 - 2.67 (m, 2 H); 
13C NMR (125 MHz, DMSO-d6) δ 160.4, 159.6, 157.4 (d, JCF = 243 Hz), 143.6, 142.8, 
138.9 (d, JCF = 10 Hz), 131.2, 128.1, 127.0, 125.2, 124.4, 118.0 (d, JCF = 3 Hz), 114.9 (d, 
JCF = 18 Hz), 109.1, 62.4, 56.8, 48.9, 40.6, 40.5, 40.3, 40.1, 40.0, 39.8, 39.6, 34.0; 
IR (ATR) νmax 3258, 1662, 1592, 1514, 1459, 1428, 1413, 1367, 1211, 1156, 1105, 1069, 
1044, 1022, 809, 787, 751, 717, 611, 585 cm-1; 
HRMS (ESI) m/z 363.0896 [calcd for C18H17N2O3FCl (M+H)+ 363.0912]. 
 (–)-2.S12: data consistent with (+)-isomer — [α]D22 –113.4 (c 0.42, DMSO). 
 
 
Tri-Boc-DMJ-II-121, 2.S13. To a solution of 2.S12 (163 mg, 0.45 mmol) in THF (15 mL) 
in a vial suitable for microwave heating, were added N,N',N''-tri-Boc-guanidine (0.485 g, 
1.350 mmol) and triphenylphosphine (0.177 g, 0.675 mmol), and the mixture was cooled 
to 0 ºC. DEAD (0.31 mL, 0.675 mmol) was next added dropwise to the mixture. The vial 
was sealed and heated to 80 °C for 1.5 h under microwave irradiation.  The reaction was 
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quenched by adding sat. aq. NaHCO3 (4 mL) and extracted with CH2Cl2 (3 × 15 mL). The 
combined organic extracts were washed with brine, dried over Na2SO4 and concentrated 
in vacuo.  Flash column chromatography (1:1 hexanes/CH2Cl2  1:1 hexanes/EtOAc) 
furnished 2.S13 (211 mg, 67%) as a white solid. 
[α]D22 +29.1 (c 0.96, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 9.35 (s, 1 H), 7.80 (d, J = 9.1 Hz, 1 H), 7.75 (dd, J = 2.4, 
10.7 Hz, 1 H), 7.38 (t, J = 8.3 Hz, 1 H), 7.27 - 7.19 (m, 6 H), 5.28 (t, J = 8.6 Hz, 1 H), 
4.19 - 4.10 (m, 2 H), 3.19 (dd, J = 7.3, 15.3 Hz, 1 H), 2.92 - 2.84 (m, 1 H), 2.84 - 2.77 
(m, 1 H), 1.53 - 1.46 (m, 27 H); 
13C NMR (125 MHz, CDCl3) δ 159.7, 157.5, 158.3 (d, JCF = 248 Hz), 153.3, 153.2, 
142.0, 141.2, 136.6 (d, JCF = 10 Hz), 130.9, 128.5, 127.1, 125.1, 124.0, 117.1 (d, JCF = 18 
Hz), 116.0 (d, JCF = 4 Hz), 108.4 (d, JCF = 26 Hz), 83.6, 77.4, 77.1, 76.9, 58.7, 50.1, 48.2, 
35.2, 28.4, 28.2, 28.2, 28.1, 28.1; 
IR (thin film, KBr) νmax 3272, 2979, 1662, 1608, 1519, 1369, 1252, 1135, 1045 cm-1; 
HRMS (ESI) m/z 704.2857 [calcd for C34H44N5O8ClF (M+H)+ 704.2862]. 
 (–)-2.S13: data consistent with (+)-isomer — [α]D22 –32.4 (c 1.03, CH2Cl2); 
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DMJ-II-121, 2.8. To a solution of 2.S13 (150 mg, 0.213 mmol) in CH2Cl2 (7.1 mL) was 
added TFA (0.76 mL, 9.80 mmol) and the resulting mixture was stirred at rt overnight, 
then concentrated under a stream on N2, taken up in CH3CN/H2O (1:1, 5.5 mL) and split 
in three batches for HPLC purification. Conditions: eluent: 1:1 CH3CN/H2O (isocratic); 
flow rate: 15 mL/min; run time: 5 min. 
Product-containing fractions were combined the resulting solution was deep-frozen (–78 
ºC bath) and lyophilized (0.035 mbar) to afford the trifluoroacetate salt 2.8 as a white 
powder (67 mg, 61%). 
[α]D22 +22.7 (c 0.1, MeOH); 
1H NMR (500 MHz, DMSO-d6) δ 11.09 (s, 1 H), 9.45 (d, J = 8.7 Hz, 1 H), 7.98 (dd, J = 
2.4, 11.7 Hz, 1 H), 7.77 (dd, J = 1.6, 8.9 Hz, 1 H), 7.54-7.66 (m, 2 H), 7.11-7.33 (m, 5 
H), 5.20 (t, J = 8.7 Hz, 1 H), 3.24-3.55 (m, 2 H), 3.12 (dd, J = 15.7, 7.9 Hz, 1 H), 2.75-
2.94 (m, 1 H), 2.67 (dd, J = 9.0, 15.6 Hz, 1 H); 
13C NMR (125 MHz, DMSO-d6) δ 160.6, 158.7, 158.5 (d, JCF = 241 Hz), 156.5, 143.0, 
141.7, 139.0 (d, JCF = 10 Hz), 131.2, 130.8, 128.4, 127.3, 125.3, 124.2, 118.0 (d, JCF = 3 
Hz), 115.0 (d, JCF = 18 Hz), 109.0 (d, JCF = 26 Hz), 57.7, 45.8, 43.5, 34.5; 
19F NMR (282 MHz, DMSO-d6) δ -73.7 (3 F), -114.6 (1 F); 
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IR (thin film, KBr) νmax 3277, 1662, 1515, 1429, 1413, 1185, 1131, 975, 800, 750, 720 
cm-1; 
HRMS (ESI) m/z 404.1290 [calcd for C19H20N5O2ClF (M+H)+ 404.1295]. 
 (–)-2.8: data consistent with (+)-isomer — [α]D22 –43.6 (c 0.1, MeOH). 
 
Enantiomeric excess determined by SFC: 
(+)-2.8 (–)-2.8 (+)-2.8 + (–)2.8 (for method validation) 
   
er > 99:1 er > 99:1  
 
Method: column CHIRALPAK IC; eluent: 40% MeOH (+0.5% NEt3) in supercritical 
CO2; flow rate: 4 mL/min; pressure: 12 MPa. Retention times: (+)-2.8: 3.2 min, (–)-2.8: 
4.1 min. 
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Chromatogram Information  
User Name Administrator  
Date Modified 2/21/2014 2:21:30 PM  
Description  
HPLC System Name  Chiral SFC 
Injection Date 2/20/2014 6:10:28 PM  
Volume  15.00 [µL] 
Sample Number  2 
Project Name Chiral SFC 
Acquisition Time  11.0 [min]  
Acquisition Sequence BNM 02_20_14 
Control Method  BNM - Solv 3 Col 1 Iso 40%B 4mLs-min 12MPa 11min  
Peak ID Table  
Calibration Method  
Additional Information   
 
 
Channel & Peak Information Table  
Chromatogram Name BNM-III-130-CH10  
Sample Name   
Channel Name 254.0nm 
Sampling Interval 100 [msec]  
Peak Method  (Manual)  
Formula  
Decision  
 
# Peak Name CH tR [min]  Area [µV·sec] Height [µV] Area% Height% Quantity NTP Resolution Symmetry Factor  Warning 
1 Unknown  10 3.223 1306044 142694 99.108 99.492 N/A 3098 1.341 1.332  
2 Unknown  10 3.963 11761 729 0.892 0.508 N/A 328 N/A 1.564  
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Chromatogram Information  
User Name Administrator  
Date Modified 2/21/2014 2:17:40 PM  
Description  
HPLC ystem Name  Chiral SFC 
Injection Date 2/20/2014 6:33:36 PM  
Volume  15.00 [µL] 
Sample Number  3 
Project Name Chiral SFC 
Acquisition Time  11.0 [min]  
Acquisition Sequence BNM 02_20_14 
Control Method  BN  - Solv 3 Col 1 Iso 40%B 4mLs-min 12MPa 11min  
Peak ID Table  
Calibration Method  
Additional Information   
 
 
Channel & Peak Information Table  
Chromatogram Name BNM-III-131-CH10  
Sample Name   
Chan el Name 254.0nm 
Sampling Interval 100 [msec]  
Peak Method  (Manual)  
Formula  
Decision  
 
# Peak Name CH tR [min]  Area [µV·sec] Height [µV] Area% Height% Quantity NTP Resolution Symmetry Factor  Warning 
1 Unknown  10 3.242 3523 529 0.215 0.368 N/A 3271 3.190 1.008  
2 Unknown  10 4.065 1634633 143161 99.785 99.632 N/A 3124 N/A 1.277  
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Chromatogram Information  
User Name Administrator  
Date Modified 2/21/2014 2:58:54 PM  
Description  
HPLC System N me  Chiral SFC 
Injection Date 2/21/2014 2:51:17 PM  
Volume  15.00 [µL] 
Sample Number  2 
Project Name Chiral SFC 
Acquisition Time  7.0 [min]  
Acquisition Sequence BNM 02_20_14 
Control Method  BNM - Solv 3 Col 1 Iso 40%B 4mLs-min 12MPa 7min 
Peak ID Table  
Calibration Method  
Additional Information   
 
 
Channel & Peak Information Table  
Chromatogram Name BNM-III-130+131-CH10  
Sample Name   
Channel Name 254.0nm 
Sampling Interval 100 [msec]  
Peak Method  (Manual)  
Formula  
Decision  
 
# Peak Name CH tR [min]  Area [µV·sec] Heigh  [µV] Area% Height% Quantity NTP Resolution Symmetry Factor  Warning 
1 Unknown  10 3.115 348273 879 37.947 43.525 N/A 2628 2.882 1.591  
2 Unknown  10 3.908 569509 43959 62.053 56.475 N/A 2561 N/A 1.593  
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Synthesis of Region I Analogues 
Synthesis of (+)- and (–)-2.34 
 
Oxalic acid 2.35. To a precooled (0 ºC) solution of cyclohexylmethanamine (2.S14, 396 
mg, 3.50 mmol) in THF (13 mL) were added Et3N (0.82 mL, 5.9 mmol) and ethyl 2-
chloro-2-oxoacetate (2.S15, 0.44 mL, 3.9 mmol), dropwise. The cold bath was removed 
and the reaction mixture was stirred at rt for 1 h.  Excess acyl chloride was quenched by 
addition of sat. aq. NaHCO3 (4 mL). The organic layer was separated and washed 
sequentially with water, 1 N HCl, water, and brine, then dried over Na2SO4, filtered and 
concentrated in vacuo to furnish oxalate ester 2.S16, used in the next step without further 
purification. 
To a solution of 2.S16 in EtOH/H2O (1:1, 25 mL) was added NaOH (0.28 g, 7.0 mmol). 
The reaction mixture was stirred overnight at rt, then  acidified with 1 N HCl (pH = 1), 
extracted with EtOAc (3 × 30 mL), dried over Na2SO4, filtered and concentrated in 
vacuo. The residue was triturated with CH2Cl2/hexanes to furnish 2.35 (543 mg, 84% 
over 2 steps) as a white solid. 
1H NMR (500 MHz, CDCl3) δ 7.31 (br. s., 1 H), 3.23 (t, J = 6.6 Hz, 2 H), 1.82 - 1.65 (m, 
5 H), 1.62 - 1.51 (m, 1 H), 1.32 - 1.12 (m, 3 H), 1.04 - 0.93 (m, 2 H); 
13C NMR (125 MHz, CDCl3) δ 159.8, 157.6, 46.9, 37.7, 30.8, 26.3, 25.7; 
H
N
O
O
EtO
H
N
O
O
HO
NaOH
H2O, EtOH
overnight, rt
H2N
O
O
EtO Cl
Et3N
THF
0º C to rt, 1 h
2.S14
2.S15
2.S16 2.35
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IR (ATR) νmax 3291, 2921, 2849, 1762, 1678, 1556, 1450, 1350, 1339, 1315, 1276, 1248, 
1173, 1153, 973, 776, 716 cm-1; 
HRMS (ESI, neg.) m/z 184.0977 [calcd for C9H14NO3 (M–H)– 184.1974]. 
 
 
Oxalamide 2.S17. To a solution of amine 2.32 (70 mg, 0.25 mmol), acid 2.35 (56 mg, 
0.30 mmol) and TBTU (105 mg, 0.328 mmol) in CH2Cl2 (5.1 mL) was added DIPEA (66 
µL, 0.378 mmol). The resulting mixture was stirred at rt overnight, diluted with EtOAc 
(15 mL), and washed with water (5 mL), 1 N HCl (5 mL), sat. aq. NaHCO3 (5 mL), and 
brine. The organic layer was then dried over Na2SO4, filtered and concentrated.  
Purification by flash column chromatography (7:3 hexanes/EtOAc) furnished 2.S17 (91 
mg, 81%) as a white solid. 
[α]D22 +75.3 (c 0.56, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.65 (br. d, J = 9.1 Hz, 1 H), 7.57 (br. t, J = 5.6 Hz, 1 H), 
7.26 - 7.18 (m, 4 H), 5.32 (app. t, J = 7.9 Hz, 1 H), 3.83 (dd, J = 5.2, 10.1 Hz, 1 H), 3.78 
(dd, J = 6.1, 9.9 Hz, 1 H), 3.19 (t, J = 6.6 Hz, 2 H), 3.10 (dd, J = 8.3, 16.1 Hz, 1 H), 2.84 
(dd, J = 8.3, 16.1 Hz, 1 H), 2.56 - 2.46 (m, 1 H), 1.80 - 1.72 (m, 4 H), 1.69 (br. d, J = 11.3 
Hz, 1 H), 1.60 - 1.50 (m, 1 H + H2O), 1.31 - 1.13 (m, 3 H), 1.04 - 0.94 (m, 2 H), 0.89 (s, 
9 H), 0.08 (s, 3 H), 0.07 (s, 3 H); 
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13C NMR (125 MHz, CDCl3) δ 160.0, 159.9, 142.4, 141.9, 128.3, 127.0, 125.0, 124.3, 
64.1, 56.9, 51.0, 46.1, 37.9, 33.8, 30.9, 26.4, 26.0, 25.9, 18.4, -5.3, -5.3; 
IR (KBr, thin film) νmax 3280, 2924, 2853, 1654, 1522, 1459, 1252, 1115, 837 cm-1; 
HRMS (ESI) m/z 445.2872 [calcd for C25H41N2O3Si (M+H)+ 445.2886]. 
(–)-2.S17: data consistent with (+)-isomer — [α]D22 –75.8 (c 0.61, CH2Cl2). 
 
 
 
BNM-III-132, 2.34.  To a solution of 2.S17 (90 mg, 0.202 mmol) in THF (4 mL) at rt was 
added TBAF (1.0 M solution in THF, 0.41 mL, 0.41 mmol), and the resulting mixture 
was stirred overnight at the same temperature, with a white solid forming within 2 hours 
of addition of TBAF. The reaction mixture was next diluted with EtOAc (50 mL), and 
washed with water (10 mL). The organic layer was then concentrated, using toluene for 
azeotropic removal of any remaining water, to furnish 2.S18, used in the next step 
without further purification. 
To a solution of crude alcohol 2.S18 in THF (7 mL) in a vial suitable for microwave 
reactions were addded N,N',N''-tri-Boc-guanidine (218 mg, 0.606 mmol) and 
triphenylphosphine (79 mg, 0.303 mmol), and the mixture was cooled to 0 ºC. DEAD 
(0.14 mL, 0.31 mmol) was then added dropwise to the mixture. The vial was sealed and 
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heated to 80 ºC under microwave irradiation for 1.5 h. The reaction was quenched by 
addition of sat. aq. NaHCO3 and extracted with CH2Cl2 (3 × 10 mL). Organic layers were 
combined, washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The 
residue was run through a plug of silica gel, eluting with 1:1 hexanes/CH2Cl2, then 
EtOAc to remove excess tri-N-Boc guanidine, and used in the next step without further 
purification. A ½-aliquot of the residue obtained was next taken up in CH2Cl2 (1.7 mL), 
to which TFA (0.32 mL, 4.2 mmol) was added. The solution was stirred for 4 h at rt, then 
concentrated in vacuo, taken up in H2O/CH3CN/TFA (4:1:1, 0.6 mL) and subjected to 
HPLC purification. Conditions: eluent: H2O/CH3CN (9:1  6:4, linear gradient); flow 
rate: 15 mL/min; run time: 10 min. Product-containing fractions were combined the 
resulting solution was deep-frozen (–78 ºC bath) and lyophilized (0.035 mbar) to afford 
the trifluoroacetate salt 2.34 as a white powder (14 mg, 28% from 2.S17). 
[α]D22 +25.6 (c 0.13, MeOH); 
1H NMR (500 MHz, DMSO-d6) δ 9.12 (d, J = 8.9 Hz, 1 H), 8.78 (t, J = 6.2 Hz, 1 H), 
7.62 (t, J = 5.4 Hz, 1 H), 7.28 - 7.17 (m, 3 H), 7.09 (d, J = 7.3 Hz, 1 H), 5.12 (t, J = 8.6 
Hz, 1 H), 3.40 - 3.25 (m, 2 H), 3.10 (dd, J = 8.0, 15.6 Hz, 1 H), 3.06 - 2.97 (m, 2 H), 2.83 
- 2.73 (m, 1 H), 2.64 (dd, J = 9.1, 15.5 Hz, 1 H), 1.73 - 1.58 (m, 5 H), 1.58 - 1.48 (m, 1 
H), 1.23 - 1.09 (m, 3 H), 0.95 - 0.84 (m, 2 H); 
13C NMR (125 MHz, DMSO-d6) δ 161.2, 160.5, 158.6 (q, JCF = 31 Hz, TFA), 157.6, 
143.2, 141.7, 128.3, 127.3, 125.2, 124.2, 57.4, 45.7, 45.6, 43.6, 40.7, 37.8, 34.5, 31.0, 
26.6, 25.9; 
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19F NMR (282 MHz, DMSO-d6) δ -73.7 (3F), -114.6 (1F); 
IR (ATR) νmax 3280, 2924, 1652, 1516, 1515, 1452, 1370, 1282, 1202, 1132, 838, 801, 
744, 722 cm-1; 
HRMS (ESI) m/z 372.2383 [calcd for C20H30N5O2 (M+H)+ 372.2400]. 
 (–)-2.8: data consistent with (+)-isomer — [α]D22 –62.3 (c 0.06, MeOH). 
 
 
Synthesis of 2.36 and 2.37 
 
Oxalate ester 2.S20. To a precooled (0 ºC) solution of naphthalen-2-amine (2.S19, 215 
mg, 1.50 mmol) in THF (5.8 mL) were added Et3N (0.35 mL, 2.5 mmol) and ethyl 2-
chloro-2-oxoacetate (2.S15, 0.19 mL, 1.7 mmol), dropwise. The cold bath was removed 
and the reaction mixture was stirred at rt for 1 h.  Excess acyl chloride was quenched by 
addition of sat. aq. NaHCO3. EtOAc (25 mL) was added. The organic layer was separated 
and washed sequentially with water, 1 N HCl, water, and brine, then dried over Na2SO4, 
filtered, and concentrated in vacuo to furnish 2.S20 (369 mg, quant.) as a purple solid. 
1H NMR (500 MHz, CDCl3) δ 9.04 (br. s., 1 H), 8.35 (d, J = 2.0 Hz, 1 H), 7.90 - 7.79 (m, 
3 H), 7.59 (dd, J = 2.2, 8.7 Hz, 1 H), 7.54 - 7.44 (m, 2 H), 4.47 (q, J = 7.1 Hz, 2 H), 1.47 
(t, J = 7.2 Hz, 3 H); 
EtO
O
O
H
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O
EtO Cl
Et3N
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0º C to rt, 1 h2.S19
2.S15H2N
2.S20
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13C NMR (125 MHz, CDCl3) δ 161.2, 154.1, 133.9, 133.8, 131.3, 129.3, 128.0, 127.8, 
127.0, 125.8, 119.4, 117.3, 64.0, 14.2; 
IR (KBr, thin film) νmax 3340, 2998, 1702, 1553, 1298, 1224, 1196, 1019, 860, 816, 705 
cm-1; 
HRMS (ESI) m/z 244.0967 [calcd for C14H14NO3 (M+H)+ 244.0974]. 
 
Oxalate ester 2.S22. Procedure identical to that employed for 2.S20. Yellow solid 
(quant.). 
1H NMR (500 MHz, CDCl3) δ 9.59 (br. s., 1 H), 9.03 (s, 1 H), 8.61 (s, 1 H), 7.92 (d, J = 
8.1 Hz, 1 H), 7.87 (d, J = 8.3 Hz, 1 H), 7.68 (t, J = 7.4 Hz, 1 H), 7.53 (t, J = 7.4 Hz, 1 H), 
4.45 (q, J = 7.1 Hz, 2 H), 1.45 (t, J = 7.0 Hz, 3 H); 
13C NMR (125 MHz, CDCl3) δ 160.4, 154.3, 151.6, 144.9, 137.7, 131.2, 127.7, 127.2, 
127.1, 126.7, 109.1, 63.9, 14.2; 
IR (KBr, thin film) νmax 3175, 2999, 1742, 1704, 1530, 1362, 1298, 1195, 1018, 755 cm-
1; 
HRMS (ESI) m/z 245.0918 [calcd for C13H13N2O3 (M+H)+ 245.0926]. 
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Oxalamide 2.40. i) Preparation of sodium oxalate 2.38: To a solution of ethyl oxalate 
2.S20 (50 mg, 0.206 mmol) in EtOH/H2O (1:1, 1.4 mL) was added NaOH (16 mg, 0.41 
mmol). The mixture was stirred overnight at rt, then concentrated in vacuo, adding 
toluene to azeotropically remove water, furnishing 2.38 as a white solid. ii) Coupling: To 
a solution of amine 2.17 (20 mg, 0.048 mmol) and TBTU (19.85 mg, 0.062 mmol) in 
CH2Cl2 (0.8 mL) were added freshly prepared 2.38 (excess) and DIPEA (12 µL, 0.071 
mmol). The resulting mixture was stirred at rt overnight, diluted with EtOAc (4 mL), 
washed with water, sat. aq. NaHCO3, and brine. The organic layer was then dried over 
Na2SO4, filtered and concentrated in vacuo. Flash column chromatography (7:3 
hexanes/EtOAc) provided 2.40 (20 mg, 69%) as a purple oil. 
[α]D22 +37.8 (c 1.0, CH2Cl2);  
1H NMR (500 MHz, CDCl3) δ 9.51 (s, 1 H), 8.32 (d, J = 1.4 Hz, 1 H), 7.91 - 7.81 (m, 3 
H), 7.77 (d, J = 9.5 Hz, 1 H), 7.63 (dd, J = 1.9, 8.8 Hz, 1 H), 7.53 - 7.44 (m, 2 H), 7.24 - 
7.19 (m, 1 H), 7.19 - 7.10 (m, 2 H), 5.40 (t, J = 8.5 Hz, 1 H), 4.39 (br. s., 2 H), 3.89 - 3.80 
(m, 2 H), 3.10 (dd, J = 8.3, 16.1 Hz, 1 H), 2.91 - 2.73 (m, 4 H), 2.63 - 2.52 (m, 1 H), 1.47 
(br. s., 9 H), 0.94 - 0.87 (m, 9 H), 0.10 (s, 3 H), 0.08 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 159.9, 157.7, 141.5, 137.3, 134.0, 133.8, 131.3, 129.3, 
128.0, 127.8, 126.9, 125.7, 125.2, 119.5, 117.1, 64.0, 57.1, 51.2, 34.0, 33.4, 28.6, 26.0, 
18.4, -5.3; 
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IR (KBr, thin film) νmax 3290, 2926, 1663, 1522, 1500, 1390, 1364, 1251, 1146, 837 cm-
1; 
HRMS (ESI) m/z 640.3181 [calcd for C35H47N3O5NaSi (M+Na)+ 640.3183]. 
(–)-2.40: data consistent with (+)-isomer — [α]D23 –37.2 (c 2.0, CH2Cl2). 
 
 
 
Oxalamide 2.41. Procedure analogous to that employed for 2.40. Yellow oil (85%). 
[α]D23 +15.0 (c 1.0, CH2Cl2);  
1H NMR (500 MHz, CDCl3) δ 9.95 (s, 1 H), 9.08 (s, 1 H), 8.58 (s, 1 H), 7.96 (d, J = 8.3 
Hz, 1 H), 7.88 (d, J = 8.3 Hz, 1 H), 7.75 - 7.67 (m, 2 H), 7.55 (t, J = 7.4 Hz, 1 H), 7.25 - 
7.19 (m, 1 H), 7.13 (br. s., 2 H), 5.41 (t, J = 8.5 Hz, 1 H), 4.47 - 4.32 (m, 2 H), 3.89 - 3.79 
(m, 2 H), 3.11 (dd, J = 8.2, 16.0 Hz, 1 H), 2.89 - 2.74 (m, 4 H), 2.62 - 2.53 (m, 1 H), 1.47 
(br. s., 9 H), 0.89 (s, 9 H), 0.10 (s, 3 H), 0.08 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 159.4, 157.9, 151.8, 145.0, 141.5, 137.8, 137.3, 131.1, 
127.7, 127.1, 126.6, 125.1, 123.5, 108.7, 64.1, 57.0, 51.3, 34.0, 33.5, 29.8, 28.6, 28.2, 
26.0, 18.4, -5.3, -5.3; 
IR (KBr, thin film) νmax 3290, 2926, 1663, 1522, 1500, 1390, 1364, 1251, 1146, 837 cm-
1; 
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HRMS (ESI) m/z 619.3314 [calcd for C34H47N4O5Si (M+H)+ 619.3316]. 
(–)-2.41: data consistent with (+)-isomer — [α]D23 –21.7 (c 0.83, CH2Cl2). 
 
 
 
Alcohol 2.42. To a solution of 2.40 (19 mg, 0.031 mmol) in THF (1 mL) at rt was added 
TBAF (1.0 M solution in THF, 62 µL, 0.062 mmol) and the solution was stirred 
overnight at rt. The reaction mixture was next diluted with EtOAc (4 mL) and washed 
with water and brine. The organic layer was dried over Na2SO4, filtered and concentrated 
in vacuo.  Flash column chromatography (1:1 hexanes/EtOAc) furnished 2.42 (13 mg, 
84%) as a white solid. 
[α]D23 –40.4 (c 0.92, CH2Cl2);  
1H NMR (500 MHz, CDCl3) δ 8.31 (s, 1 H), 7.90 - 7.79 (m, 3 H), 7.62 (dd, J = 2.0, 8.7 
Hz, 1 H), 7.54 - 7.44 (m, 2 H), 7.26 - 7.13 (m, 3 H), 5.32 (d, J = 7.1 Hz, 1 H), 4.42 (br. s., 
2 H), 3.91 - 3.77 (m, 2 H), 3.16 (dd, J = 8.5, 16.1 Hz, 1 H), 2.91 - 2.69 (m, 4 H), 2.68 - 
2.56 (m, 1 H), 1.70 - 1.63 (m, 1 H), 1.48 (s, 9 H); 
13C NMR (125 MHz, CDCl3) δ 157.0, 141.3, 137.7, 133.8, 133.7, 131.3, 129.3, 128.0, 
127.8, 127.0, 125.8, 125.4, 119.5, 119.4, 117.3, 117.2, 64.4, 58.4, 52.2, 34.1, 33.4, 28.6; 
IR (KBr, thin film) νmax 3403, 3277, 2917, 1685, 1654, 1431 cm-1; 
HRMS (ESI) m/z 526.2319 [calcd for C29H33N3O5Na (M+Na)+ 526.2312]. 
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(+)-2.42: data consistent with (–)-isomer — [α]D23 +52.1 (c 1.0, CH2Cl2). 
 
 
 
Alcohol 2.43. Procedure analogous to that employed for 2.42. White solid (86%). 
[α]D22 –60.7 (c 1.0, CH2Cl2);  
1H NMR (500 MHz, CDCl3) δ 9.93 (s, 1 H), 9.08 (s, 1 H), 8.56 (s, 1 H), 8.00 - 7.91 (m, 2 
H), 7.87 (d, J = 8.3 Hz, 1 H), 7.70 (t, J = 7.5 Hz, 1 H), 7.56 (t, J = 7.5 Hz, 1 H), 7.26 - 
7.13 (m, 3 H), 5.34 (t, J = 8.0 Hz, 1 H), 4.42 (br. s., 2 H), 3.91 - 3.78 (m, 2 H), 3.16 (dd, J 
= 8.5, 16.1 Hz, 1 H), 3.09 (br. s., 1 H), 2.90 - 2.69 (m, 4 H), 2.67 - 2.57 (m, 1 H), 1.48 (s, 
9 H); 
13C NMR (125 MHz, CDCl3) δ 160.3, 157.4, 151.8, 144.9, 141.3, 137.7, 131.1, 127.7, 
127.2, 127.1, 126.7, 125.3, 108.8, 64.4, 58.4, 52.3, 34.1, 33.4, 28.6; 
IR (KBr, thin film) νmax 3366, 3277, 2924, 1659, 1508, 1391, 1363, 1143 cm-1; 
HRMS (ESI) m/z 505.2447 [calcd for C28H33N4O5 (M+H)+ 505.2451]. 
(+)-2.43: data consistent with (–)-isomer — [α]D23 +53.2 (c 0.5, CH2Cl2). 
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Guanidine 2.44. To a suspension of 2.42 (13 mg, 0.026 mmol), guanidine 2.24 (19 mg, 
0.052 mmol) and triphenylphosphine (27 mg, 0.10 mmol) in THF (1 mL) at rt was added 
DEAD (47 µL, 0.10 mmol). The mixture was stirred overnight at rt, then  the reaction 
was quenched by addition of sat. aq. NaHCO3 (2 mL). The mixture was then extracted 
with CH2Cl2 (3 × 2 mL). The resulting organic extracts were combined, washed with 
brine, dried over Na2SO4, filtered and concentrated in vacuo. Flash column 
chromatography (98:2 CH2Cl2/MeOH) furnished 2.44 (13 mg, 63%) as a white solid.  
[α]D22 +20.2 (c 1.0, CH2Cl2);  
1H NMR (500 MHz, CDCl3) δ 10.55 (br. s., 1 H), 9.45 (s, 1 H), 8.32 (s, 1 H), 7.94 - 7.78 
(m, 4 H), 7.61 (dd, J = 1.8, 8.7 Hz, 1 H), 7.54 - 7.42 (m, 2 H), 7.24 - 7.08 (m, 3 H), 5.29 
(t, J = 8.4 Hz, 1 H), 4.38 (br. s., 2 H), 4.24 - 4.10 (m, 2 H), 3.18 (dd, J = 7.6, 15.6 Hz, 1 
H), 2.96 - 2.86 (m, 1 H), 2.86 - 2.71 (m, 4 H), 1.54 - 1.43 (m, 36 H); 
13C NMR (125 MHz, CDCl3) δ 160.2, 157.4, 153.4, 141.2, 137.3, 134.1, 133.8, 131.2, 
129.2, 127.9, 127.8, 126.9, 125.7, 125.1, 119.4, 117.0, 83.6, 58.5, 50.1, 34.9, 34.0, 28.6, 
28.2, 28.1; 
IR (KBr, thin film) νmax 3279, 2977, 1759, 1696, 1662, 1522, 1500, 1392, 1367, 1240, 
1146 cm-1; 
HRMS (ESI) m/z 845.4448 [calcd for C45H61N6O10 (M+H)+ 845.4449]. 
(–)-2.44: data consistent with (+)-isomer — [α]D23 –23.7 (c 1.0, CH2Cl2). 
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Guanidine 2.45. Procedure analogous to that employed for 2.44. White solid (60%). 
[α]D23 +11.8 (c 0.67, CH2Cl2);  
1H NMR (500 MHz, CDCl3) δ 10.47 (br. s., 1 H), 9.88 (s, 1 H), 9.07 (s, 1 H), 8.58 (s, 1 
H), 7.96 (d, J = 8.1 Hz, 1 H), 7.89 - 7.79 (m, 2 H), 7.70 (t, J = 7.5 Hz, 1 H), 7.55 (t, J = 
7.5 Hz, 1 H), 7.23 - 7.18 (m, 1 H), 7.18 - 7.07 (m, 2 H), 5.35 - 5.26 (m, 1 H), 4.45 - 4.31 
(m, 2 H), 4.18 (dd, J = 8.3, 14.3 Hz, 1 H), 4.12 (dd, J = 5.7, 14.1 Hz, 1 H), 3.19 (dd, J = 
7.7, 15.7 Hz, 1 H), 2.96 - 2.86 (m, 1 H), 2.85 - 2.72 (m, 4 H), 1.50 (s, 27 H), 1.46 (br. s., 
9 H); 
13C NMR (125 MHz, CDCl3) δ 159.7, 157.6, 153.4, 151.7, 145.1, 141.2, 137.7, 137.3, 
131.1, 127.7, 127.1, 127.0, 126.5, 125.2, 108.6, 83.6, 58.4, 50.0, 37.1, 34.8, 34.0, 28.6, 
28.2, 28.1; 
IR (KBr, thin film) νmax 3290, 2927, 1758, 1685, 1508, 1449, 1368, 1244, 1142 cm-1; 
HRMS (ESI) m/z 846.4404 [calcd for C44H60N7O10 (M+H)+ 846.4402]. check 
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BNM-IV-023, 2.36. To a solution of 2.44 (6.0 mg, 0.0071 mmol) in CH2Cl2 (1.2 mL) was 
added TFA (25 µL, 0.333 mmol). The resulting solution was stirred at rt for 48 h then 
concentrated under a stream of N2 and taken up in H2O/CH3CN/TFA (6:1:1, 0.8 mL) and 
subjected to HPLC purification. Conditions: eluent: H2O/CH3CN (9:1  6:4, linear 
gradient); flow rate: 15 mL/min; run time: 10 min. Product-containing fractions were 
combined the resulting solution was deep-frozen (–78 ºC bath) and lyophilized (0.035 
mbar) to afford the trifluoroacetate salt 2.36 (2.5 mg, 52%) as a white powder. 
[α]D22 +14.6 (c 0.042, MeOH);  
1H NMR (500 MHz, DMSO-d6) δ 10.93 (s, 1 H), 9.46 (d, J = 9.0 Hz, 1 H), 8.80 - 8.64 
(m, 2 H), 8.48 (s, 1 H), 7.93 (s, 2 H), 7.87 (dd, J = 8.0, 17.0 Hz, 2 H), 7.69 (t, J = 5.6 Hz, 
1 H), 7.55 - 7.49 (m, 1 H), 7.49 - 7.45 (m, 1 H), 7.36 - 7.31 (m, 2 H), 7.29 (s, 1 H), 5.22 
(t, J = 8.9 Hz, 1 H), 4.10 (t, J = 5.6 Hz, 2 H), 3.48 - 3.41 (m, 2 H + H2O), 3.13 (dd, J = 
7.9, 15.8 Hz, 1 H), 2.89 (d, J = 6.0 Hz, 1 H), 2.69 (dd, J = 9.4, 15.6 Hz, 1 H), 2.52 (t, J = 
5.3 Hz,, 3 H + DMSO); 
13C NMR (125 MHz, DMSO-d6) δ 160.4, 158.6, 158.1, 157.9, 157.0, 143.3, 142.2, 
135.3, 133.1, 130.5, 130.4, 129.6, 128.5, 127.6, 127.6, 126.6, 125.4, 125.0, 120.6, 118.4, 
117.0, 116.0, 56.9, 51.2, 45.5, 42.9, 33.8, 32.1; 
IR (ATR) νmax 3287, 1670, 1523, 1501, 1435, 1202, 1134, 837, 801, 722 cm-1; 
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HRMS (ESI) m/z 445.2339 [calcd for C25H29N6O2 (M+H)+ 445.2352]. 
(–)-2.36: data consistent with (+)-isomer — [α]D22 –2.8 (c 0.050, MeOH). 
 
 
 
BNM-IV-024, 2.37. Procedure analogous to that employed for 2.37. White solid (83%). 
[α]D22 –0.3 (c 0.030, MeOH);  
1H NMR (500 MHz, DMSO-d6) δ 10.20 (s, 1 H), 9.62 (d, J = 9.0 Hz, 1 H), 9.25 (s, 1 H), 
8.80 - 8.67 (m, 2 H), 8.48 (s, 1 H), 8.14 (d, J = 8.1 Hz, 1 H), 8.01 (d, J = 8.3 Hz, 1 H), 
7.83 - 7.76 (m, 1 H), 7.70 (t, J = 5.7 Hz, 1 H), 7.66 - 7.61 (m, 1 H), 7.37 - 7.28 (m, 3 H), 
5.24 (t, J = 8.9 Hz, 1 H), 4.10 (t, J = 5.8 Hz, 2 H), 3.49 - 3.36 (m, 2 H + H2O), 3.14 (dd, J 
= 8.1, 16.0 Hz, 1 H), 2.96 - 2.84 (m, 1 H), 2.68 (dd, J = 9.4, 15.8 Hz, 1 H), 2.51 (t, J = 5.3 
Hz, 3 H + H2O); 
13C NMR (125 MHz, DMSO-d6) δ 159.9, 158.2, 158.0, 157.9, 157.0, 152.1, 145.0, 
143.1, 142.2, 136.9, 131.5, 130.6, 129.6, 127.9, 126.7, 126.7, 126.5, 125.1, 125.0, 107.7, 
57.2, 51.1, 45.4, 42.9, 33.8, 32.1; 
IR (ATR) νmax 3356, 1671. 1509, 1201, 1134, 836, 801, 722 cm-1; 
HRMS (ESI) m/z 446.2306 [calcd for C24H28N7O2 (M+H)+ 446.2304]. 
(+)-2.37: data consistent with (–)-isomer — [α]D22 +2.6 (c 0.067, MeOH). 
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Synthesis of Region III Analogues 
 
Synthesis of 2.46 
 
Dioxolane 2.S23. To a solution of bromoindanone 2.47 (2.00 g, 9.48 mmol) in benzene 
(40 mL) were added ethylene glycol (10.6 mL, 190 mmol) and TsOH monohydrate 
(0.018 g, 0.095 mmol). The flask was fitted with a Dean-Stark apparatus pre-filled with 
benzene and a reflux condenser and heated to 115ºC over 48 h. The reaction mixture was 
diluted with EtOAc and neutralized with sat. aq. NaHCO3 (20 mL). Layers were 
separated and the resulting aqueous layer was extracted with EtOAc (3 × 40 mL). The 
combined organic layers were dried over Na2SO4, filtered and concentrated in vacuo. 
Flash column chromatography (95:5 hexanes/EtOAc) afforded 2.S23 as a clear, pale 
yellow oil (1.717 g, 71%).  
1H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 8.75 Hz, 2 H), 7.23 (d, J = 8.0 Hz, 1 H), 4.21-
4.15 (m, 2 H), 4.12-4.05 (m, 2 H), 2.94 (t, J = 6.9 Hz, 2 H), 2.30 (t, J = 7.0 Hz, 2 H); 
13C NMR (125 MHz, CDCl3) δ 146.0, 141.2, 130.2, 128.4, 124.8, 123.8, 116.7, 65.4, 
37.2, 28.4; 
IR (KBr, thin film) νmax 2946, 2880, 1598, 1469, 1314, 1039 cm-1; 
HRMS (ESI) m/z 255.0029 [calcd for C11H12O2Br (M+H)+ 255.0021]. 
 
O Ethylene glycol
TsOH (1 mol%)
Br
2.S23
OO
Br
2.47
 211 
 
 
Aldehyde 2.48.  To a precooled (–78ºC) solution of 2.S23 (1.755 g, 6.88 mmol) in THF 
(9.5 mL) was slowly added butyllithium (3.6 mL of a 2.1 M solution in hexane, 7.6 
mmol). The reaction mixture was stirred at –78 ºC for 10 min, then N,N-
dimethylformamide (0.60 mL, 8.3 mmol) was added. The resulting mixture was stirred at 
–78º C for an additional 15 min, then allowed to warm to rt and stirred for a final 30 min. 
The reaction was quenched with sat. aq. NaHCO3 (5 mL) and diluted with EtOAc (20 
mL). The mixture was washed with water and brine, dried over Na2SO4, filtered and 
concentrated in vacuo. Flash column chromatography (9:1   8:2 hexanes/EtOAc) 
afforded 2.48 as a clear orange oil (1.35 g, 86%).  
1H NMR (500 MHz, CDCl3) δ 10.03 (s, 1 H), 7.78 (t, J = 7.4 Hz, 2 H), 7.51 (d, J = 7.8 
Hz, 1 H), 4.25-4.19 (m, 2 H), 4.15-4.09 (m, 2 H), 3.02 (t, J = 7.2 Hz, 2 H), 2.36 (t, J = 7.0 
Hz, 2 H); 
13C NMR (125 MHz, CDCl3) δ 192.4, 148.7, 144.7, 137.8, 129.2, 126.6, 123.9, 116.5, 
65.6, 37.3, 28.4; 
IR (KBr, thin film) νmax 2885, 1698, 1434, 1229, 1170, 1041, 923 cm-1; 
HRMS (ESI) m/z 205.0859 [calcd for C12H13O3 (M+H)+ 205.0865].  
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Carbamate 2.S25. At 0 ºC, methylamine (11.8 mL of a 2 M solution in THF, 23.5 mmol) 
was added to 2.48 (1.35 g, 5.88 mmol). The reaction was warmed to rt and stirred for 30 
min, then cooled to 0 ºC. Methanol (10 mL) was then added, followed by sodium 
borohydride (0.112 g, 2.97 mmol). The resulting mixture was stirred at 0 ºC for 40 min. 
A second portion of sodium borohydride (0.112 g, 2.97 mmol) was then added. The 
reaction mixture was stirred for an additional 40 min, then quenched with water (10 mL) 
and extracted with EtOAc (3 × 20 mL). The combined organic layers were washed with 
brine, dried over Na2SO4, filtered and concentrated in vacuo. The resulting crude amine 
(2.S4) was dissolved in acetonitrile (12 mL) and Boc2O (1.47 g, 6.64 mmol) was added 
portionwise. The mixture was stirred at rt for 15 min, then concentrated in vacuo. Flash 
column chromatography (90:10  80:20 hexanes/EtOAc) afforded 2.S25 as a clear pale 
yellow oil (1.60 g, 85%).  
 
1H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 7.5 Hz, 1 H), 7.11 (br. s, 2 H), 4.43 (s, 2 H), 
4.23-4.17 (m, 2 H), 4.12-4.06 (m, 2 H), 2.94 (t, J = 6.9 Hz, 2 H), 2.77-2.83 (2 br. s, 3 H, 
rotamers 1 and 2), 2.32 (t, J = 6.9 Hz, 2 H), 1.49 (s, 9 H); 
13C NMR (125 MHz, CDCl3, mixture of rotamers) δ 146.7, 144.2, 141.2, 139.9, 123.3, 
117.1, 85.3, 65.3, 52.7, 37.3, 34.0, 28.6, 28.5, 27.5; 
IR (KBr, thin film) νmax 2973, 1805, 1691, 1390, 1119, 1043 cm-1; 
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HRMS (ESI) m/z 320.1854 [calcd for C18H26NO4 (M+H)+ 320.1862].  
 
 
 
Ketone 2.49. To a solution of 2.S25 (8.78 g, 26.1 mmol) in Acetone (104 mL) was added 
bis(acetonitrile)dichloropalladium(II) (0.136 g, 0.522 mmol). The resulting solution was 
stirred at rt for 30 min then concentrated in vacuo, taken up in EtOAc (200 mL) and  
washed with sat aq NaHSO3 (3 × 35 mL) and brine. The organic layer was finally dried 
over Na2SO4, filtered and concentrated in vacuo.  Flash chromatography (7:3  6:4 
hexanes/EtOAc) furnished 2.49 as a white solid (6.72 g, 93%). 
1H NMR (500 MHz, CDCl3) δ 7.74 (d, J = 7.9 Hz, 1 H), 7.33 (s, 1 H), 7.24 (d, J = 6.0 
Hz, 1 H), 4.52 (s, 2 H), 3.14 (t, J = 5.8 Hz, 2 H), 2.85-2.89 (2 br s, 3 H, rotamers 1 and 2), 
2.72 (t, J = 5.8 Hz, 2 H), 1.47-1.51 (2 br s, 9 H); 
13C NMR (125 MHz, CDCl3, mixture of rotamers) δ 155.9, 145.8, 136.5, 126.9, 126.5, 
124.1, 80.2, 52.9, 36.6, 34.5, 28.6, 26.1, 25.9, 23.1; 
IR (KBr, thin film) νmax 2929, 1702, 1610, 1393, 1247, 1148 cm-1; 
HRMS (ESI) m/z 298.1432 [calcd for C16H21NO3Na (M+Na)+ 298.1419].  
 
 
Acetone
PdCl2(CH3CN)2
rt, 30 min
2.S25
OO
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Boc
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β-Ketoester 2.50. To a precooled (–78 ºC) solution of 2.49 (6.710 g, 24.37 mmol) in THF 
(240 mL) was added NaHMDS (1.0 M in THF, 53.6 mL, 53.6 mmol) slowly. The 
mixture was stirred at –78 ºC for 10 min, then ethyl carbonocyanidate (3.34 mL, 34.1 
mmol) was added and the mixture was stirred at –78 ºC for an additional 1 h. The 
reaction was  quenched with sat. aq. NH4Cl (50 mL) and diluted with EtOAc (200 mL). 
Water (100 mL) was added, layers were separated and the organic layer was extracted 
with EtOAc (3 × 100 mL). The combined organic layers were washed with brine, dried 
over Na2SO4, filtered and concentrated in vacuo. Flash column chromatography (9:1  
7:3 hexanes/EtOAc) furnished 2.50 (8.72 g, 99%) as a purple oil. 
1H NMR (500 MHz, CDCl3) δ 10.46 (s, enol OH), 7.67 (m, 1 H), 7.35 (s, 1 H), 7.26 (s, 1 
H), 4.51 (br s, ketoester 2 H and enol 2 H), 4.35 (q, J = 7.1 Hz, enol 2 H), 4.29-4.23 (m, 
ketoester 2 H), 3.73 (dd, J = 7.8, 3.7 Hz, ketoester 1 H), 3.55 (dd, J = 4.0, 17.3 Hz, 
ketoester 1 H), 3.52 (s, enol 2 H), 3.36 (dd, J = 8.3, 17.3 Hz, ketoester 1 H), 2.85-2.90 (2 
br s, ketoester 3 H and enol 3 H, rotamer 1 and 2), 1.51 (br s, ketoester 9 H), 1.46 (br s, 
enol 9 H), 1.37 (t, J = 7.2 Hz, enol 3 H), 1.32 (t, J = 7.2 Hz, ketoester 3 H); 
13C NMR (125 MHz, CDCl3, mixture of rotamers + enol) δ 199.1, 169.3, 154.4, 136.3, 
134.7, 127.4, 125.0, 120.9, 80.3, 61.9, 60.2, 53.7, 34.5, 32.6, 30.4, 28.6, 28.5, 14.6, 14.3; 
IR (KBr, thin film) νmax 2980, 1712, 1611, 1393, 1149, 910, 731 cm-1; 
HRMS (ESI) m/z 370.1625 [calcd for C19H25NO5Na (M+Na)+ 370.1630]. 
 
2.49
O
NMe
Boc
O
NMe
Boc O
OEt
a) NaHMDS
b) NCCO2Et
THF, –78 ºC, 90 min
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β-Hydroxyester 2.S26. RuCl(p-cymene)[(S,S)-Ts-DPEN] (21 mg, 0.033 mmol) was 
added in one portion to a solution of (±)-2.50 (0.560 g, 1.612 mmol) in HCOOH/Et3N 
(5:2, 0.85 mL). The reaction mixture was stirred at rt for 3 days, diluted with CH2Cl2 (20 
mL) and washed with H2O (2 × 5 mL). The organic layer was dried over Na2SO4, 
filtrered and concentrated in vacuo. Flash column chromatography (7:3 hexanes/EtOAc) 
afforded 2.S26 as a clear pale pink oil (515 mg, 91%).  
[α]D21 –11.3 (c 0.42, CH2Cl2) 
1H NMR (500 MHz, CDCl3) δ 7.40 (d, J = 7.6 Hz, 1 H), 7.13 (s, 2 H), 5.34-5.31 (m, 1 
H), 4.42 (s, 2 H), 4.25 (q, J = 7.2 Hz, 2 H), 3.45-3.37 (m, 2 H), 3.13-3.05 (m, 1 H), 2.83-
2.79 (m, 3 H), 1.49 (s, 9 H), 1.33 (t, J = 7.3 Hz, 3 H); 
13C NMR (125 MHz, CDCl3, mixture of rotamers) δ 173.2, 142.5, 141.9, 139.4, 125.2, 
75.6, 61.1, 49.7, 34.1, 33.0, 28.6, 14.4; 
IR (KBr, thin film) νmax 3448, 2925, 1686, 1392, 1146 1041 cm-1; 
 
HRMS (ESI) m/z 372.1769 [calcd for C19H27NO5Na (M+Na)+ 372.1787);  
 
 (+)-2.S26: data consistent with (–)-isomer — [α]D21 +5.4 (c 1.0, CH2Cl2). 
 
 
 
 
 
RuCl(p-cymene)
[(S,S)-Ts-DPEN] 
1.5 mol%
5:2 HCO2H/Et3N
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Enantiomeric excess determined by SFC: 
 
(–)-2.S26 + (+)-2.S26 (–)-2.S26 (+)-2.S26 
   
 er = 99:1 er = 99:1 
 
Method: column: Chiralpak AS-H; eluent: 10% MeOH in supercritical CO2; flow rate: 4 
mL/min; pressure: 12 MPa. Retention times: (–)-2.S26: 2.0 min, (+)-2.S26: 1.9 min. 
 
 
Diol 2.S27. To a precooled (0 ºC) suspension of LiAlH4 (1.82 g, 48.0 mmol) in THF (50 
mL) was added a solution of 2.S26 (6.077 g, 16.00 mmol) in THF (160 mL) dropwise via 
cannula over 5 min. The suspension was vigorously stirred for 30 min at 0 ºC.  The 
reaction was quenched by slow addition of 15% aq. Rochelle's salt (50 mL). The cold 
bath was removed and vigorous stirring was resumed for 30 min. Water (50 mL) and 
EtOAc (200 mL) were added and the resulting mixture was filtered through Celite to 
remove metal salts. The layers were partitioned and the aqueous layer was extracted with 
THF, 0 ºC, 30 min
OH
OH
(–)-2.S27
LiAlH4
NMe
Boc
OH
NMe
Boc O
OEt
(–)-2.S26
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EtOAc (3 × 100 mL). The organic layers were combined, dried over Na2SO4, filtered and 
concentrated.  Flash chromatography (1:1 hexanes/EtOAc  EtOAc) furnished 2.S27 as 
a clear colorless oil. 
[α]D22  –5.8 (c 1.0, EtOAc); 
1H NMR (500 MHz, CDCl3) δ 7.37 (d, J = 7.6 Hz, 1 H), 7.10-7.08 (m, 2 H), 5.30 (d, J = 
4.7 Hz, 1 H), 4.41 (s, 2 H), 3.94 (dd, J = 4.5, 11.2 Hz, 1 H), 3.90-3.87 (m, 1 H), 2.89 (d, J 
= 7.8 Hz, 2 H), 2.81 (br s, 3 H), 2.69 (br s, 3 H), 1.49 (s, 9 H); 
13C NMR (125 MHz, CDCl3) δ 143.7, 143.3, 138.9, 124.9, 80.0, 77.4, 63.1, 60.6, 45.4, 
34.1, 32.8, 28.6, 21.2, 14.3; 
IR (KBr, thin film) νmax 3388, 2927, 1671, 1393, 1247, 1146, 1039, 960, 875 cm-1; 
HRMS (ESI) m/z 330.1670 [calcd for C17H25NO4Na (M+Na)+ 330.1681]. 
  
(+)-2.S27: data consistent with (–)-isomer — [α]D23 +2.2 (c 1.0, EtOAc). 
 
 
 
Silyl ether 2.51. To a precooled (0 ºC) solution of 2.S27 (4.19 g, 13.6 mmol) and 
imidazole (1.85 g, 27.2 mmol) in CH2Cl2 (136 mL) was added TBSCl (3.49 g, 23.2 
mmol). The mixture was stirred for 30 min at 0 ºC, diluted with EtOAc (300 mL), washed 
with water and brine, dried over Na2SO4, filtered and concentrated. Flash column 
CH2Cl2, 0 ºC, 30 min
OH
OTBS
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NMe
Boc
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OH
(–)-2.S27
NMe
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chromatography (9:1  8:2 hexanes/EtOAc) furnished 2.51 (5.72, 96%) as a clear 
colorless oil. 
[α]D22 –6.1 (c 0.53, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.39 (d, J = 8.1 Hz, 1 H), 7.10 (br s, 2 H), 5.27 (t, J = 5.8 
Hz, 1 H), 4.42 (s, 2 H), 3.99 (dd, J = 4.7, 10.3 Hz, 1 H), 3.90 (dd, J = 7.2, 10.3 Hz, 1 H), 
3.27 (s, 1 H), 2.91 (dd, J = 8.2, 16.0 Hz, 1 H), 2.85-2.79 (m, 4 H), 2.71-2.68 (m, 1 H), 
1.49 (s, 9 H), 0.87 (s, 9 H), 0.10 (s, 3 H), 0.07 (s, 3 H); 
13C NMR (125 MHz, CDCl3, mixture of rotamers) δ 144.0, 143.1, 138.4, 124.9, 63.8, 
45.1, 33.9, 33.3, 28.6, 25.9, 18.2, –5.3, –5.4;  
IR (KBr, thin film) νmax 3433, 2928, 2855, 1698, 1472, 1392, 1251, 1145, 1080, 837, 775 
cm-1; 
HRMS (ESI) m/z 444.2530 [calcd for C23H39NO4SiNa (M+Na)+ 444.2546]. 
 
 (+)-2.51: data consistent with (–)-isomer — [α]D22 +4.06 (c 0.37, CH2Cl2) 
 
 
 
 
Azide 2.S28.  To a solution of 2.51 (1.604 g, 3.65 mmol) in toluene (37 mL) was added 
DPPA (2.36 mL, 11.0 mmol). The mixture was stirred at rt for 5 min then DBU (1.65 
mL, 11.0 mmol) was added. After stirring at rt for 10 min, the mixture was heated to 70 
Toluene
rt to 70 ºC, overnight
N3
OTBS
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(+)-2.S28
N
Boc
Me
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OTBSNMe
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ºC and stirred for 14 h, then allowed to cool to rt , diluted with EtOAc (100 mL), and 
washed with water and brine. The organic layer was then dried over Na2SO4, filtered and 
concentrated in vacuo over Celite (3 g).  Flash column chromatography (dry loading, 
95:5 hexanes/EtOAc) furnished 2.S28 as a clear, colorless oil (1.50 g, 87%). 
[α]D22 +25.0 (c 0.36, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 7.33 (d, J = 7.7 Hz, 1 H), 7.11 (s, 2 H), 4.75 (d, J = 5.5 
Hz, 1 H), 4.42 (s, 2 H), 3.79 (dd, J = 5.4, 10.2 Hz, 1 H), 3.66 (dd, J = 6.3, 10.3 Hz, 1 H), 
3.07 (dd, J = 8.2, 16.1 Hz, 1 H), 2.76-2.88 (2 br s, 3 H, rotamer 1 and 2), 2.71 (dd, J = 
6.6, 16.1 Hz, 1 H), 2.65-2.60 (m, 1 H), 1.49 (br s, 9 H), 0.90 (s, 9 H), 0.08 (s, 3 H), 0.07 
(s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 143.0, 139.6, 130.2, 126.3, 124.8, 120.4, 67.4, 63.7, 49.6, 
34.1, 33.3, 28.6, 26.0, 18.5, –5.2, –5.3;  
IR (KBr, thin film) νmax 3433, 2927, 2092, 1692, 1391, 1366, 1250, 1147, 775 cm-1; 
HRMS (ESI) m/z 469.2603 [calcd for C23H38N4O3SiNa (M+Na)+ 469.2611]. 
 
 (–)-2.S28: data consistent with (+)-isomer — [α]D22 –28.3 (c 0.53, CH2Cl2) 
 
 
 
Oxalamide 2.52. A flask containing a solution of 2.S28 (3.99 g, 8.93 mmol) in EtOH 
(128 mL) was evacuated and backfilled with nitrogen gas (× 5). To this solution was 
NH2
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added palladium on carbon (10% w/w, 0.475 g, 0.447 mmol). The reaction flask was then 
evacuated and backfilled with hydrogen gas (× 5) and the suspension was stirred at rt 
under a hydrogen atmosphere overnight, then filtered through Celite and concentrated in 
vacuo. The resulting amine (2.S29) was used in the next step without further purification. 
To a solution of freshly prepared S.29 in CH2Cl2 (150 mL) were added oxalic acid 2.18 
(2.33 g, 10.7 mmol) and TBTU (3.73 g, 11.6 mmol), and finally DIPEA (2.34 mL, 13.4 
mmol). The resulting mixture was stirred at rt overnight,  diluted with EtOAc (250 mL), 
washed with water, 1 N HCl, sat. aq. NaHCO3, and brine, then dried over Na2SO4, 
filtered, and concentrated in vacuo.  Flash column chromatography (7:3 hexanes/EtOAc) 
furnished 2.52 as a clear colorless oil (5.24 g, 86%). 
[α]D22 +33.8 (c 0.54, CH2Cl2). 
1H NMR (500 MHz, CDCl3) δ 9.44 (s, 1 H), 7.74 (dd, J = 2.4, 10.7 Hz, 1 H), 7.69 (d, J = 
9.3 Hz, 1 H), 7.38 (t, J = 8.3 Hz, 1 H), 7.29-7.26 (m, 1 H), 7.17 (d, J = 7.8 Hz, 1 H), 7.09 
(br s, 2 H), 5.36 (t, J = 8.3 Hz, 1 H), 4.42 (s, 2 H), 3.81 (d, J = 5.3 Hz, 2 H), 3.08 (dd, J = 
8.2, 16.1 Hz, 1 H), 2.87-2.80 (m, 4 H), 2.59-2.52 (m, 1 H), 1.49 (s, 9 H), 0.88 (s, 9 H), 
0.08 (s, 3 H), 0.07 (s, 3 H); 
13C NMR (125 MHz, CDCl3) δ 159.4, 159.2, 157.7, 142.9, 140.6, 138.8, 136.5, 136.4, 
131.0, 124.3, 116.1 (d, JCF = 3.5 Hz), 108.4 (d, JCF = 26.1 Hz), 63.9, 57.0, 51.1, 34.1, 
33.6, 28.6, 26.0, 18.4, –5.3;  
IR (KBr, thin film) νmax 3281, 2927, 1667, 1595, 1515, 1146, 837, 776 cm-1; 
HRMS (ESI) m/z 642.2553 [calcd for C31H43N3O5SiClFNa (M+Na)+  642.2542]. 
 
(–)-2.52: data consistent with (+)-isomer — [α]D22 –31.3 (c 0.20, CH2Cl2) 
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Alcohol 2.S30. To a solution of 2.52 (5.64 g, 8.73 mmol) in THF (175 mL) at rt was 
added TBAF (1.0 M in THF, 17.5 mL, 17.5 mmol), and the mixture was stirred overnight 
at rt before being  diluted with EtOAc (250 mL), and washed with water and brine. The 
organic layer was dried over Na2SO4, filtered, and concentrated in vacuo over Celite (5 
g). Flash column chromatography (1:1 hexanes/EtOAc, EtOAc and 9:1 EtOAc/MeOH) 
furnished 2.S30 contaminated with n-Bu4NOH. The residue was taken up in EtOAc (150 
mL) and washed with sat. aq. CuSO4 (3 × 40 mL) and brine, dried over Na2SO4, filtered 
and concentrated in vacuo to furnish pure 2.S30 as a white solid (4.34 g, 95%). 
[α]D22 +48.2 (c 0.56, EtOAc). 
1H NMR (500 MHz, DMSO-d6) δ 11.06 (s, 1 H), 9.30 (d, J = 8.7 Hz, 1 H), 7.96 (d, J = 
10.9 Hz, 1 H), 7.75 (d, J = 8.3 Hz, 1 H), 7.59 (t, J = 8.6 Hz, 1 H), 7.12 (d, J = 7.1 Hz, 1 
H), 7.08 (br. s., 1 H), 7.03 (d, J = 7.3 Hz, 1 H), 5.22 (t, J = 8.1 Hz, 1 H), 4.70 (t, J = 4.8 
Hz, 1 H), 4.34 (s, 2 H), 3.61 - 3.49 (m, 2 H), 3.08 - 3.00 (m, 1 H), 2.78 - 2.66 (m, 5 H), 
1.42 (br. s., 9 H); 
13C NMR (125 MHz, DMSO-d6) δ 160.4, 159.6, 143.3, 138.2, 131.2, 124.5, 109.1 (d, JCF 
= 25.9 Hz), 79.4, 62.5, 56.5, 49.1, 34.0, 28.7; 
IR (KBr, thin film) νmax 3391, 3269, 2921, 1735, 1663, 1517, 1241 cm-1; 
 
HRMS (ESI) m/z 528.1689 [calcd for C25H29N3O5FClNa (M+Na)+ 528.1677].  
OH
HN
O
O
H
N
Cl
F
THF, rt
TBAF
N
Boc
Me(+)-2.52
OTBS
HN
O
O
H
N
Cl
F
N
Boc
Me
(+)-2.S30
 222 
(–)-2.S30: data consistent with (+)-isomer —[α]D22 –52.9 (c 0.40, CH2Cl2) 
 
 
Guanidine 2.53. To a solution of 2.S30 (0.561 g, 1.11 mmol) in THF (22 mL) were added 
N,N',N''-tri-Boc-guanidine (0.797 g, 2.22 mmol) and triphenylphosphine (0.436 g, 1.66 
mmol), and the mixture was cooled to 0 ºC. DEAD (0.76 mL, 1.7 mmol) was added 
dropwise to the mixture, which was subsequently warmed to rt and stirred overnight.  The 
reaction was quenched by addition of sat. aq. NaHCO3 (10 mL) and extracted with 
EtOAc (3 × 10 mL). The organic layers were combined and washed with brine, dried 
over Na2SO4, filtered and concentrated in vacuo. Flash column chromatography (8:2 
hexanes/CH2Cl2, then 95:5  70:30 hexanes/EtOAc) furnished 2.53 as a white solid 
(0.634 g, 64%). 
[α]D22 +28.2 (c 1.28, CH2Cl2); 
1H NMR (500 MHz, CDCl3) δ 9.32 (s, 1 H), 7.79-7.74 (m, 2 H), 7.39 (t, J = 8.5 Hz, 1 H), 
7.24-7.22 (m, 1 H), 7.16 (d, J = 7.9 Hz, 1 H), 7.08 (br s, 2 H), 5.26 (t, J = 8.6 Hz, 1 H), 
4.41 (s, 2 H), 4.16-4.11 (m, 4 H), 3.17 (q, J = 7.7 Hz, 1 H), 2.90-2.76 (m, 5 H), 1.55-1.47 
(m, 36 H); 
IR (KBr, thin film) νmax 3407, 3289, 1759, 1665, 1515, 1243, 1148 cm-1; 
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13C NMR (125 MHz, CDCl3) δ 159.7, 159.2, 157.5, 153.3, 142.5, 140.3, 138.7, 136.5, 
130.9, 124.1, 116.0, 108.4 (d, JCF = 25.9 Hz), 83.6, 58.5, 50.1, 48.3, 35.1, 34.0, 29.8, 
28.6, 28.2, 28.1; 
HRMS (ESI) m/z 847.3828 [calcd for C41H57N6O10ClF (M+H)+ 847.3809]. 
 
(–)-2.53: data consistent with (+)-isomer —[α]D22 –40.0 (c 0.13, CH2Cl2) 
 
 
BNM-III-170, 2.46. To a solution of 2.53 (0.634 g, 0.711 mmol) in CH2Cl2 (25 mL) was 
added TFA (2.5 mL, 32.7 mmol), and the resulting solution was stirred at rt for 24 h, then 
concentrated in vacuo. The residue was taken up in CH3CN/H2O (1:1, ~4 mL) and 
purified in a Biotage Isolera system in two identical runs. Conditions: cartridge: C18 
SNAP Ultra (12 g); flow rate: 12 mL/min; gradient time: 10 min; eluent: 90:10  25:75 
H2O/CH3CN (+0.1% TFA). Product-containing fractions were combined the resulting 
solution was deep-frozen (–78 ºC bath) and lyophilized (0.035 mbar) to afford the 
trifluoroacetate salt 2.46 (398 mg, 83%) as a white powder. 
[α]D22 +26.1 (c 0.15, CH3OH); 
1H NMR (500 MHz, DMSO-d6) δ 11.08 (s, 1 H), 9.47 (d, J = 8.9 Hz, 1 H), 8.89 (s, 2 H), 
7.98 (dd, J = 2.4, 11.8 Hz, 1 H), 7.83 (t, J = 5.5 Hz, 1 H), 7.77 (dd, J = 2.0, 9.0 Hz, 1 H), 
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7.61 (t, J = 8.7 Hz, 1 H), 7.36 (s, 1 H), 7.31-7.21 (m, 3 H), 5.18 (t, J = 8.8 Hz, 1 H), 4.11 
(s, 2 H), 3.45-3.33 (m, 4 H), 3.12 (dd, J = 8.0, 15.7 Hz, 1 H), 2.91-2.83 (m, 1 H), 2.69 
(dd, J = 9.2, 15.5 Hz, 1 H), 2.55 (s, 3 H); 
13C NMR (125 MHz, DMSO-d6) δ 160.5, 159.3, 158.9 (q, JCF = 31 Hz, TFA), 157.6, 
157.3 (d, JCF = 244 Hz), 144.0, 142.2, 138.8 (d, JCF = 10 Hz), 132.0, 131.1, 128.9, 126.6, 
124.4, 118.9, 117.8 (d, JCF = 3 Hz), 116.5, 114.9 (d, JCF = 18 Hz), 109.0 (d, JCF = 27 Hz), 
57.4, 51.7, 45.8, 43.4, 34.3, 32.5; 
19F NMR (282 MHz, DMSO-d6) δ -73.6 (6 F), -114.6 (1 F); 
IR (ATR) νmax 3261, 1662, 1517, 1429, 1194, 1130, 975, 831, 799, 721 cm-1; 
HRMS (ESI) m/z 447.1708 [calcd for C21H25N6O2ClF (M+H)+ 447.1712]. 
 
(–)-2.46: data consistent with (+)-isomer — [α]D22 –44.3 (c 0.13, CH3OH). 
 
 
 
Synthesis of 2.54–2.62. 
Method A: Exemplary Procedure 
 
BNM-IV-125, 2.58. To a solution of 2.46 (15 mg, 0.022 mmol) in MeOH (1.1 mL) at rt 
were added benzaldehyde (23 µL, 0.22 mmol) and acetic acid (1.5 µL, 0.027 mmol). The 
resulting mixture was stirred at rt for 10 min.  Sodium cyanoborohydride (1.7 mg, 0.027 
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mmol) was then added and the resulting mixture was stirred at room temperature 
overnight. The reaction mixture was then concentrated under a stream of nitrogen. Water 
(1.3 mL), CH3CN (0.2 mL) and TFA (0.1 mL) were added and the resulting mixture was 
purified by HPLC in a single injection. Eluant: 90:10 to 40:60 water/acetonitrile. 
Gradient time: 20 min. Flow rate: 15 mL/min. Product retention time: 10.7 min. Product 
fractions were combined and the resulting solution was deep-frozen (–78 ºC) and 
lyophilized (0.08 mbar) to afford the bistrifluoroacetate salt 2.58 as a white powder (14 
mg, 82%). 
 
 
BNM-IV-114, 2.54. Method A, from 2.46 and acetaldehyde. Yield: 13.3 mg, 85%. 
[α]D23 –21.6 (c 0.05, CH3OH); 
1H NMR (500 MHz, DMSO-d6) δ 11.08 (s, 1 H), 9.81 (br. s., 1 H), 9.47 (d, J = 8.8 Hz, 1 
H), 7.98 (dd, J = 2.4, 11.8 Hz, 1 H), 7.86 (t, J = 5.4 Hz, 1 H), 7.76 (dd, J = 1.6, 8.9 Hz, 1 
H), 7.60 (t, J = 8.7 Hz, 1 H), 7.40 (s, 1 H), 7.36 - 7.30 (m, 1 H), 7.26 - 7.20 (m, 1 H), 5.19 
(t, J = 8.8 Hz, 1 H), 4.38 - 4.31 (m, 1 H), 4.23 - 4.15 (m, 1 H), 3.27 - 3.50 (m, 2 H), 3.22 - 
3.08 (m, 2 H), 3.07 - 2.98 (m, 1 H), 2.91 - 2.82 (m, 1 H), 2.75 - 2.66 (m, 1 H), 2.66 - 2.61 
(m, 3 H), 1.24 (t, J = 7.3 Hz, 3 H); 
13C NMR (125 MHz, DMSO-d6) δ 160.0, 158.8, 158.4 (q, JCF = 32 Hz, TFA), 157.1, 
156.8 (d, JCF = 244 Hz), 144.0, 141.9, 138.3 (d, JCF = 10 Hz), 130.6, 129.7, 129.6, 127.3, 
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124.0, 117.3 (d, JCF = 3 Hz), 114.4 (d, JCF = 17 Hz), 108.5 (d, JCF = 25 Hz), 57.8, 56.9, 
49.9, 45.3, 42.9, 38.0, 33.8, 8.9; 
IR (ATR) νmax 3267, 1663, 1518, 1428, 1187, 1132 cm-1; 
HRMS (ESI) m/z 475.2036 [calcd for C23H29N6O2ClF (M+H)+ 475.2025]. 
 
 
BNM-IV-123, 2.55. Method A, from 2.46 and propionaldehyde. Yield: 9.4 mg, 59%. 
[α]D23 –0.7 (c 0.075, CH3OH); 
1H NMR (500 MHz, DMSO-d6) δ 11.07 (s, 1 H), 9.83 (br. s., 1 H), 9.46 (d, J = 8.8 Hz, 1 
H), 7.99 (dd, J = 2.4, 11.8 Hz, 1 H), 7.85 (t, J = 5.4 Hz, 1 H), 7.78 (dd, J = 1.7, 8.8 Hz, 1 
H), 7.61 (t, J = 8.7 Hz, 1 H), 7.42 (s, 1 H), 7.35 (d, J = 7.9 Hz, 1 H), 7.26 (d, J = 7.9 Hz, 1 
H), 5.21 (t, J = 8.8 Hz, 1 H), 4.42 - 4.33 (m, 1 H), 4.27 - 4.16 (m, 1 H), 3.50 - 3.41 (m, 2 
H), 3.15 (dd, J = 8.0, 15.7 Hz, 1 H), 3.06 (br. s., 1 H), 3.00 - 2.84 (m, 2 H), 2.77 - 2.64 
(m, 4 H), 1.81 - 1.61 (m, 2 H), 0.91 (t, J = 7.4 Hz, 3 H); 
13C NMR (125 MHz, DMSO-d6) δ 160.0, 158.7, 158.3 (q, JCF = 33 Hz, TFA), 157.0, 
156.8 (d, JCF = 243 Hz), 144.0, 141.9, 138.2 (d, JCF = 10 Hz), 130.6, 129.6, 129.6, 127.3, 
123.9, 118.3, 117.3 (d, JCF = 4 Hz), 115.9, 114.4 (d, JCF = 18 Hz), 108.4 (d, JCF = 25 Hz), 
58.3, 56.9, 56.2, 45.3, 42.8, 38.7, 33.7, 16.8, 10.8; 
IR (ATR) νmax 3283, 1666, 1515, 1428, 1193, 1133 cm-1; 
HRMS (ESI) m/z 489.2180 [calcd for C24H31N6O2ClF (M+H)+ 489.2181]. 
HN
HN
NH2+
NH2
O
O
H
N
Cl
F
NH+
• 2 CF3COO–
(–)-BNM-IV-123 (2.55)
 227 
 
BNM-IV-117, 2.56. Method A, from 2.46 and acetone. Yield: 12.4 mg, 78%. 
[α]D23 +8.1 (c 0.11, CH3OH); 
1H NMR (500 MHz, DMSO-d6) δ 11.07 (s, 1 H), 9.55 (br. s., 1 H), 9.46 (dd, J = 4.6, 8.7 
Hz, 1 H), 7.99 (dd, J = 2.4, 11.8 Hz, 1 H), 7.83 (t, J = 5.4 Hz, 1 H), 7.78 (dd, J = 1.5, 8.8 
Hz, 1 H), 7.62 (t, J = 8.7 Hz, 1 H), 7.45 (s, 1 H), 7.38 (d, J = 7.9 Hz, 1 H), 7.26 (d, J = 7.7 
Hz, 1 H), 5.21 (t, J = 8.7 Hz, 1 H), 4.37 (d, J = 13.0 Hz, 1 H), 4.15 (td, J = 6.1, 12.2 Hz, 1 
H), 3.58 - 3.49 (m, 1 H), 3.48 - 3.41 (m, 1 H), 3.40 - 3.37 (m, 1 H), 3.15 (td, J = 7.5, 15.2 
Hz, 1 H), 2.89 (sxt, J = 7.3 Hz, 1 H), 2.77 - 2.67 (m, 1 H), 2.61 - 2.54 (m, 3 H), 1.35 - 
1.28 (m, 6 H); 
13C NMR (125 MHz, DMSO-d6) δ 160.5, 159.2, 158.8 (q, JCF = 31 Hz, TFA), 157.6, 
157.3 (d, JCF = 245 Hz), 144.4, 142.4, 138.8 (d, JCF = 10 Hz), 131.1, 130.5, 130.1, 127.7, 
124.5, 117.8 (d, JCF = 4 Hz), 114.9 (d, JCF = 17 Hz), 109.0 (d, JCF = 26 Hz), 57.4, 56.4, 
56.3, 56.0, 45.8, 43.4, 34.7, 34.7, 34.3, 17.4, 15.5; 
IR (ATR) νmax 3279, 1665, 1514, 1427, 1199, 1179, 1130 cm-1; 
HRMS (ESI) m/z 489.2178 [calcd for C24H31N6O2ClF (M+H)+ 489.2181]. 
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BNM-IV-124, 2.57. Method A, from 2.46 and isobutyraldehyde. Yield: 14.0 mg, 86%. 
[α]D23 +19.8 (c 0.125, CH3OH); 
1H NMR (500 MHz, DMSO-d6) δ 11.11 (s, 1 H), 9.50 (d, J = 7.1 Hz, 2 H), 7.99 (dd, J = 
2.3, 11.8 Hz, 1 H), 7.89 (br. s., 1 H), 7.77 (dd, J = 2.0, 8.9 Hz, 1 H), 7.61 (t, J = 8.7 Hz, 1 
H), 7.42 (s, 1 H), 7.35 (d, J = 7.7 Hz, 1 H), 7.24 (d, J = 7.7 Hz, 1 H), 5.20 (t, J = 8.8 Hz, 1 
H), 4.40 - 4.30 (m, 1 H), 4.29 - 4.20 (m, 1 H), 3.40 - 3.30 (m, 2 H), 3.13 (dd, J = 7.3, 15.3 
Hz, 1 H), 2.94 - 2.79 (m, 3 H), 2.78 - 2.64 (m, 4 H), 2.19 - 2.00 (m, 1 H), 0.94 (d, J = 6.5 
Hz, 3 H), 0.92 (d, J = 6.5 Hz, 3 H); 
13C NMR (125 MHz, DMSO-d6) δ 160.0, 158.7, 158.4 (q, JCF = 32 Hz, TFA), 157.1, 
156.8 (d, JCF = 244 Hz), 144.0, 141.8, 138.3 (d, JCF = 10 Hz), 130.6, 129.9, 129.2, 127.6, 
123.9, 117.3 (d, JCF = 3 Hz), 114.4 (d, JCF = 17 Hz), 108.5 (d, JCF = 26 Hz), 62.0, 59.0, 
56.9, 45.3, 42.8, 33.7, 23.5, 20.4, 20.0; 
IR (ATR) νmax 3287, 1667, 1512, 1427, 1176, 1127 cm-1; 
HRMS (ESI) m/z 503.2336 [calcd for C25H33N6O2ClF (M+H)+ 503.2338]. 
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BNM-IV-125, 2.58. Method A, from 2.46 and benzaldehyde. Yield: 14 mg, 82%. 
[α]D22 +11.3 (c 0.13, CH3OH); 
1H NMR (500 MHz, DMSO-d6) δ 11.11 (s, 1 H), 10.13 (br. s., 1 H), 9.49 (d, J = 8.5 Hz, 
1 H), 7.99 (dd, J = 11.9, 2.4 Hz, 1 H), 7.85 (t, J = 5.4 Hz, 1 H), 7.77 (dd, J = 8.9, 1.6 Hz, 
1 H), 7.61 (t, J = 8.7 Hz, 1 H), 7.45 - 7.55 (m, 6 H), 7.41 (s, 1 H), 7.36 (d, J = 7.7 Hz, 1 
H), 7.25 (d, J = 7.9 Hz, 1 H), 5.20 (t, J = 8.7 Hz, 1 H), 4.45 (d, J = 12.1 Hz, 2 H), 4.21 
(br. s., 2 H), 3.27 - 3.50 (m, 2 H), 3.13 (dt, J = 15.1, 7.3 Hz, 1 H), 2.80 - 2.93 (m, 1 H), 
2.66 - 2.77 (m, 1 H), 2.53 (br. s., 3 H); 
13C NMR (125 MHz, DMSO-d6) δ 160.1, 158.9, 158.3 (q, JCF = 32 Hz, TFA), 157.0, 
156.8 (d, JCF = 244 Hz), 144.2, 141.9, 138.3 (d, JCF = 10 Hz), 131.3, 130.6, 129.8, 129.6, 
129.4, 128.9, 127.5, 123.9, 117.3 (d, JCF = 3 Hz), 114.4 (d, JCF = 18 Hz), 108.5 (d, JCF = 
26 Hz), 58.6, 56.9, 45.3, 42.9, 37.9, 33.8; 
IR (ATR) νmax 3280, 1665, 1515, 1428, 1412, 1195, 1133, 1067 cm-1; 
HRMS (ESI) m/z 537.2183 [calcd for C28H31N6O2ClF (M+H)+ 537.2181]. 
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BNM-IV-139, 2.59. Method A, from 2.46 and 2-phenylacetaldehyde. Yield: 14 mg, 83%. 
[α]D22 –2.3 (c 0.1, CH3OH); 
1H NMR (500 MHz, DMSO-d6) δ 11.11 (s, 1 H), 10.09 (br. s., 1 H), 9.50 (d, J = 8.7 Hz, 
1 H), 7.99 (dd, J = 2.2, 11.7 Hz, 1 H), 7.85 (t, J = 5.4 Hz, 1 H), 7.78 (dd, J = 1.8, 8.7 Hz, 
1 H), 7.61 (t, J = 8.7 Hz, 1 H), 7.43 (s, 1 H), 7.39 - 7.31 (m, 4 H), 7.29 - 7.22 (m, 4 H), 
5.20 (t, J = 8.8 Hz, 1 H), 4.47 (d, J = 13.1 Hz, 1 H), 4.35 - 4.17 (m, 1 H), 3.48 - 3.40 (m, 
1 H), 3.39 - 3.29 (m, 2 H), 3.24 (d, J = 5.4 Hz, 1 H), 3.17 - 3.05 (m, 2 H), 3.05 - 2.97 (m, 
1 H), 2.92 - 2.83 (m, 1 H), 2.79 - 2.66 (m, 4 H); 
 
 
13C NMR (125 MHz, DMSO-d6) δ 160.0, 158.7, 158.4 (q, JCF = 32 Hz, TFA), 157.1, 
156.8 (d, JCF = 243 Hz), 144.0, 141.9, 138.3 (d, JCF = 10 Hz), 136.8, 130.6, 129.6, 129.6, 
128.7, 128.2, 127.3, 126.9, 124.0, 117.3 (d, JCF = 117.3 Hz), 114.4 (d, JCF = 17 Hz), 
108.6, 108.4, 61.2, 58.4, 56.9, 55.6, 45.3, 42.9, 40.8, 38.8, 33.8, 30.6, 29.4; 
IR (ATR) νmax 3281, 1665, 1517, 1428, 1187, 1136 cm-1; 
HRMS (ESI) m/z 551.2331 [calcd for C29H33N6O2ClF (M+H)+ 551.2338]. 
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BNM-IV-137, 2.60. Method A, from 2.46 and glyoxylic acid. Yield: 40 mg, 85%. 
[α]D22 +31.7 (c 0.07, CH3OH); 
1H NMR (500 MHz, DMSO-d6) δ 11.11 (s, 1 H), 9.49 (d, J = 8.7 Hz, 1 H), 8.05 - 7.90 
(m, 2 H), 7.77 (dd, J = 1.7, 8.6 Hz, 1 H), 7.61 (t, J = 8.6 Hz, 1 H), 7.39 (s, 1 H), 7.33 (d, J 
= 7.7 Hz, 1 H), 7.24 (d, J = 7.7 Hz, 1 H), 5.19 (t, J = 8.7 Hz, 1 H), 4.27 (br. s., 2 H), 3.94 
(s, 2 H), 3.48 - 3.30 (m, 3 H), 3.14 (dd, J = 7.9, 15.7 Hz, 1 H), 2.95 - 2.80 (m, 1 H), 2.76 - 
2.65 (m, 4 H); 
13C NMR (125 MHz, DMSO-d6) δ 167.7, 160.0, 158.7, 158.6 (q, JCF = 32 Hz, TFA), 
157.1, 156.8 (d, JCF = 244 Hz), 143.9, 141.9, 138.3 (d, JCF = 10 Hz), 130.6, 129.6, 127.3, 
124.0, 117.3 (d, JCF = 3 Hz), 114.4 (d, JCF = 17 Hz), 108.5 (d, JCF = 26 Hz), 59.0, 56.9, 
54.9, 45.3, 42.9, 40.3, 33.8; 
19F NMR (282 MHz, DMSO-d6) δ -73.8 (6 F), -114.6 (1 H); 
IR (ATR) νmax 3277, 1666, 1515, 1428, 1184, 1132 cm-1; 
HRMS (ESI) m/z 505.1771 [calcd for C23H27N6O4ClF (M+H)+ 505.1776]. 
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Method B: Exemplary Procedure 
 
BNM-IV-147, 2.61. To a solution of 2.46 (40 mg, 0.059 mmol) in DMF (400 µL) at rt 
were added DIPEA (22 µL, 0.124 mmol) and 1H-pyrazole-1-carboximidamide•HCl (18 
mg, 0.124 mmol). The resulting mixture was stirred at room temperature for 36 h. Were 
then added to the reaction vessel water (1.8 mL) and acetonitrile (0.3 mL), and the 
resulting solution (total volume: 2.5 mL) was purified by HPLC in a single injection. 
Eluent: 90:10 to 60:40 water/acetonitrile. Gradient time: 15 min. Flow rate: 15 mL/min. 
Product retention time: 9.5 min. Product fractions were combined and the resulting 
solution was deep-frozen (–78 ºC) and lyophilized (0.08 mbar) to afford the 
bistrifluoroacetate salt 2.61 as a white powder (35 mg, 82%). 
 
 
BNM-IV-147, 2.61. Method B from 2.46. Yield: 35 mg, 82%. 
[α]D22 +11.8 (c 0.16, CH3OH); 
1H NMR (500 MHz, DMSO-d6) δ 11.09 (s, 1 H), 9.45 (d, J = 8.7 Hz, 1 H), 7.98 (d, J = 
11.9 Hz, 1 H), 7.89 - 7.71 (m, 2 H), 7.61 (t, J = 8.6 Hz, 1 H), 7.51 (br. s., 5 H), 7.21 - 
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7.11 (m, 3 H), 7.07 (d, J = 7.9 Hz, 1 H), 5.17 (t, J = 8.5 Hz, 1 H), 4.56 (s, 2 H), 3.61 - 
3.21 (m, 2 H + H2O), 3.12 (dd, J = 15.9, 7.9 Hz, 1 H), 2.91 (s, 3 H), 2.84 (q, J = 6.3 Hz, 1 
H), 2.67 (dd, J = 15.5 Hz, 8.9, 1 H); 
13C NMR (125 MHz, DMSO-d6) δ 160.0, 158.8, 158.4 (q, JCF = 32 Hz, TFA), 157.0, 
156.8 (d, JCF = 244 Hz), 142.2, 141.9, 138.4 (d, JCF = 10 Hz), 135.4, 130.7, 125.8, 124.0, 
123.5, 117.4 (d, JCF = 3 Hz), 114.4 (d, JCF = 18 Hz), 108.5 (d, JCF = 26 Hz), 56.9, 52.6, 
45.3, 42.9, 40.1, 36.1, 33.9; 
IR (ATR) νmax 3275, 1663, 1614, 1517, 1429, 1202, 1136 cm-1; 
HRMS (ESI) m/z 489.1929 [calcd for C22H27N8O2ClF (M+H)+ 489.1930]. 
 
 
BNM-IV-197, 2.62. Method B from 2.9. Yield: 7.5 mg, 71%. 
[α]D22 –27.4 (c 0.05, CH3OH); 
1H NMR (500 MHz, DMSO-d6) δ 11.11 (s, 1 H), 9.47 (d, J = 8.7 Hz, 1 H), 7.99 (dd, J = 
2.1, 11.8 Hz, 1 H), 7.82 - 7.75 (m, 2 H), 7.61 (t, J = 8.7 Hz, 1 H), 7.48 (s, 5 H), 7.30 (d, J 
= 7.7 Hz, 1 H), 7.10 (d, J = 7.9 Hz, 1 H), 7.06 (s, 1 H), 5.18 (t, J = 8.7 Hz, 1 H), 4.60 - 
4.48 (m, 2 H), 3.52 - 3.25 (m, 2 H + H2O), 3.12 (dd, J = 8.1, 15.7 Hz, 1 H), 2.93 - 2.77 
(m, 4 H), 2.66 (dd, J = 9.0, 15.6 Hz, 1 H); 
13C NMR (125 MHz, DMSO-d6) δ 159.9, 158.7, 158.2 (q, JCF = 32 Hz, TFA), 157.0, 
156.7, 156.8 (d, JCF = 244 Hz), 143.0, 140.9, 138.2 (d, JCF = 10 Hz), 134.2, 130.6, 126.7, 
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125.0, 122.8, 117.3 (d, JCF = 3 Hz), 114.4 (d, JCF = 17 Hz), 108.4 (d, JCF = 25 Hz), 57.0, 
52.4, 45.3, 42.9, 35.9, 33.6; 
IR (KBr, thin film) νmax 3348, 2947, 1671, 1627, 1513, 1424, 1336, 1156 cm-1; 
HRMS (ESI) m/z 489.1940 [calcd for C22H27N8O2ClF (M+H)+ 489.1930]. 
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Crystallographic Data Relevant to Part I 
X-ray Structure Determination of Compound (+)-1.90 (Dr. P. J. Carroll) 
 
           
Compound (+)-1.90, C18H30SiO5, crystallizes in the monoclinic space group P21 (systematic 
absences 0k0: k=odd) with a=6.7431(7)Å, b=7.2421(9)Å, c=21.168(2)Å, b=93.220(8)°, V=1032.09(19)Å3, 
Z=2, and dcalc=1.141 g/cm3 . X-ray intensity data were collected on a Bruker APEXII CCD area detector 
employing graphite-monochromated Cu-Kα radiation (l=1.54178 Å) at a temperature of 143(1)K. 
Preliminary indexing was performed from a series of thirty-six 0.5° rotation frames with exposures of 10 
seconds. A total of 4718 frames were collected with a crystal to detector distance of 37.6 mm, rotation 
widths of 0.5° and exposures of 10 seconds:  
 
scan type 2q w f c frames 
f 92.00 88.66 348.71 -26.26 739 
f 87.00 76.65 30.72 62.65 739 
f 17.00 53.92 9.46 -37.41 599 
f 92.00 132.53 111.63 -22.49 496 
w 77.00 352.46 182.82 78.00 149 
w -23.00 331.94 256.68 -41.06 207 
w -18.00 243.80 41.87 38.14 205 
w 22.00 340.71 190.04 98.03 72 
w 92.00 350.02 317.53 90.29 148 
f 92.00 198.97 312.21 -82.85 531 
w 72.00 152.50 201.26 -87.80 86 
f 92.00 209.22 292.98 -95.28 508 
w 92.00 152.22 266.47 -93.68 171 
w -43.00 354.65 135.01 -80.21 68 
 Rotation frames were integrated using SAINTi, producing a listing of unaveraged F2 and s(F2) 
values which were then passed to the SHELXTLii program package for further processing and structure 
O O O O
O
t-BuSiMe2
 !! 400 
solution. A total of 6279 reflections were measured over the ranges 2.09 ≤ θ ≤ 63.86°, -5 ≤ h ≤ 7, -8 ≤ 
k ≤ 8, -23 ≤ l ≤ 24 yielding 3047 unique reflections (Rint = 0.0341). The intensity data were corrected for 
Lorentz and polarization effects and for absorption using SADABS iii  (minimum and maximum 
transmission 0.5876, 0.7524). 
The structure was solved by direct methods (SHELXS-97iv). Refinement was by full-matrix least 
squares based on F2 using SHELXL-97.v All reflections were used during refinement. The weighting 
scheme used was w=1/[s2(Fo2 )+ (0.0566P)2 + 0.2093P] where P = (Fo 2 + 2Fc2)/3. Non-hydrogen atoms 
were refined anisotropically and hydrogen atoms were refined using a riding model.  Refinement converged 
to R1=0.0461 and wR2=0.1099 for 2688 observed reflections for which F > 4s(F) and R1=0.0537 and 
wR2=0.1137 and GOF =1.060 for all 3047 unique, non-zero reflections and 224 variables.vi The maximum 
D/s in the final cycle of least squares was 0.002 and the two most prominent peaks in the final difference 
Fourier were +0.320 and -0.241 e/Å3. 
Table A.1.1. lists cell information, data collection parameters, and refinement data. Final 
positional and equivalent isotropic thermal parameters are given in Tables A.1.2. and A.1.3.  Anisotropic 
thermal parameters are in Table A.1.4.  Tables A.1.5. and A.1.6. list bond distances and bond angles.  
Figure A.1.161 is an ORTEPvii representation of the molecule with 30% probability thermal ellipsoids 
displayed. 
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Figure A.1.161 ORTEP drawing of the title compound with 30% probability thermal ellipsoids. 
C1
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C5 C6
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C8 C9
C10
C11
C12
C13
C14
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C16 C17
C18
O1
O2
O3
O4
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Si1
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Table A.1.1.  Summary of Structure Determination of Compound 1350 
Empirical formula  C18H30SiO5 
Formula weight  354.51 
Temperature  143(1) K 
Wavelength  1.54178 Å 
Crystal system  monoclinic 
Space group  P21      
Cell constants:   
a  6.7431(7) Å 
b  7.2421(9) Å 
c  21.168(2) Å 
b 93.220(8)° 
Volume 1032.09(19) Å3 
Z 2 
Density (calculated) 1.141 Mg/m3 
Absorption coefficient 1.187 mm-1 
F(000) 384 
Crystal size 0.50 x 0.12 x 0.08 mm3 
Theta range for data collection 2.09 to 63.86° 
Index ranges -5 ≤ h ≤ 7, -8 ≤ k ≤ 8, -23 ≤ l ≤ 24 
Reflections collected 6279 
Independent reflections 3047 [R(int) = 0.0341] 
Completeness to theta = 63.86° 96.0 %  
Absorption correction Semi-empirical from equivalents 
Max. and min. transmission 0.7524 and 0.5876 
Refinement method Full-matrix least-squares on F2 
Data / restraints / parameters 3047 / 1 / 224 
Goodness-of-fit on F2 1.060 
Final R indices [I>2sigma(I)] R1 = 0.0461, wR2 = 0.1099 
R indices (all data) R1 = 0.0537, wR2 = 0.1137 
Absolute structure parameter 0.03(4) 
Largest diff. peak and hole 0.320 and -0.241 e.Å-3 
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Table A.1.2. Refined Positional Parameters for Compound 1.90 
 
  Atom x y z Ueq, Å2 
C1 0.5115(4) 0.2019(4) 0.52580(13) 0.0277(6) 
C2 0.3433(4) 0.2414(5) 0.56415(13) 0.0314(7) 
C3 0.1590(4) 0.2062(4) 0.54280(14) 0.0342(7) 
C4 0.1163(4) 0.1419(5) 0.47686(14) 0.0350(7) 
C5 0.2773(4) 0.2065(4) 0.43477(13) 0.0289(7) 
C6 0.2676(5) 0.1081(5) 0.37206(14) 0.0359(8) 
C7 0.4347(5) 0.1469(5) 0.32891(14) 0.0342(8) 
C8 0.4994(5) 0.3442(4) 0.32173(14) 0.0339(8) 
C9 0.5807(5) 0.3828(5) 0.25747(14) 0.0329(7) 
C10 0.6937(5) 0.5638(5) 0.25650(16) 0.0393(8) 
C11 0.8934(6) 0.5601(6) 0.29305(17) 0.0471(10) 
C12 1.0105(7) 0.7351(8) 0.29185(19) 0.0810(16) 
C13 0.5591(7) 0.1260(7) 0.1262(2) 0.0771(15) 
C14 0.1519(7) 0.1024(7) 0.1768(2) 0.0734(14) 
C15 0.2453(6) 0.4257(6) 0.08938(15) 0.0494(10) 
C16 0.0794(8) 0.5376(8) 0.1159(2) 0.0794(15) 
C17 0.1601(7) 0.3180(7) 0.03149(18) 0.0732(14) 
C18 0.4103(9) 0.5512(9) 0.0686(2) 0.101(2) 
O1 0.4753(3) 0.1658(3) 0.46401(9) 0.0309(5) 
O2 0.6817(3) 0.1923(3) 0.54744(10) 0.0375(5) 
O3 0.5114(4) 0.0218(3) 0.30095(11) 0.0498(7) 
O4 0.9523(4) 0.4254(5) 0.32131(14) 0.0632(8) 
O5 0.4155(3) 0.3966(3) 0.21184(10) 0.0410(6) 
Si1 0.34815(13) 0.26275(14) 0.15226(4) 0.0394(3) 
Ueq=1/3[U11(aa*)2+U22(bb*)2+U33(cc*)2+2U12aa*bb*cos γ+2U13aa*cc*cos β+2U23bb*cc*cosα] 
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Table 3. Positional Parameters for Hydrogens in Compound 1.90 
 
  Atom x y z Uiso, Å2 
H2 0.3661 0.2921 0.6043 0.042 
H3 0.0551 0.2219 0.5694 0.046 
H4a -0.0112 0.1901 0.4610 0.047 
H4b 0.1091 0.0082 0.4761 0.047 
H5 0.2644 0.3398 0.4277 0.038 
H6a 0.1431 0.1405 0.3496 0.048 
H6b 0.2646 -0.0237 0.3801 0.048 
H8a 0.6010 0.3726 0.3545 0.045 
H8b 0.3872 0.4249 0.3276 0.045 
H9 0.6676 0.2813 0.2459 0.044 
H10a 0.7142 0.5962 0.2129 0.052 
H10b 0.6128 0.6598 0.2740 0.052 
H12a 1.1265 0.7243 0.3200 0.121 
H12b 0.9303 0.8360 0.3051 0.121 
H12c 1.0500 0.7575 0.2497 0.121 
H13a 0.6630 0.2076 0.1145 0.116 
H13b 0.5161 0.0518 0.0904 0.116 
H13c 0.6080 0.0474 0.1601 0.116 
H14a 0.2070 0.0196 0.2086 0.110 
H14b 0.1014 0.0327 0.1409 0.110 
H14c 0.0459 0.1719 0.1937 0.110 
H16a 0.1313 0.6092 0.1512 0.119 
H16b -0.0218 0.4558 0.1295 0.119 
H16c 0.0236 0.6187 0.0837 0.119 
H17a 0.0513 0.2427 0.0435 0.110 
H17b 0.2617 0.2407 0.0156 0.110 
H17c 0.1141 0.4033 -0.0008 0.110 
H18a 0.3563 0.6389 0.0383 0.152 
H18b 0.5100 0.4783 0.0496 0.152 
H18c 0.4686 0.6155 0.1046 0.152 
 
 !! 405 
Table A.1.4.   Refined Thermal Parameters (U's) for Compound 1.90 
 
  Atom U11 U22 U33 U23 U13 U12 
C1 0.0210(15) 0.0285(16) 0.0338(15) 0.0034(13) 0.0028(12) -0.0009(13) 
C2 0.0252(16) 0.0417(19) 0.0278(14) -0.0012(14) 0.0064(11) 0.0054(15) 
C3 0.0257(16) 0.0372(19) 0.0405(17) 0.0067(14) 0.0075(13) 0.0020(14) 
C4 0.0180(15) 0.0451(19) 0.0421(17) 0.0010(15) 0.0021(13) -0.0025(15) 
C5 0.0194(14) 0.0336(17) 0.0334(15) 0.0024(13) -0.0011(11) -0.0011(13) 
C6 0.0312(17) 0.042(2) 0.0335(17) 0.0020(14) -0.0057(13) -0.0059(15) 
C7 0.0419(19) 0.0351(19) 0.0249(15) 0.0000(14) -0.0046(14) -0.0012(16) 
C8 0.0381(19) 0.0352(18) 0.0283(15) -0.0029(14) 0.0008(13) -0.0003(15) 
C9 0.0329(17) 0.0386(18) 0.0266(16) -0.0025(13) -0.0033(13) 0.0001(15) 
C10 0.046(2) 0.0408(19) 0.0321(17) -0.0034(14) 0.0074(15) -0.0090(17) 
C11 0.039(2) 0.057(2) 0.046(2) -0.0192(19) 0.0134(17) -0.016(2) 
C12 0.090(3) 0.099(4) 0.056(2) -0.022(3) 0.018(2) -0.058(3) 
C13 0.072(3) 0.092(4) 0.065(3) -0.038(3) -0.011(2) 0.022(3) 
C14 0.075(3) 0.074(3) 0.069(3) 0.017(2) -0.010(2) -0.028(3) 
C15 0.060(2) 0.060(2) 0.0274(17) -0.0024(16) -0.0029(16) -0.006(2) 
C16 0.108(4) 0.078(3) 0.050(2) -0.008(2) -0.018(3) 0.037(3) 
C17 0.084(3) 0.094(4) 0.039(2) -0.005(2) -0.019(2) 0.006(3) 
C18 0.131(5) 0.110(5) 0.060(3) 0.039(3) -0.015(3) -0.054(4) 
O1 0.0185(10) 0.0447(12) 0.0296(10) -0.0058(9) 0.0014(8) -0.0002(10) 
O2 0.0219(11) 0.0483(13) 0.0420(12) -0.0055(10) -0.0020(9) 0.0028(10) 
O3 0.0720(19) 0.0371(14) 0.0416(14) -0.0004(11) 0.0142(13) 0.0043(13) 
O4 0.0388(16) 0.067(2) 0.082(2) -0.0115(17) -0.0107(14) 0.0018(15) 
O5 0.0447(13) 0.0450(14) 0.0329(12) -0.0031(10) -0.0025(10) 0.0038(11) 
Si1 0.0379(5) 0.0482(5) 0.0316(4) -0.0037(4) -0.0019(3) -0.0039(5) 
The form of the anisotropic displacement parameter is: 
exp[-2π2(a*2U11h2+b*2U22k2+c*2U33l2+2b*c*U23kl+2a*c*U13hl+2a*b*U12hk)] 
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  Table A.1.5. Bond Distances in Compound 1.90, Å 
 
C1-O2  1.214(3) C1-O1  1.343(3) C1-C2  1.459(4) 
C2-C3  1.323(4) C3-C4  1.484(4) C4-C5  1.516(4) 
C5-O1  1.470(3) C5-C6  1.505(4) C6-C7  1.516(5) 
C7-O3  1.214(4) C7-C8  1.504(4) C8-C9  1.520(4) 
C9-O5  1.436(4) C9-C10  1.517(5) C10-C11  1.515(5) 
C11-O4  1.200(5) C11-C12  1.494(6) C13-Si1  1.843(5) 
C14-Si1  1.857(4) C15-C16  1.514(6) C15-C18  1.521(6) 
C15-C17  1.537(5) C15-Si1  1.882(4) O5-Si1  1.635(2) 
 
 
 
 
Table A.1.6. Bond Angles in Compound 1.90, ° 
 
O2-C1-O1 118.2(2) O2-C1-C2 123.3(3) O1-C1-C2 118.4(2) 
C3-C2-C1 121.1(3) C2-C3-C4 120.7(3) C3-C4-C5 110.4(2) 
O1-C5-C6 105.7(2) O1-C5-C4 110.8(2) C6-C5-C4 112.0(2) 
C5-C6-C7 116.5(3) O3-C7-C8 121.7(3) O3-C7-C6 120.4(3) 
C8-C7-C6 117.8(3) C7-C8-C9 112.7(3) O5-C9-C10 107.6(3) 
O5-C9-C8 108.0(3) C10-C9-C8 112.2(3) C11-C10-C9 114.3(3) 
O4-C11-C12 122.5(4) O4-C11-C10 121.9(3) C12-C11-C10 115.6(4) 
C16-C15-C18 110.8(5) C16-C15-C17 108.4(4) C18-C15-C17 108.6(3) 
C16-C15-Si1 108.9(3) C18-C15-Si1 109.5(3) C17-C15-Si1 110.6(3) 
C1-O1-C5 118.8(2) C9-O5-Si1 130.5(2) O5-Si1-C13 111.35(16) 
O5-Si1-C14 109.04(18) C13-Si1-C14 108.8(3) O5-Si1-C15 104.44(15) 
C13-Si1-C15 112.6(2) C14-Si1-C15 110.5(2)   
 !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!iBruker (2009) SAINT. Bruker AXS Inc., Madison, Wisconsin, USA. 
 iiBruker (2009) SHELXTL. Bruker AXS Inc., Madison, Wisconsin, USA. 
 iiiSheldrick, G.M. (2007) SADABS. University of Gottingen, Germany. 
 ivSheldrick, G.M. (2008) Acta Cryst. A64,112-122. 
 vSheldrick, G.M. (2008) Acta Cryst. A64,112-122. 
 viR1 = Σ||Fo| - |Fc|| / Σ |Fo| 
wR2 = [Σw(Fo2 - Fc2)2/Σw(Fo2)2]½ 
GOF = [Σw(Fo2 - Fc2)2/(n - p)]½ 
where n = the number of reflections and p = the number of parameters refined. 
 vii“ORTEP-II: A Fortran Thermal Ellipsoid Plot Program for Crystal Structure Illustrations”. C.K. 
Johnson (1976) ORNL-5138. 
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Computational Data Relevant to Part I 
Geometry optimization and calculation of 1H NMR shifts in benzene of model 
compounds 1.138a and 1.138b. 
 
 
Atom 
Coordinates (Å) 
Atom 
Coordinates (Å) 
X Y Z X Y Z 
C 1 -2.796483 -0.029877 -0.40245 H 13 3.285064 0.426999 -1.679812 
C 2 -1.336934 0.01195 -0.531313 C 14 0.912968 -1.606538 0.863188 
C 3 -0.456929 0.544828 0.578306 H 15 0.359361 -2.139378 0.089862 
C 4 -0.360467 2.074119 0.485533 H 16 1.923957 -2.015305 0.914728 
H 5 0.249723 2.473155 1.299581 H 17 0.429123 -1.804003 1.822498 
H 6 0.097764 2.380226 -0.456092 H 18 1.527181 0.391422 1.37222 
H 7 -1.348983 2.533846 0.551108 H 19 -0.933715 0.276026 1.527101 
C 8 0.939976 -0.104764 0.583767 O 20 -2.023743 -1.233513 -0.301768 
O 9 1.546649 0.195097 -0.676373 H 21 -0.922814 0.097739 -1.532613 
C 10 2.952875 0.057178 -0.709922 H 22 -3.42257 0.043035 -1.287172 
H 11 3.429368 0.652619 0.080256 H 23 -3.259183 0.295189 0.526171 
H 12 3.272435 -0.985617 -0.605358    Energy = -425.7021739 Hartree 
 
Table A.1.7. Geometry optimization of model compound 1.138a at the B3LYP level 
of theory employing the 6-311+G(2d,p) basis set. 
!  
O
H H
H
CH3H
CH3
H OCH3
1.138a
1
2 3
4 (5)
6
7
8
9
10 11
12
13
14
15
16
17
18
19
20
21
22
23
!408 
 
 
Atom 
Coordinates (Å) 
Atom 
Coordinates (Å) 
X Y Z X Y Z 
C 1 -2.279095 -1.135236 -0.351379 H 13 3.346232 -0.889929 -0.581528 
C 2 -1.317761 -0.041433 -0.525326 C 14 0.97982 -1.641662 0.84365 
C 3 -0.446019 0.479885 0.597485 H 15 2.000416 -2.027024 0.879792 
C 4 -0.392193 2.012351 0.555342 H 16 0.513709 -1.861102 1.807433 
H 5 0.175027 2.404879 1.403374 H 17 0.439589 -2.182543 0.065187 
H 6 -1.399181 2.430076 0.597718 H 18 1.551869 0.365645 1.35842 
H 7 0.087255 2.358867 -0.361785 H 19 -0.910923 0.1761 1.541838 
C 8 0.965125 -0.136883 0.574562 O 20 -2.727454 0.224925 -0.399442 
O 9 1.549194 0.176847 -0.692309 H 21 -0.934201 0.13424 -1.527027 
C 10 2.961668 0.126047 -0.726269 H 22 -2.565949 -1.745471 -1.203591 
H 11 3.268312 0.476774 -1.711377 H 23 -2.375687 -1.614259 0.619456 
H 12 3.400339 0.781158 0.037699    Energy = -425.701691 Hartree 
 
Table A.1.8. Geometry optimization of model compound 1.138b at the B3LYP level 
of theory employing the 6-311+G(2d,p) basis set. 
 !  
O
H H
H
CH3H
CH3
H OCH3
1.138b
1 2
3
4
5
6
7
8
9
10
11
1213
14 15
16
17
18
19
20
2122
23
!409 
 
 
 
Nucleus 1.138a 1.138b  δ (ppm) δ (ppm) δb – δa (ppm)  
5 0.8620 0.8135 -0.0485 
6 1.4583 1.3205 -0.1378 
7 0.8717 1.4760 0.6043 
Avg. 5–7 1.0640 1.2033 0.1393 
11 3.0007 3.6830 0.6823 
12 3.7613 2.9945 -0.7668 
13 3.7057 3.6722 -0.0335 
Avg. 11–13 3.4892 3.4499 -0.0393 
15 1.3341 1.6924 0.3583 
16 1.6530 0.7615 -0.8915 
17 0.8284 1.0176 0.1892 
Avg. 15–17 1.2718 1.1572 -0.1147 
18 3.3556 3.3361 -0.0195 
19 0.9612 0.9106 -0.0506 
21 2.9815 2.8133 -0.1682 
22 2.6220 2.7639 0.1419 
23 2.2426 2.4691 0.2265 
 
Table A.1.9. Calculation of 1H NMR shifts in benzene of model compounds 1.138a 
and 1.138b at the B3LYP level of theory employing the 6-311+G(2d,p) basis set. !
O
H H
H
CH3H
CH3
H OCH321
22
23 19 5, 6, 7
18 11, 12, 13
O
H H
H
CH3H
CH3
H OCH321
22
23
19 5, 6, 7
18 11, 12, 13
1.138a 1.138b
15, 16, 17 15, 16, 17
 !! 410 
 
 
 
 
 
 
!!
Spectroscopic Data Relevant to Part II !  
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